netFormulary
 Report : A-Z of formulary items 17/06/2021 00:47:17
[Back]
 
Section Name Details
13.02.01  Zeroveen®

100g, 500g

13.10.05  Drapolene®

Cream 100g, 200g, 350g

 

Antiseptics

07.04.02 Desmopressin Noqdirna®

*Oral lyophilisates: 25microgram, 50 microgram


*Only to be used in line with NICE guidance (NG 171, NG 97)

15.02 Levobupivacaine with Fentanyl 

unlicensedunlicensed Infusion bag: Levobupivacaine 0.1% with fentanyl 2 micrograms, 500 mL CD

13.11.07 ‘Free Range’ Larvae 
13.10.05 2.5% castor oil & colophony 2.5% in a collodion base Collodion Flexible BP

100ml, 500ml

13.05.02 5-Methoxypsoralen 

20mg tablets

 

Psoralens (used with phototherapy)

13.05.02 8-Methoxypsoralen 

10mg tablets

 

Psoralens (used with phototherpay)

05.03.01 Abacavir Ziagen®

Tablets: 300mg
Oral solution: 20mg/ml

05.03.01 Abacavir and Lamivudine Kivexa®

Tablets: 600mg/300mg

05.03.01 Abacavir,Lamivudine and Zidovudine Trizivir®

Tablets: 150/300/300mg

10.01.03 Abatacept 

IV infusion: 250 mg
Injection (pre-filled syringe): 125 mg (for rheumatoid arthritis only)

Note: 4th line with MTX on failure after 6 months of 3rd line

02.09 Abciximab  Vial: 10mg/5ml
08.03.04.01 Abemaciclib Verzenios®

Approved for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before in accordance with NICE

Abemaciclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in people who have had endocrine therapy only if:

  • exemestane plus everolimus would be the most appropriate alternative and

  • the conditions in the managed access agreement for abemaciclib with fulvestrant are followed.

08.03.04.02 Abiraterone 

Tablets: 250mg

08.01.05 Abraxane® Paclitaxel

Powder for suspension for infusion: 5mg - restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.

04.10.01 Acamprosate  Tablets: 333mg
06.01.02.03 Acarbose  Tablets: 50mg*
*For existing patients only, no new patients. Unless for reactive hypoglycaemia on advice of specialist
11.06 Acetazolamide 

Tablets: 250 mg
MR Capsules: 250 mg

11.06 Acetazolamide 

Injection: 500 mg vial

12.01.01 Acetic Acid (glacial) (1st line for mild otitis externa) Earcalm ®

Ear spray: 2%

11.08.01 Acetylcysteine  

Eye drops: acetylcysteine 5%, hypromellose 0.35% (Ilube®)
unlicensed unlicensed Eye drops (preservative-free): 5%,

23.01 Acetylcysteine  

Injection: 2 g/10 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

05.03.02.01 Aciclovir  Injection (for IV infusion): 250mg, 500mg
05.03.02.01 Aciclovir  Tablets: 200mg, 400mg, 800mg
Dispersible tablets: 200mg, 400mg, 800mg
Oral suspension (sugar-free available): 200mg/5ml, 400mg/5ml
11.03.03 Aciclovir 

Eye ointment: 3%

13.10.03 Aciclovir 5% 

cream

13.05.02 Acitretin Neotigason®

10mg and 20mg capsules

03.01.02 Aclidinium Eklira Genuair®

Eklira Genuair® breath actuated DPI: 375mcg/puff (equivalent to 322mcg aclidinium)

 

03.01.04 Aclidinium and formoterol inhaler Duaklir Genuair ®

Duaklir Genuair® breath actuated DPI: 340/12mcg/puff

01.05.03 Adalimumab 
10.01.03 Adalimumab Amgevita®(biosimilar) or Humira®

Amgevita is the biosimilar which is recommended for use first line

 

Pre-filled syringe or pen: 40 mg
Injection (vial): 40 mg/0.8 mL

Note: Subcutaneous first choice with MTX

13.05.03 Adalimumab 

40mg injection (prefilled syringe)

13.06 Adapalene 

0.1% gel and cream

13.06 Adapalene 

0.1%  gel and cream

 

1st line topical retinoids

13.06 Adapalene/Benzoyl Peroxide Epiduo

Adapalene 0.1%

02.03.02 Adenosine  Vials: 6mg/2ml
02.07.03 Adrenaline / Epinephrine  Ampoules: 1mg/1ml (1 in 1,000), 1mg/10ml (1 in 10,000)
Pre-filled syringe: 1mg/10ml (1 in 10,000)
03.04.03 Adrenaline / epinephrine EpiPen® & Jext®

Auto-injector: 150 micrograms, 300 micrograms

Use either Jext® or Epipen® but do not interchange

03.04.03 Adrenaline / epinephrine Emerade®

Autoinjector: 500 micrograms (Emerade®)

03.04.03 Adrenaline / epinephrine 1 in 1,000  Injection: 500 micrograms/0.5ml, 1mg/1ml
22 Adult resuscitation trolley drug list 

RedAdrenaline 1 mg/1 mL (1:1000) ampoules 
RedAdrenaline 1 mg/10 mL (1:10,000) prefilled syringe
RedAmiodarone 300 mg/10 mL prefilled syringe
RedAtropine 3 mg/10 mL prefilled syringe 
RedCalcium chloride 1000 mg/10 mL (10%) prefilled syringe
RedNaloxone 400 micrograms/1 mL ampoules
RedSodium bicarbonate 8.4%, 200 mL 
RedSodium chloride 0.9% flush, 10 mL prefilled syringe 
RedSodium chloride 0.9% solution, 1000 mL


*These medications are red in the context of the adult resuscitation trolley. Please see other chapters for formulary status when used for other indications

12.03.05 Aequasyal 

By initiation of head and neck specialist only (2nd or 3rd line for patients undergoing radiotherapy)

08.01.05 Afatinib 

Film coated tablets: 20mg, 30mg, 40mg, 50mg

08.01.05 Aflibercept Zaltrap®

Vials: 100mg/4ml, 40mg/1ml

11.08.02 Aflibercept 

Intravitreal injection: 4 mg/ 0.1mL (dose 2mg/0.05ml)

04.03.04 Agomelatine  Tablets: 25mg
- NETAG approved for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses (as described by NICE and as stated in the BNF). Prescribing and monitoring should be initiated by specialist mental health physicians. After a minimum of 12 weeks, prescribing may be transferred to primary care.
23.01 Alcohol (ethanol) 

Injection: 2 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

13.11 Alcohol hand rub gel 
13.11 Alcohol impregnated wipes 

contains 70% isopropyl alcohol or methylated spirit

08.01.05 Alectinib Alecensa® 150mg capsules
08.02.03 Alemtuzumab 

Concentrate for IV infusion: 30mg in 1ml
- for use in lymphocytic leukaemia & prevention of graft vs. host disease on bone marrow transplant patients
-approved for use in high-risk kidney and pancreas transplantation


Concentrate for IV infusion 12mg in 1.2ml
-approved as an option for treating adults with active relapsing– remitting multiple sclerosis in line with NICE (subject to NHS ENGLAND funding)


 

06.06.02 Alendronic Acid Binosto

Effervescent tablets: 70mg

06.06.02 Alendronic Acid  Tablets: 10mg, 70mg
09.06.04 Alfacalcidol 

Capsules: 0.25 micrograms, 0.5 micrograms, 1 microgram
Oral drops (sugar-free): 2 micrograms/1 mL
Injection: 1 microgram/0.5 mL, 2 micrograms/1 mL

04.07.02 Alfentanil 

Injection: 500 micrograms/1 mL, 5 mg/1 mL

Specialist initiation only - consult pain team or palliative care before use.

15.01.04.03 Alfentanil 

Injection (amps): 500 mcg/1 mL, 5 mg /1 mL

07.04.01 Alfuzosin Hydrochloride 

M/R tablets: 10mg

03.04.01 Alimemazine  Tablets*: 10mg
Syrup*: 7.5mg/5ml, 30mg/5ml
*Hospital use only as pre-medication in paediatric patients
02.12 Alirocumab Praluent®

Solution for injection (pre-filled pen): 75mg/ml, 150mg/ml

To be used in line with NICE TA393
N.B. Supply currently only available via secondary care. No prescribing in primary care.

02.05.05.03 Aliskiren  Tablets: 150mg, 300mg
13.05.01 Alitretinoin Toctino®

10mg, 30mg capsules

10.01.04 Allopurinol  Tablets: 100 mg, 300 mg
10.01.04 Allopurinol 

Tablets: 100mg, 300mg

12.01.03 Almond Oil 

Ear drops

06.01.02.03 Alogliptin 

Tablets: 6.25mg, 12.5mg, 25mg

09.06.05 Alpha Tocopheryl Acetate 

Suspension:  500 mg/5 mL
Capsules: 200units (for use in children with cystic fibrosis)

09.06.05 Alpha Tocopheryl Acetate 

unlicensed unlicensed Injection: 100mg/2ml 

07.04.05 Alprostadil 

Dual chamber injections: 10microgram, 20 microgram
Injections: 10microgram, 20 microgram, 40microgram (Caverject®)
Starter pack and dual chamber injections: 10microgram, 20micrograms, 40microgram (Viridal Duo®)
Cream: 3mg/g (Vitaros®)

02.10.02 Alteplase  Vials: 10mg, 20mg, 50mg
13.12 Aluminimum Chloride Hexahydrate 20% in Alcoholic Base Driclor®Anhydrol forte®

Aluminium chloride hexahydrate 20% solution in an alcoholic basis

04.09.01 Amantadine  Capsules: 100mg
Syrup: 50mg/5ml
05.01.04 Amikacin 

Injection: 100mg/2ml, 500mg/2ml

02.02.03 Amiloride Hydrochloride  Tablets: 5mg
Liquid: 5mg/5ml
03.01.03 Aminophylline Phyllocontin®

SR tablets: 225mg

Prescribe by brand name.

03.01.03 Aminophylline IV  Injection: 250mg/10ml
02.03.02 Amiodarone  Tablets: 100mg, 200mg
02.03.02 Amiodarone  Infusion: 150mg/3ml
04.02.01 Amisulpride  Tablets: 50mg, 200mg
Oral solution: 100mg/1ml
04.03.01 Amitriptyline  Tablets: 10 mg, 25 mg, 50 mg
Sugar-free oral solution: 25 mg/5 mL
04.07.03 Amitriptyline   Tablets: 10 mg, 25 mg, 50 mg
Oral solution: 25 mg/5 mL, 50 mg/5 mL
04.07.04.02 Amitriptyline  Tablets: 10 mg, 25 mg, 50 mg
Liquid: 25 mg/5 mL, 50 mg/5 mL
06.01.05 Amitriptyline  See section 4.3 for preparations
02.06.02 Amlodipine  Tablets: 5mg, 10mg
05.01.01.03 Amoxicillin  Capsules: 250mg, 500mg
Oral suspension (sugar-free available): 125mg/5ml, 250mg/5ml
Oral sachets (sugar-free): 3g/sachet
05.01.01.03 Amoxicillin  Injection: 250mg, 500mg, 1g
05.02 Amphotericin  Injection (for IV infusion): 50mg
Liposomal injection (for IV infusion) (AmBisome®): 50mg
11.03.02 Amphotericin 

unlicensed unlicensed Eye drops: 0.15%

08.01.05 Amsacrine 

Injection: 75mg in 15ml

09.01.04 Anagrelide Xagrid®

2nd line for ITP and patients at risk of essential thrombocythaemia
Capsules: 500micrograms

10.01.04 Anakinra  unlicensedunlicensed

Solution for injection (pre-filled syringe): 100mg/0.67mL

Note: for the indication of acute gout in hospital setting only
08.03.04.01 Anastrozole 

Tablets: 1mg

12.03.01 Antacid with Oxetacaine 

unlicensedunlicensed Suspension


Used to relieve symptoms in patients who have had radiotherapy and may be of value in some patients with acute oesophagitis. Not for routine use as an antacid

08.02.02 Antithymocyte immunoglobulin (horse)  

unlicensedunlicensed Injection: 250mg in 5ml -NETAG approved for aplastic anaemia in adults

08.02.02 Antithymocyte immunoglobulin (rabbit)  

Injection: 25mg injection
– used in the management of transplant rejection

01.07.01 Anusol®  Cream
Suppositories
01.07.02 Anusol-HC  Suppositories
Ointment
02.08.02 Apixaban  Tablets: 2.5mg, 5mg
04.09.01 Apomorphine  Injection: 20 mg/2 mL, 50 mg/5 mL
Pre-filled multiple dose pen injection device: 30 mg/3 mL
Pre-filled syringe: 50 mg/10 mL
11.08.02 Apraclonidine 

Eye drops: 0.5%
Unit dose eye drops: 1%

11.06 Apraclonidine hydrochloride 

Eye drops: 0.5% Single use (preservative free): 1%

10.01.03 Apremilast 

Tablets: 30mg

13.05.03 Apremilast Otezla®
04.06 Aprepitant 

Capsules: 80mg, 125mg

13.02.01 Aquadrate ®- Urea 10% Aquadrate®

30g, 100g

 

2nd line urea containing emollients

01.06.03 Arachis Oil  Enema
02.08.01 Argatroban monohydrate 

Infusion vial: 250mg/2.5 mL 

04.02.01 Aripiprazole  Tablets: 5mg, 10mg, 15mg, 30mg

Orodispersible tablets: 10mg, 15mg
- for doses over 5 mg for those patients who have difficulty swallowing

Oral solutions: 1mg/1ml
- only for doses of 5 mg or less, or when titrating patients on doses of increments of less than 5 mg, in patients who have difficulty swallowing tablets
04.02.01 Aripiprazole  IM Injection: 7.5mg/ml
- approved for use in rapid tranquilisation in patients with acute psychosis. NTW use only
04.02.02 Aripiprazole  Injection: 400mg long acting injection
-NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-Acting Injections in the North of England
08.01.05 Arsenic Trioxide 

Ampoule: 10mg in 10ml
-NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL)

NICE TA for acute promyelocytic leukaemia
05.04.01 Artesunate Malacef 60

Injection: 60mg

09.06.03 Ascorbic Acid 

Tablets: 50 mg, 100 mg, 200 mg, 500 mg

02.09 Aspirin  

Dispersible tablets: 75mg, 300mg (loading dose)

02.09 Aspirin  

Suppository: 150mg, 300mg
For use in patients following stroke

04.07.04.01 Aspirin  Soluble Tablets: 300 mg
07.01.04 Aspirin 

Dispersible tablets: 75mg

14.04 AstraZeneca COVID-19 vaccine 
05.03.01 Atazanavir Reyataz®

Capsules: 150mg, 200mg, 300mg

05.03.01 Atazanavir sulfate and cobicistat Evotaz®

Tablets: 300mg/150mg

02.04 Atenolol  Tablets: 25mg, 50mg, 100mg
Sugar-free syrup: 25mg/5ml
08.01.05 Atezolizumab 

Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed

Also available through patient access scheme for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
04.04 Atomoxetine  Capsules: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg
02.12 Atorvastatin  Tablets: 10mg, 20mg, 40mg, 80mg
Chewable tablets: 10mg, 20mg - to be used when solid dosage forms cannot be used
07.01.03 Atosiban 

Injection: 6.75mg in 0.9ml
Concentrate for IV infusion: 37.5mg in 5ml (7.5mg/ml)

15.01.05 Atracurium Besilate 

Injection (amps): 25 mg/2.5 mL, 50 mg/5 mL

11.05 Atropine 

Eye drops: 0.5%
Minims® (preservative free): 1%
unlicensed unlicensed Eye drops (preservative free): 1%
unlicensed unlicensed Eye ointment: 1%

15.01.03 Atropine  

Injection (amps): 600 micrograms/1 mL 

23.01 Atropine sulphate  

Injection: 600 micrograms/1 mL ampoules


Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

07.04.05 Avanafil 

Tablets: 50mg, 100mg, 200mg

09.01.04 Avatrombopag 
13.02.01 Aveeno cream Aveeno®

100ml, 300ml, 500ml

08.01.05 Avelumab  Bavencio ®

20mg/ml concentrate for infusion.

08.01.05 Axicabtagene ciloleucel 
08.01.05 Axitinib 

Film coated tablets: 1mg, 3mg, 5mg and 7mg

08.01.03 Azacitidine Vidaza®

Vial: 100mg

01.05.03 Azathioprine  Tablets: 25mg, 50mg

Maximum dose for TPMT- deficient patients 5mg
08.02.01 Azathioprine 

Tablets: 25mg & 50mg
unlicensedunlicensed Suspension: 50mg in 5ml
Injection: 50mg

10.01.03 Azathioprine  Tablets: 25 mg, 50 mg
13.06 Azelaic Acid 

15% gel Finacea

20% cream Skinoren

12.02.01 Azelastine and fluticasone Dymista®

Nasal spray: Azelastine 137 micrograms & fluticasone 50 micrograms/spray

Second line treatment following a trial of a combination of nasal steroid and oral antihistamine.

12.02.01 Azelastine Hydrochloride 

Nasal spray: 140 micrograms (0.14 mL)/spray

05.01.05 Azithromycin  Tablets: 250mg, 500mg
Capsules: 250mg
Oral suspension: 200mg/5ml

The tablets have a lower acquisition cost than the capsules

N.B. Green+ for use in COPD
11.03.01 Azithromycin Azyter®

Eye drops: 1.5% (single use)

05.01.02.03 Aztreonam  Injection: 1g, 2g
Powder for inhalation: 75mg

Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy
10.02.02 Baclofen  Tablets: 10 mg
Oral solution (sugar-free available): 5 mg/5 mL
13.02.01 Balneum® Plus cream 
01.05.01 Balsalazide Sodium Colazide® Capsules: 750mg
10.01.03 Baricitinib Olumiant

Film coated tablets: 2mg, 4mg

17 Barium sulfate  E-Z-HD®

For oral use: 98.45%

17 Barium sulfate  Polibar®

For rectal use: 94.015%

08.02.02 Basiliximab Simulect®

Vial for preparing IV infusion: 20mg


-approved for limited use in adult renal translplant patients with high risk of acute organ rejection


-approved for severe graft versus host disease post haematopoietic stem cell transplantation


 

08.02.04 BCG Connaught 

Vial: 81mg for bladder instillation

14.04 BCG vaccine 

Bacillus Calmette-Guérin Vaccine (BCG Vaccine, Dried/Tub/BCG)  
unlicensed unlicensed Injection: 1 mL multidose ampoules containing freeze dried powder for preparing intradermal injections (InterVax). 


 


Tuberculin Purified Protein Derivative (Tuberculin PPD)
unlicensed unlicensed Vial (1.5 mL): 20 units/mL (2 units/0.1 mL dose) (for routine use); 100 units/mL (10 units/0.1 mL dose) (Statens Serum Institut). 

03.02 Beclometasone Clenil Modulite® Beclometasone is the first line corticosteroid; Clenil is first choice for asthma

Clenil Modulite® CFC-free MDI: 50mcg, 100mcg, 200mcg, 250mcg per puff

N.B. CFC-free beclometasone must be prescribed by brand name
03.02 Beclometasone Qvar® Beclometasone is the first line corticosteroid

QVAR® CFC-free MDI: 50mcg, 100mcg per puff
QVAR® breath-actuated MDI: 50mcg, 100mcg per puff
Extra-fine particle inhaler

N.B. CFC-free beclometasone must be prescribed by brand name.

50mcg QVAR is equivalent to 100mcg for a conventional beclometasone inhaler and 100mcg is equivalent to 250mcg conventional beclometasone.
03.02 Beclometasone and formoterol Fostair®

Fostair ® CFC-free MDI: 100/6mcg per puff 
Fostair ® CFC-free MDI: 200/6mcg/puff

N.B. Extra fine-particle aerosol - 100mcg of beclomethasone in Fostair ® is equivalent to a 250mcg dose in a conventional beclomethasone metered dose inhaler

Fostair ® NEXThaler (breath actuated DPI): 100/6mcg, 200/6mcg per puff

The 100/6mcg inhalers are first choice ICS/LABA combination inhalers in the Sunderland COPD guideline.

The 200/6mcg inhalers are approved for use in the treatment of ASTHMA only.

12.02.01 Beclometasone Dipropionate 

Nasal spray: 50 micrograms/ spray

03.01.04 Beclomethasone/Formoterol/Glycopyrronium 87/5/9 Trimbow®

Trimbow®   87/5/9mcg MDI

Triple therapy inhaler -ICS/LABA/LAMA for COPD.

If spacer required, manufacturer recommends AeroChamberPlus.

Formulary approved for use in COPD only.

 

10.01.03 Belimumab Benlysta®

Vial for intravenous infusion: 120mg

08.01.01 Bendamustine 

Injections: 25mg & 100mg


-approved for the first line treatment of CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate in line with NICE


-NECDAG approved for use in combination with rituximab for patients with CLL not fit for FCR chemotherapy and not fit for alemtuzumab.


-approved for Low Grade Non-Hodgkins Lymphoma in line with NICE -not recommended for (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen NICE

02.02.01 Bendroflumethiazide  Tablets: 2.5mg
03.04.02 Benralizumab Fasenra®
  • Approved for treating severe eosinophilic asthma in adults in line with NICE
  • 05.01.01.01 Benzathine penicillin 

    unlicensed unlicensed Injection: 2.4MU vial

    10.01.04 Benzbromarone 

    Tablets: 100mg

    13.06 Benzoyl Peroxide 

    5% gel           

    12.03.01 Benzydamine 

    Mouthwash: 0.15%
    Spray: 0.15% 

    05.01.01.01 Benzylpenicillin  Injection: 600mg, 1.2g
    11.03.01 Benzylpenicillin 

    unlicensed Eye drops: 100,000 units/mL

    04.06 Betahistine Dihydrochloride  Tablets: 8mg, 16mg
    07.01.04 Betamethasone 

    Injection: 4mg/ml

    11.04.01 Betamethasone 

    Eye/Ear/Nose drops: 0.1%
    Eye ointment: 0.1%

    12.01.01 Betamethasone Betnovate Scalp application

    unlicensedunlicensed Solution (as ear drops for eczema): 0.1% (Betnovate Scalp Application)

    12.03.01 Betamethasone 

    Tablets (soluble): 500 micrograms (Betnesol®)
    Used as mouth gargle

    13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic®

    Ointment and scalp application

     

    potent topical corticosteroids with other ingredients

    13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®

    100g

     

    1st line Moderaltely potent topical corticosteroids

    13.04 Betamethasone (as Valerate) 0.1% 

    Cream, lotion, ointment, scalp application.

     

    1st line Potent topical corticosteroids

    13.04 Betamethasone (as Valerate) 0.1% with Clioquinol 3% 

    Cream, ointment

     

    2nd line potent topical corticosteroids with antimicrobials

    13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet®

    Cream

     

    potent topical corticosteroids with other ingredients

    13.04 Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% was Betnovate-N®

    Cream, ointment

     

    1st line potent topical corticosteroids with antimicrobials

    13.04 Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm®

    Cream

    1st line potent topical corticosteroids with antimicrobials

    12.01.01 Betamethasone sodium phosphate 

    Ear/eye/nose drops: 0.1%

    12.02.01 Betamethasone Sodium Phosphate 

    Eye/ear/nose drops: 0.1%

    11.04.01 Betamethasone with Neomycin  

    Eye drops: betamethasone 0.1%, neomycin sulfate 0.5%

    12.01.01 Betamethasone with Neomycin  Betnesol N®

    Ear drops: 0.1% with neomycin sulfate 0.5%

    08.01.05 Bevacizumab Avastin®

    Vial: 100mg/4ml
    Syringe: 5mg/0.2ml
    Solution for infusion: 25mg/1ml


    *Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable

    08.01 Bicalutamide  Tablets: 50mg, 150mg
    08.03.04.02 Bicalutamide 

    Tablets: 50mg, 150mg 
    -initiated with specialist advice

    11.06 Bimatoprost 

    Eye drops: 100 micrograms/1 mL, 300 micrograms/1 mL
    Unit dose eye drops (preservative-free): 300 micrograms/1 mL

    11.06 Bimatoprost with Timolol 

    Eye drops: bimatoprost 300 micrograms/1 mL, timolol 5 mg/1 mL (Ganfort®)

    13.11.07 BioFOAM dressing 
    01.05.03 Biosimilar Infliximab Inflectra®

    Vial (powder for reconstitution): 100mg

    12.03.05 Biotene Oralbalance® 

    Gel

    12.03.05 BioXtra® 

    Gel: 40 mL
    Spray: 50 mL
    Mouth rinse: 250 mL      

    06.01.01.02 Biphasic Insulin Aspart NovoMix® 30 Cartridge: 3ml for NovoPen® Novopen penmate

    Prefilled pen: 3ml FlexPen®
    06.01.01.02 Biphasic Insulin Lispro Humalog® Mix Cartridge: 3ml for HumaPen® Savvio or Autopen® Classic

    Prefilled pen: 3ml KwikPen®

    Hospital note - Minimal stock levels of cartridges held
    Humalog Mix 50®: KwikPen® pre-loaded pen – not stocked but available on request
    06.01.01.02 Biphasic Isophane Insulin Humulin® M3 Cartridge: 3ml for HumaPen® Savvio or Autopen® Classic

    Prefilled pen: 3 ml KwikPen®

    Vial: 10ml

    01.06.02 Bisacodyl  Tablets: 5mg
    Suppositories: 5mg*, 10mg
    *5mg suppository for use in paediatrics only
    12.02.03 Bismuth and Iodoform Paste (BIPP) 

    Impregnated gauze: 1.25cm x 100cm and 2.5cm x 100cm

    02.04 Bisoprolol  Tablets: 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg
    The 5mg and 10mg tablets should be used where possible due to lower cost.
    02.08.01 Bivalirudin  Injection: 250 mg
    08.01.02 Bleomycin 

    Injection: 15,000 units (strength formerly expressed as 15mg)
    -unlicensedunlicensed also approved for use in intralesional sclerotherapy in the treatment of low-flow vascular lesions – unlicensed indication

    08.02 Blinatumomab Blincyto®

    Vials: 38.5microgram

    13.11.06 Bonney’s Blue  

    Paint containing brilliant green and crystal violet

    12.01.01 Boric acid (insufflation) 

    Powder: 10g

    08.01.05 Bortezomib 

    Injection: 3.5mg

    02.05.01 Bosentan  Tablets: 62.5mg
    08.01.05 Bosutinib 

    Film coated tablets: 100mg, 500mg

    13.12 Botulinum toxin  
    04.09.03 Botulinum Toxin Type A 

    Botox®: 50 units, 100 units, 200 units
    Dysport®: 300 units, 500 units
    Xeomin ®: 50units, 100 units, 200 units

     

    N.B. Botox® is also licensed for the prophylaxis of headache in adults with chronic migraine (NICE TA260)

    08.01.05 Brentuximab vedotin Adcetris®

    Vial: 50mg

    07.03.01 Brevinor® 

    Tablets: ethinylestradiol 35 microgram/norethisterone 500 microgram

    08.01.05 Brigatinib Alunbrig®
  • Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE
  • 11.06 Brimonidine Tartrate 

    Eye drops: 0.2%

    11.06 Brimonidine Tartrate with timolol 

    Eye drops: brimonidine 0.2%, timolol 0.5% (Combigan®)

    11.06 Brinzolamide 

    Eye drops: 1% (10 mg/1 mL)

    11.06 Brinzolamide and brimonidine Simbrinza®

    Eye drops: brinzolamide 10mg/ml, brimonidine tartrate 2 mg/mL

    11.06 Brinzolamide with timolol 

    Eye drops: brinzolamide 10 mg/1 mL, timolol 5 mg/1 mL (Azarga®)

    04.08.01 Brivaracetam  Tablets: 25mg, 50mg
    Oral solution: 10mg/ml
    Solution for injection/infusion: 10mg/ml
    08.02.04 Brodalumab Kyntheum ®

    210mg solution for infusion

    Brodalumab for treating moderate to severe plaque psoriasis (TA511) 21.3.18

    13.05.03 Brodalumab ▼ 

    210mg solution in pre-filled syringe

    11.08.02 Brolucuzumab 

    Intravitreal injection: 120mg/1mL (dose 6mg/0.05ml)

    06.07.01 Bromocriptine  Tablets: 1mg, 2.5mg
    01.05.02 Budenoside Budenofalk

    Rectal foam: 2mg/dose

    01.05.02 Budesonide Jorveza®

    1mg orodispersible tablets

    For the treatment of eosinophilic oesophagitis

    01.05.02 Budesonide Budenofalk® Entocort ®

    CR capsules: 3mg (Entocort)

    Capsules:3mg (Budenofalk)

    03.02 Budesonide  Alternative corticosteroid

    Breath actuated DPI (Turbohaler®): 100mcg, 200mcg, 400mcg per puff
    Respules®: 250mcg/1ml, 500mcg/1ml, 500mcg/2ml
    03.02 Budesonide and formoterol Symbicort®

    Symbicort Turbohaler® 
    100/6: Budesonide with formoterol 100/6mcg per puff
    200/6: Budesonide with formoterol 200/6mcg per puff
    400/12: Budesonide with formoterol 400/12 mcg per puff

     

    Not a first-line choice on the Sunderland COPD guideline for newly diagnosed COPD patients. May be continued in existing patients if guideline alternatives are unsuitable.

    03.02 Budesonide and formoterol DuoResp Spiromax®

    DuoResp Spiromax ® 

    160/4.5: Budesonide with formoterol 160/4.5mcg per puff
    320/9: Budesonide with formoterol 320/9mcg per puff

    Not a first-line choice on the Sunderland COPD guideline for newly diagnosed COPD patients. May be continued in existing patients if guideline alternatives are unsuitable.

    02.02.02 Bumetanide  Tablets: 1mg, 5mg
    Liquid: 1mg/5ml
    15.02 Bupivacaine Hydrochloride 

    Injection: 0.5% (100 mg/4 mL), in glucose 8%, 4 mL ampoules (Marcain Heavy®)

    04.07.02 Buprenorphine 

    Transdermal patches: 5mcg, 10mcg, 15mcg, 20mcg/hour over 7 days*
    Transdermal patches: Transtec® 35mcg, 52.5mcg, 70mcg/hour over 96 hours

    *Sevodyne preferred brand in primary care

     

     

    Red Sublingual tablets: 200micrograms

    * For treatment of post-operative pain only*

    04.10.03 Buprenorphine 

    Sublingual Tablets: 400 micrograms, 2 mg, 8 mg

    RED when used to treat substance misuse, where initiation by specialist includes specialist substance misuse services

    04.10.03 Buprenorphine and Naloxone Suboxone®

    Sublingual tablets: 8mg/2mg

    RED when used to treat substance misuse, where initiation by specialist includes specialist substance misuse services

    04.10.02 Bupropion Hydrochloride 

    MR Tablets: 150 mg

    06.06.02 Burosumab Crysvita®
  • 10mg/1ml, 20mg/1ml & 30mg/1ml solution for injection
  • Approved for treating X-linked hypophosphataemia in children and young people in accordance with NICE
  • 06.04.04 Buserelin 

    Nasal spray: 100 micrograms per spray; 336 dose spray (Suprefact®)
    Nasal spray: 150 micrograms per spray; 268 dose spray (Suprecur®)

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    08.03.04.02 Buserelin 

    Injection: 5 mg in 5 mL

    Nasal spray: 100 micrograms per spray; 336 dose spray (Suprefact®)
    Nasal spray: 150 micrograms per spray; 268 dose spray (Suprecur®)

    04.01.02 Buspirone Hydrochloride  Tablets: 5mg
    08.01.01 Busulfan 

    Tablets: 2mg
    Injection: 60mg in 10ml
    unlicensedunlicensed Capsules: 25mg

    03.04.03 C1 Esterase Inhibitor Berinert®

    Injection: powder for reconstitution, 500 unit vial and 1,500 unit vial (Berinert®)

    Treatment of hereditary angioedema (HAE) and pre-procedure prevention

    08.01.05 Cabazitaxel 

    Concentrate for IV infusion: 40mg/1ml

    06.07.01 Cabergoline  Tablets: 500micrograms
    08.01.05 Cabozantinib 
  • Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy
  • 13.05.02 Calcipotriol 50microgram/g, (0.005%) Dovonex

    Ointment, scalp application

    13.04 Calcipotriol 50microgram/g, Betamethasone 0.05% Dovobet®

    Ointment, gel

     

    1st line potent topical corticosteroids with other ingredients

    13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet®

    Gel, ointment

     

    1st line other topical preperations

    13.05.02 Calcipotriol and betamethasone dipropionate Enstilar Cutaneous Foam 

    60g foam

    09.06.04 Calcitriol 

    Capsules: 0.25 micrograms, 0.5 micrograms

    09.05.02.02 Calcium Acetate 

    Tablets: 1 g (Phosex)
    Tablets: 475mg, 950mg (Renacet)

    09.05.02.02 Calcium carbonate 

    Tablets: 1.5 g (Adcal)


    Please note preferred brands may vary between primary and secondary care

    09.05.01.01 Calcium Chloride 

    Injection:10% equivalent to calcium 6.8 mmol/10 mL

    23.01 Calcium chloride 

    Injection: 10 mmol/10 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    08.01 Calcium Folinate (Folinic acid) 

    Tablets: 15mg
    Injection: 3mg, 15mg, 30mg and 300mg
    An unlicensed 1mg per 1ml mouthwash can be prepared if needed unlicensedunlicensed 

    09.05.01.01 Calcium Gluconate 

    Injection: 10%, equivalent to calcium 2.25 mmol/10 mL

    23.01 Calcium gluconate 

    Injection: 10 % (1 g/10 mL) ampoules
    Gel: 25 g tube


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    09.05.01.01 Calcium Salts 

    Chewable tablets (as carbonate 1.5 g): equivalent to calcium 600 mg, 15 mmol (Adcal®)


    Effervescent tablets: equivalent to calcium 1 g, 25 mmol (Sandocal 1000®)


    Syrup (per 5 mL): equivalent to calcium 102 mg, 2.55 mmol (Alliance Calcium Syrup)

    09.05.02.02 Calcium/Magnesium Salts 

    Tablets: Calcium acetate 435 mg and Magnesium carbonate 235 mg (Osvaren)

    06.01.02.03 Canagliflozin  Tablets: 100mg, 300mg
    02.05.05.02 Candesartan  Tablets: 2mg, 4mg, 8mg, 16mg, 32mg
    04.06 Cannabidiol  Epidyolex®

    Oral solution: 100mg/1mL

    Approved for use according to criteria in NICE TA614 and TA615

    10.02.02 Cannabis extract Sativex®

    Oromucosal spray: cannabidiol 2.5mg/dronabinol 2.7mg per dose

    Approved to treat moderate to severe spasticity in adults with multiple sclerosis in line with NICE NG144

    08.01.03 Capecitabine 

    Tablets: 150mg & 500mg

    12.03.01 Caphosol® 

    Oral rinse: 30 doses

    09.01.04 Caplacizumab Cablivi®

    Vial: powder and solvent for injection 10 mg

    04.07.03 Capsaicin Axsain® Cream: 0.075%
    10.03.02 Capsaicin  Cream: 0.025% (Zacin®)
    For osteoarthritis
    04.02.03 Carbamazepine  Tablets: 100mg, 200mg, 400mg
    Sugar-free liquid: 100mg/5mL
    - see section 4.8 for other formulations

    04.07.03 Carbamazepine  Tablets: 100 mg, 200 mg, 400 mg
    SR Tablets: 200 mg, 400 mg
    Liquid: 100 mg/5 mL

    Indicated in trigeminal neuralgia and compression neuralgia
    04.08.01 Carbamazepine  Tablets: 100 mg, 200 mg, 400 mg
    SR Tablets: 200 mg, 400 mg
    Liquid: 100 mg/5 mL
    Suppositories: 125 mg, 250 mg

    CHM advise brand specific prescribing
    17 Carbex® granules   Containing: citric acid, sodium bicarbonate, simeticone
    06.02.02 Carbimazole  Tablets: 5mg, 20mg
    03.07 Carbocisteine  Capsules: 375mg
    Oral liquid: 125mg/5ml, 250mg/5ml
    11.08.01 Carbomer 980 

    Eye drops (liquid gel): 0.2%
    Also available as single dose units (preservative-free)

    15.01.02 Carbon dioxide 
    08.01.05 Carboplatin 

    Injections: 50mg in 5ml, 450mg in 45ml

    07.01.01 Carboprost 

    Injection 250 micrograms in 1ml

    08.01.05 Carfilzomib Kyrolis®

    Vial: powder for infusion 10 mg, 30 mg and 60 mg

    11.08.01 Carmellose 

    Eye drops: 0.5%,
    Single dose units (preservative-free): 0.5%, 1% (Celluvisc®)

    08.01.01 Carmustine BiCNU®

    Implants: 7.7mg

    02.04 Carvedilol  Tablets: 3.125mg, 6.25mg, 12.5mg, 25mg
    05.02.04 Caspofungin  Injection: 50mg, 70mg
    13.02.02 Cavilon Advanced Skin Protectant Cavilon®Film

    Advanced liquid dressing (3M Health Care Ltd) 2.7ml

    92g

    05.01.02.01 Cefalexin  Capsules: 250mg, 500mg
    Oral suspension: 125mg/5ml, 250mg/5ml
    05.01.02.01 Cefixime  Tablets: 200mg
    Oral solution: 100mg/5ml
    05.01.02.01 Cefotaxime  Injection: 500mg, 1g, 2g
    05.01.02.01 Ceftazidime  Injection: 500mg, 1g, 2g, 3g
    05.01.02 Ceftolozane & tazobactam Zerbaxa®

    Solution for infusion: 1g/0.5g

    05.01.02.01 Ceftriaxone  Injection: 250mg, 1g, 2g
    05.01.02.01 Cefuroxime  Injection: 250mg, 750mg, 1.5g
    10.01.01 Celecoxib  Capsules: 100mg, 200mg
    08.02.04 Cemiplimab Libtayo®

    Cemiplimab (Libtayo®) is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate.

    It is recommended only if the conditions in the managed access agreement are followed.

    08.01.05 Ceritinib 

    Capsule: 150mg

    10.01.03 Certolizumab Pegol 

    Pre-filled syringe: 200 mg


    Note: Option if anti-TNF withdrawn during 1st 6 months due to adverse effects

    Also approved for:
    -Adults with severe active Ankylosing Spondylitis who have had an inadequate response to, or are intolerant to NSAIDs
    -In combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate

    13.05.03 Certolizumab pegol 

    Indicated for treating moderate to severe plaque psoriasis as per NICE recommendations

    13.05.03 Certolizumab Pegol 

    200mg/ml soln in pre-filled pen or syringe

     

    03.04.01 Cetirizine  Tablets: 10mg
    Oral solution: 5mg/5ml
    08.01.05 Cetuximab 

    Vials for IV infusion: 100mg in 20ml & 500mg in 100ml

    23.01 Charcoal (activated) 

    Oral suspension: 50 gm/250 mL


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    04.01.01 Chloral Hydrate 

    Liquid: 1g/5ml
    This strength is to be prescribed in paediatric patients (NPPG and RCPCH recommendation)

    04.01.01 Chloral Hydrate  Mixture: 500mg/5ml
    08.01.01 Chlorambucil 

    Tablets: 2mg

    05.01.07 Chloramphenicol  Capsules: 250mg
    05.01.07 Chloramphenicol  Injection (for IV infusion): 1g
    11.03.01 Chloramphenicol 

    Eye drops: 0.5%
    Eye ointment: 1%
    Minims® single use, preservative free: 0.5%

    12.01.01 Chloramphenicol 

    Ear drops: 5%

    04.01.02 Chlordiazepoxide  Capsules: 5mg, 10mg
    07.04.04 Chlorhexidine 

    100ml sachets: 0.02% (1 in 5,000) solution

    11.03.02 Chlorhexidine 

    unlicensed unlicensed Eye drops: 0.02%

    12.03.02 Chlorhexidine 

    Mouthwash: 0.2% (contains alcohol)
    Mouthwash (alcohol free): 0.2%
    Spray: 0.2% – contains alcohol
    Gel: 1%

    13.11.02 Chlorhexidine Acetate 1% Dusting Powder 
    13.11.02 Chlorhexidine Gluconate 

    0.02% & 0.05% solutions, 25ml & 100ml sachets

    0.5% solution in 70% methylated spirit (pink, colourless & red staining)

    2.5% in 70% methylated spirit wipes

    0.5% hand rub (contains 70% isopropyl alcohol + emollients)

    4% surgical scrub

    2% in 70% isopropyl alcohol wipes (Sanicloth & Clinell)

    skin swabs & skin cleanser 

    3ml & 10.5ml applicators (Chloraprep)

    1% Obstetric cream

    4% scrub 100ml and 500ml (used as a soap substitute in patients with hidradenitis under special advice)

    13.04 Chlorhexidine HCl 1%, nystatin 100,000 units/g & hydrocortisone 0.5% 

    30g

     

    2nd line mildly potent topical corticosteroids with antimicrobials

    12.02.03 Chlorhexidine Hydrochloride and Neomycin Suphate  

    Naseptin®
    Cream: chlorhexidine hydrochloride 0.1%, neomycin sulfate 0.5%
    Contains peanut oil

    03.04.01 Chlorphenamine  Tablets: 4mg
    Syrup: 2mg/5ml
    Injection: 10mg/1ml
    04.02.01 Chlorpromazine  Tablets: 10mg, 25mg, 50mg, 100mg
    Oral solution: 25mg/5ml, 100mg/5ml
    Injection: 50mg/2ml
    07.05.03 Choriogonadotrophin alfa Ovitrelle®

    Prefilled syringe: 250microgram/0.5ml

    06.05.01 Choriogonadotropin Alfa Ovitrelle® Injection (pre-filled syringe): 6,500 units/0.5mL (250 micrograms/0.5mL) (Ovitrelle®)
    06.05.01 Chorionic Gonadotrophin Pregnyl® Injection: 1,500 units, 5,000 units (Pregnyl®)
    01.05.03 Ciclosporin 

    Capsules: 10mg, 25mg, 50mg, 100mg
    Oral solution: 100mg/ml
    Prescribe by brand name.

    Brands include Capimune, Capsorin, Deximune, Neoral, Sandimmun, Vanquoral

    08.02.02 Ciclosporin Sandimmun®

    IV Infusion: 50mg in 1ml & 250mg in 5ml concentrate (oily)

    08.02.02 Ciclosporin Neoral®

    Capsules: 10mg, 25mg, 50mg & 100mg
    Sugar free oral solution (oily): 100mg in 1ml

    08.02.02 Ciclosporin Sandimmun®

    Original oral formulations Sandimmun supplied on request for patients who cannot take Neoral
    unlicensedunlicensed Capsules: 25mg & 100mg
    Sugar-free oral solution (oily): 100mg in 1ml

    10.01.03 Ciclosporin Neoral® Capsules: 10 mg, 50 mg, 100 mg
    Oral solution (sugar-free): 100 mg/1 mL
    11.04.02 Ciclosporin  

    unlicensed unlicensed P/F unit dose eye drops: 0.05%

    11.04.02 Ciclosporin  

    Eye drops: 0.1%

    13.05.03 Ciclosporin 

     

    Note this SCA has not been approved Sunderland and South Tyneside APC or transfer of care.

    07.03.01 Cilest® 

    Tablets: Ethinylestradiol 35 mcg / norgestimate 250 mcg

    07.03.01 Cilique® 

    Tablets: Ethinylestradiol 35 mcg / norgestimate 250 mcg

    09.05.01.02 Cinacalcet Mimpara®

    Please note the RAG status of cinacelet is dependent on indication


    Amber Cinacalcet for the treatment of primary hyperparathyrodism


    Red Cinacalcet for the treatment of secondary hyperparahyrodism


    Tablets: 30 mg, 60 mg, 90 mg

    04.06 Cinnarizine  Tablets: 15mg
    05.01.12 Ciprofloxacin  Tablets: 100mg, 250mg, 500mg, 750mg
    Oral suspension: 250mg/5ml
    05.01.12 Ciprofloxacin  IV infusion: 2mg/ml
    11.03.01 Ciprofloxacin 

    Eye drops: 0.3%
    Eye ointment (preservative-free): 0.3%

    12.01.01 Ciprofloxacin 

    unlicensedunlicensed Eye drops: 0.3%

     

    (Off-licence use)

    08.01.05 Cisplatin 

    Injection: 50mg

    04.03.03 Citalopram  Tablets: 10 mg, 20 mg, 40 mg
    Oral drops (sugar-free): 40 mg/1 mL
    4 drops (8mg) is therapeutically equivalent to a 10 mg tablet
    08.01.03 Cladribine 

    Solution for preparing infusions: 10mg in 10ml
    Subcutaneous injection: 2mg in 1ml
    - approved for Hairy Cell Leukemia

    Tablets: 10mg

     as an option for relapsing-remitting multiple sclerosis as per NICE (see link)

    05.01.05 Clarithromycin  Tablets: 250mg, 500mg
    Oral suspension: 125/5ml, 250mg/5ml
    05.01.05 Clarithromycin  Injection (for IV infusion): 500mg
    05.01.06 Clindamycin   Capsules: 75mg, 150mg
    Suspension: 75mg/5ml
    05.01.06 Clindamycin   Injection: 300mg/2ml, 600mg/4ml
    07.02.02 Clindamycin 

    Vaginal cream: 2%

    13.06 Clindamycin 

    1% Topical solution

    1% lotion

     

    04.08.01 Clobazam  Tablets: 10 mg
    Oral Suspension: 5mg/5 mL - licensed product, Tapclob®, now available
    Should only be prescribed on the NHS to patients for the treatment of epilepsy under SLS regulations. Prescriptions should be endorsed “SLS”.
    13.04 Clobetasol Propionate 0.05% Dermovate®

    Cream, ointment, scalp application & shampoo

     

    1st line very potent topical corticosteroids

    13.04 Clobetasol Propionate with neomycin and nystatin Dermovate-NN®

     

    2nd line very potent topical corticosteroids with antimicrobials

    13.04 Clobetasone Butyrate 0.05% Eumovate®

    30g, 100g

     

    1st line moderately potent topical corticosteroids

    13.04 Clobetasone butyrate with nystatin & oxytetracycline Trimovate®

    30g

     

    2nd line moderately potent topical corticosteroids

    04.01.01 Clomethiazole  Capsules: 192mg
    Oral solution: 157.5mg/5ml

    Chlordiazepoxide is preferred in the management of alcohol withdrawal.
    Heminevrin syrup has been discontinued.
    06.05.01 Clomifene Citrate  Tablets: 50mg
    07.05.01.01 Clomiphene 

    Tablets: 50mg

    04.03.01 Clomipramine  Capsules: 10 mg, 25 mg, 50 mg
    04.08.01 Clonazepam  Tablets: 500 micrograms, 2 mg
    Oral solution (contains alcohol): 500 micrograms/5 mL, 2 mg/5 mL
    Oral solution contains 100mg ethanol per 5mL (Rosemont Pharmaceuticals)
    02.05.02 Clonidine hydrochloride  Tablets: 25 micrograms, 100 micrograms
    02.05.02 Clonidine hydrochloride  Ampoules: 150 micrograms/1ml
    04.07.04.02 Clonidine Hydrochloride  Suspension*: 50mcg/5ml
    *Hospital use only
    02.09 Clopidogrel  Tablets: 75mg, 300mg (loading dose)
    07.02.02 Clotrimazole 

    Cream: 1%
    Thrush cream: 2%
    Vaginal cream: 10%
    Pessaries: 100mg, 200mg & 500mg
    Cream with hydrocortisone: 1%/1%

    12.01.01 Clotrimazole 

    Solution (as ear drops): 1%

    13.10.02 Clotrimazole 1% 

    cream

    04.02.01 Clozapine  Tablets: 25mg, 100mg
    First choice in patients with treatment-resistant schizophrenia
    Contact NTW pharmacy department for continued supplies of clozapine during admission and on discharge
    13.05.02 Coal Tar 2% with Salicylic Acid 2% 

    ointment

    13.05.02 Coal tar lotion Exorex®
    13.05.02 Coal Tar Solution 12%, Salicylic Acid 2%, precipitated Sulfur 4% Sebco®

    40g, 100g

    13.05.02 Coal tar strong solution 1%, 2.5% & 5% in emulsifying Ointment 
    05.01.01.03 Co-Amoxiclav (amoxicillin with clavulanic acid)  Tablets: 250/125, 500/125
    Oral suspension (sugar-free available): 125/31, 250/62, 400/57

    (Quantities are indicated in the form of x/y where x = mg amoxicillin and y = mg clavulanic acid)
    05.01.01.03 Co-Amoxiclav (amoxicillin with clavulanic acid)  Injection: 500/100 (600mg), 1000/200 (1.2g)

    (Quantities are indicated in the form of x/y where x = mg amoxicillin and y = mg clavulanic acid)
    04.09.01 Co-Beneldopa  Capsules: 12.5/50, 25/100, 50/200
    Dispersible Tablets: 12.5/50, 25/100
    CR capsules: 25/100
    05.03.01 Cobicistat Tybost®

    Tablets: 150mg

    11.99.99.99 Cocaine 

    unlicensed unlicensed P/F eye drops: 4%

    12.02.03 Cocaine 

    unlicensedunlicensed Drops: 4%

    04.09.01 Co-Careldopa  Tablets: 12.5/50, 10/100, 25/100, 25/250
    MR Tablets: 25/100, 50/200
    04.09.01 Co-Careldopa and Entacapone  Stalevo® and Sastravi® and Stanek® brands available in the following strengths
  • 50 mg/12.5 mg/200 mg Tablets: levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg
  • 75 mg/18.75 mg/200 mg Tablets: levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg
  • 100 mg/25 mg/200 mg Tablets: levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg
  • 125 mg/31.25 mg/200 mg Tablets: levodopa 125 mg, carbidopa 31.25 mg, entacapone 200 mg
  • 150 mg/37.5 mg/200 mg Tablets: levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg
  • 175 mg/43.75 mg/200 mg Tablets: levodopa 175 mg, carbidopa 43.75 mg, entacapone 200 mg
  • 200 mg/50 mg/200 mg Tablets: levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg
  • 13.06.02 Co-Cyprindiol 

    Generic co-cyprindiol is much cheaper than dianette

    07.03.01.02 Co-cyprindiol 2000/35 

    Tablets: Ethinyllestradiol 35 micrograms/ cyprioterone 2mg

    13.06.02 Co-Cyprindiol 2000/35
    (Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
     

    Tablet

    Generic co-cyprindiol is much cheaper than Dianette

    04.07.02 Codeine 

    Codeine phosphate
    Tablets: 15 mg, 30 mg, 60 mg
    Syrup: 25 mg/5 mL

    Injection 60mg/ml - hospital only

    03.09.01 Codeine Linctus BP  15mg/5ml
    10.01.04 Colchicine  Tablets: 500 micrograms
    Note: When treating acute gout, max. 6 mg per course; course not to be repeated within 3 days
    09.06.04 Colecalciferol  

    Capsules: 800 units, 20,000 units
    Tablets: 800units, 1000units, 25,000 units


    Liquid: Secondary care: contact pharmacy for advice regarding available brands. Primary care: use most clinically and cost effective option


    Note,Green +  for bariatric indications

    09.06.04 Colecalciferol and Calcium Carbonate  

    Please note, the following preparations are listed generically. Please be aware that the branded products issued by primary and secondary care, and patients may be changed onto an equivalent preparation depending on which products are most cost-effective.


    Tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg) Colecalciferol
    Chewable tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg) Colecalciferol
    Eff Tablets: 1.5g Calcium Carbonate (600mg Calcium) and 400 units (10mcg)
    Caplets: 750mg calcium carbonate (300mg Calcium) an 200units (5mcg) – used by secondary care, review use in primary care as more cost-effective options are available.             



    Secondary care: contact pharmacy for advice regarding available brands. Primary care: use most clinically and cost effective option

    01.09.02 Colesevelam 

    Tablets: 625mg
    Colesevelam is used for the treatment of bile acid malabsorption, but is not licensed for this indication.

    01.09.02 Colestyramine 

    Sachets: 4g

    05.01.07 Colistimethate inhaler Colobreathe® Dry powder for inhalation: 1.66 million units per capsule (Colobreathe®)

    Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy.
    05.01.07 Colistimethate sodium  Injection: 1,000,000 units, 2,000,000 units
    Powder for nebulised solution: 1,000,000 units
    01.01.01 Co-magaldrox Maalox® Sugar-free suspension

    Prescribers should choose the product with the lowest acquisition cost. In the community - Mucogel is cheaper.
    01.01.01 Co-magaldrox Mucogel® Sugar-free suspension

    Prescribers should choose the product with the lowest acquisition cost. In the community - Mucogel is cheaper.
    06.04.01.01 Combined continuous HRT patch Evorel® Conti Evorel® Conti
    Patches: Pack containing 8 patches releasing 50mcg estradiol/24 hours and 170mcg noresthisterone acetate/24 hours
    06.04.01.01 Combined continuous HRT tablet - high dose Kliofem® Kliofem®
    Tablets: 2mg estradiol and 1mg norethisterone acetate


    06.04.01.01 Combined continuous HRT tablet - low dose Premique low-dose® Premique low-dose®
    Tablets: 0.3mg conjugated oestrogen + medroxyprogesterone acetate 1.5mg
    06.04.01.01 Combined continuous HRT tablet - standard dose Kliovance® Kliovance®
    Tablets: 1mg estradiol and 500mcg norethisterone acetate

    06.04.01.01 Combined cyclical HRT patch Evorel® Sequi Evorel Sequi®
    Patches: Pack containing 4 patches releasing 50mcg estradiol/24 hours and 4 patches releasing 50mcg estradiol and 170mcg norethisterone acetate/24 hours
    06.04.01.01 Combined cyclical HRT tablet Elleste Duet® Elleste Duet®
    Tablets: Pack of 16 x 1mg estradiol tablets + 12 x 1mg estradiol and 1mg norethisterone tablets
    06.04.01.01 Combined cyclical HRT tablet Prempak-C® Prempak-C®
    Tablets: 0.625 (pack of 28 x 625mcg conjugated oestrogen tablets + 12 norgestrel 150mcg tablets)

    Tablets: 1.25 (pack of 28 x 1.25mg conjugated oestrogen tablets + 12 norgestrel 150mcg tablets)

    06.04.01.01 Combined cyclical HRT tablet Femoston® 2/10 Femoston® 2/10
    Tablets: Pack of 14 x 2mg estradiol tablets + 14 tablets containing estradiol 2mg and dydrogesterone 10mg

    06.04.01.01 Combined cyclical HRT tablet Femoston® 1/10 Femoston® 1/10
    Tablets: Pack of 14 x 1mg estradiol tablets + 14 tablets containing estradiol 1mg and dydrogesterone 10mg

    05.01.08 Co-trimoxazole  480mg in 5ml ampoules for IV infusion
    05.01.08 Co-trimoxazole  Tablets: 480mg, 960mg
    Suspension: 480mg/5ml
    08.01.05 Crizotinib 

    Capsules: 200mg, 250mg

    13.11.06 Crystal Violet 

    0.5% paint

    04.06 Cyclizine  Tablets: 50 mg
    Injection: 50 mg/1 mL
    Suspension*: 50mg/5ml
    *For paediatric use only
    11.05 Cyclopentolate  

    Eye drops: 0.5%, 1%
    Minims® (preservative free): 0.5%, 1%

    11.05 Cyclopentolate with phenylephrine 

    unlicensed unlicensed Eye drops (preservative free): 1%

    08.01.01 Cyclophosphamide 

    Tablets: 50mg 
    Injection: 1g

    23.01 Cyproheptadine hydrochloride 

    Tablets: 4 mg


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    07.05.05 Cyproterone 

    Tablets: 50mg

    08.03.04.02 Cyproterone 

    Tablets: 50mg & 100mg

    06.04.02 Cyproterone Acetate  Tablets: 50mg
    06.04.04 Cyproterone Acetate 

    Tablets: 50mg & 100mg

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    13.09 cyproterone acetate 2mg & ethinylestradiol 35 micrograms Co-cyprindiol

     

    tablet

    Generic co-cyprindiol is much cheaper than Dianette

    08.01.03 Cytarabine 

    Injections: 100mg in 5ml, 1g in 10ml
    Vial: 50mg (cytarabine encapsulated in liposomes)

    02.08.02 Dabigatran  Capsules: 75mg, 110mg, 150mg
    08.01.05 Dabrafenib Tafinlar®

    Capsules: 50mg and 75mg

  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE
  • 08.01.05 Dacarbazine 

    Injection: 500mg

    08.01.05 Dacomitinib Vizimpro®

    Dacomitinib is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides it according to the commercial arrangement.

    08.01.02 Dactinomycin 

    Injection: 500 microgram

    02.08.01 Dalteparin  Injection: (pre-filled syringe): 2,500 units/0.2ml, 5,000 units/0.2ml, 7,500 units/0.3ml, 10,000/0.4ml, 12,500 units/0.5ml, 15,000 units/0.6ml, 18,000 units/0.72ml
    02.08.01 Danaparoid sodium  Injection (ampoule): 750 units/0.6ml
    06.07.02 Danazol  Capsules: 100mg, 200mg
    10.02.02 Dantrolene  Capsules: 25 mg, 100 mg
    15.01.08 Dantrolene Sodium Dantrium Intravenous®

    Injection (vials): 20 mg

    23.01 Dantrolene sodium  

    Injection: 20 mg vials


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    06.01.02.03 Dapagliflozin  Tablets: 5mg, 10mg
    05.01.10 Dapsone 

    Tablets: 50mg, 100mg

    Used for the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists)

    05.01.07 Daptomycin  Injection (for IV infusion): 350mg, 500mg
    08.01.05 Daratumumab Darzalex ®

    20mg/ml concentrate for infusion

    09.01.03 Darbepoetin Alfa Aranesp®

    Prefilled syringes: 10, 15, 20,30, 40, 50, 60, 80, 100, 150, 300 micrograms
    Sureclick pens: 20,40,60,80, 100, 150, 300micrograms

    08.03.04.02 Darolutamide Nubeqa®

    Tablets: 300 mg

    05.03.01 Darunavir Prezista®

    Tablets: 75mg, 150mg, 400mg, 600mg, 800mg
    Oral suspension: 100mg/ml

    05.03.01 Darunavir and cobicistat Rezolsta®

    Tablets: 800mg/150mg

    08.01.05 Dasatinib 

    Tablets: 20mg, 50mg

    08.01.02 Daunorubicin 

    Injection: 20mg
    Prefilled syringes: 10mg, 15mg, 35mg & 40mg

    08.01.03 Daunorubicin/ cytarabine Vyxeos
  • Approved for untreated acute myeloid leukaemia in line with NICE
  • 13.02.02 Deegan’s ointment 

    For use on neonatal and paediatric wards only

    10.03.02 Deep heat  Rub: 35gram
    Hospital use only
    09.01.03 Deferasirox Exjade®

    Tablets:  90mg, 180mg, 360mg

    08.03.04.02 Degarelix Firmagon®

    Green+ Traffic Light OR Amber Traffic Light

     

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Vials (with diluent): 80mg & 120mg

    06.05.02 Demeclocycline  Capsules: 150mg
    06.06.02 Denosumab 

    Injection (pre-filled syringe): 60mg/1mL
    Vials: 120mg/1.7ml

    To be used in line with NICE TA204

     

    Note: Recommendation that denosumab is reclassified from Amber to Green Plus at JFC meeting May 2018. Green Plus leaflet discussed at June MOGG meeting - required changes and deferred to August 2018 meeting.

     

    13.02.01 Dermol 500 lotion Liquid paraffin 2.5%, isopropyl myristate 2.5%, benzalkonium dihydrochloride 0.1%c Dermol 500 lotion®

    500ml

     

    1st line emollients with antibacterial properties

    13.02.01 Dermol cream Liquid paraffin 2.5%, isopropyl myristate 2.5%, benzalkonium chloride 0.1% chlorhexadine dihydrocodiene 0.1% Dermol®

    500ml

     

    1st line emollients with antibacterial properties

    09.01.03 Desferrioxamine Mesilate 

    Injection: 500mg, 2g

    23.01 Desferrioxamine mesilate 

    Injection: 500 mg, 2 g vials


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    15.01.02 Desflurane Suprane®

    240ml

    06.05.02 Desmopressin  Metered nasal spray: 10 micrograms/spray
    Tablets: 100 micrograms, 200 micrograms
    Oral lyophilisate: 60 micrograms, 120 micrograms, 240 micrograms
    *Oral lyophilisate (Noqdirna): 25mcg, 50mcg
    Intranasal solution: 100 micrograms/1mL

    *Only to be used in line with NICE guidance CG171 and CG97
    06.05.02 Desmopressin  Injection: 4 micrograms/1mL, 15 micrograms/1mL
    Metered nasal spray: 150 micrograms/spray (Unlicensed)
    07.04.02 Desmopressin 

    Tablets: 100 microgram, 200 microgram
    Sublingual tablets: 120 microgram

    07.03.02 Desogestrel 

    Tablets: 75 microgram


    (Brands: Cerelle®(preferred) , Cerazette®, Zellata®

    06.03.02 Dexamethasone  Tablets: 500 micrograms, 2mg
    Oral solution (sugar-free): 2 mg/5mL
    Soluble tablets: 2mg,4mg, 8mg

    N.B. Sodium content of soluble tablets:
    2mg tablet - 14.96 mg sodium
    4 mg tablet - 29.95 mg sodium
    8 mg tablet - 60.50 mg sodium
    06.03.02 Dexamethasone  Injection: (as sodium phosphate) 3.3mg/1mL, 6.6mg/2mL
    11.04.01 Dexamethasone 

    Eye drops: 0.1%
    Minims® (preservative free): 0.1%

    10.01.02.02 Dexamethasone (as sodium phosphate)  Injection: 3.3 mg/1 mL, 4 mg/1 mL, 6.6 mg/2 mL, 8 mg/2 mL
    11.04.01 Dexamethasone intravitreal implant 

    Intravitreal implant: 700 micrograms

    11.04.01 Dexamethasone with framycetin and gramicidin Sofradex®

    Eye/Ear drops

    12.01.01 Dexamethasone with framycetin sulfate and gramicidin Sofradex®

    Ear drops: 0.05% with framycetin sulfate 0.5% and gramicidin 0.005% (Sofradex®)

    12.01.01 Dexamethasone with Neomycin Otomize®

    Ear spray: 0.1% with neomycin sulfate 3250 units/1 mL and glacial acetic acid 2% (Otomize®)

    11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®

    Eye drops: 0.1%
    Eye ointment: 0.1%

    04.04 Dexamfetamine 

    Tablets: 5mg

    ADHD in children and adults : AMBER -  see shared care guideline.

    Narcolepsy: Doses up to 30mg GREEN +, doses over 30mg RED

    15.01.04.04 Dexmedetomidine  

    Injection (vials): 1 mg/10 mL

    08.01 Dexrazoxane Savene®

    Vials: 500mg (with diluent)
    - for use in line with NECN extravasation

    06.01.04 Dextro Energy® Tablets  Tablets: (47g) – glucose 80%
    24.01 Diagnostic Agents used at City Hospitals Sunderland  

    Accu-chek Inform II® Test Strip
    Combur 9® Strips
    RedEdrophonium Injection
    Glucose Powder 75 g
    Redunlicensed unlicensed Indigocarmin 0.4% (20 mg/5 mL) injection ampoules
    RedIndocyanine Green 25 mg Vial
    Ketostix® Test Strip
    Redunlicensed unlicensed Patent Blue V® 2 mL vial
    Redunlicensed unlicensed Adenosine injection 1 mg/1 mL, 100 mL, 120 mL, 130 mL
    Redunlicensed unlicensed Ajmaline injection 50 mg/10 mL ampoules

    10.02.01 Diaminopyridine  Tablets: 20mg
    04.07.02 Diamorphine 

    Injection: 5 mg, 10 mg, 30 mg, 100 mg, 500 mg
    N.B. 10mg strength also used in maternity

    Specialist initiation only - consult pain team or palliative care before use.

    04.01.02 Diazepam  Tablets: 2mg, 5mg
    2mg tablets are the preferred strength in primary care. 10mg diazepam tablets should no longer be used

    Oral solution: 2mg/5ml
    Injection: 10mg/2ml - for use in epilepsy
    Rectal tubes: 2.5mg/1.25ml, 5mg/2.5ml, 10mg/2.5ml
    04.08.02 Diazepam  Injection: 5 mg/1 mL
    Rectal solution: 2.5 mg, 5 mg, 10 mg
    10.02.02 Diazepam 

    Tablets: 2 mg, 5 mg
    Oral solution (sugar-free available): 2 mg/5 mL

    23.01 Diazepam (emulsion) 

    Injection: 10 mg/2 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    06.01.04 Diazoxide  Suspension: 5mg/5ml*
    *Hospital use only - for insulin resistance in paediatrics
    11.08.02 Diclofenac 

    Eye drops: 0.1%
    Unit dose eye drops (preservative-free): 0.1%

    10.01.01 Diclofenac sodium  Tablets: 25mg, 50mg
    10.01.01 Diclofenac Sodium 

    Injection: 75 mg/3 ml
    To be used in secondary care only

    23.01 Dicobalt edetate  

    Injection: 300 mg/20 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    05.03.01 Didanosine Videx®

    Chewable tablets: 25mg
    E/C capsules: 125mg, 200mg, 250mg, 400mg

    08.03.01 Diethylstilbestrol 

    Tablets: 1mg

    02.01.01 Digoxin  Tablets: 62.5 micrograms, 125 micrograms, 250 micrograms
    Liquid: 50 micrograms/1ml
    Injection: 500 micrograms/2ml
    23.01 Digoxin specific antibody fragments (Digifab®)  

    Injection: 40 mg vial


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    04.07.02 Dihydrocodeine 

    SR Tablets: 60mg, 90mg, 120mg
    SR formulation only to be used on advice of pain specialists

    Not recommended for regular use. Codeine is the first line weak opioid.

    04.07.02 Dihydrocodeine 

    Tablets: 30mg

     

    Not recommended for regular use. Codeine is the first line weak opioid.

    02.06.02 Diltiazem  Tablets: 60mg
    SR preparation (twice daily): 60mg, 90mg, 120mg, 180mg
    XL preparation (once daily): 120mg, 180mg, 200mg, 240mg, 300mg, 360mg

    Must be prescribed by brand
    01.07.04 Diltiazem Cream 2%  Cream: 2%
    For use in patients with anal fissures who do not respond to or cannot tolerate topical glyceryl trinitrate. This is an unlicensed product.
    08.02.04 Dimethyl fumarate 

    Capsules: 120mg, 240mg

    13.05.02 Dimethyl fumarate Skilarence

    30mg and 120mg tablets

     

    Other treatments for psoriasis

    13.10.04 Dimeticone 4% Hedrin®

    50ml lotion, 150ml lotion

    07.01.01 Dinoprostone 

    Injection: 0.75mg in 0.75ml
    Vaginal tablets: 3mg
    Vaginal gel: 1mg/2.5ml, 2mg/2.5ml

    08.02.04 Dinutuximab beta Qarziba®
  • 20mg/4.5mL concentrate for solution for infusion
  • Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE
  • 14.04 Diphtheria vaccines for Children Under 10 years 

    Diphtheria, Tetanus, Pertussis (acellular, 3-component), polio,Haemophilus influenzae type b (Hib) and hepatitis B vaccine (DTaP/IPV/Hib/HepB)
    Vial with solvent in a pre-filled syringe 0.5 mL (Infanrix hexa®)
    May contain traces of formaldehyde, neomycin and polymyxin B


     


    Diphtheria, Tetanus, Pertussis (acellular, 3-component) and Poliomyelitis (inactivated) vaccine (DTaP/IPV)
    Prefilled syringe: 0.5 mL (Infanrix-IPV®)
    May contain traces of formaldehyde, neomycin and polymyxin B


     


    Diphtheria (low dose), Tetanus, Pertussis (acellular, 5-component) and Poliomyelitis (inactivated) vaccine (dTaP/IPV)
    Prefilled syringe: 0.5 mL (REPEVAX®, Boostrix-IPV®)
    REPEVAX® may contain traces of formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin
    Boostrix-IPV® may contain traces of neomycin and polymyxin B


     


    Diphtheria, Tetanus, Pertussis (acellular, 5-component), Poliomyelitis (inactivated) and Haemophilus influenzae type b vaccine (DTaP/IPV/Hib)
    Prefilled syringe: 0.5mL (Pediacel®)

    14.04 Diphtheria vaccines for over 10 years and adults 

    Diphtheria (low dose), Tetanus and Poliomyelitis (Inactivated) vaccine (Td/IPV)
    Prefilled syringe: 0.5 mL (Revaxis®)
    May contain traces of streptomycin, neomycin and polymyxin B

    13.02.01 Diprobase® Diprobase ointment®

    50g, 500g

     

    2nd line ointments

    02.09 Dipyridamole  SR capsules: 200mg
    Sugar-free suspension: 50mg/5ml
    14.05.02 Disease-specific immunoglobulins 

    Preparations stocked by pharmacy:


    Tetanus immunoglobulin (HTIG): 250 units


     


    Other immunoglobulins


    The following immunoglobulins are kept at the Pharmacy Distribution Centre, Royal Victoria Infirmary, Newcastle upon Tyne, and can be obtained via the Clinical Virology Team at Newcastle Hospitals:



    • Hepatitis B immunoglobulin (HBIG): contact on-call virologist (24/7)

    • Rabies immunoglobulin (HRIG) and also vaccine: contact first on-call for Health Protection at Public Health England NE (24/7)

    • Varicella-zoster immunoglobulin (VZIG): contact virologist (office hours, or 24/7 if close to end of window period - 10 days in pregnancy, 7 days in immunosuppressed)

    • Human Normal Immunoglobulin (HNIG) for HAV and measles post-exposure prophylaxis: contact on-call virologist 24/7


    From blood bank


    Anti D (Rh0) immunoglobulin

    11.03.01 Disodium Edetate 

    unlicensed Eye drops: 0.37%

    06.06.02 Disodium Pamidronate  IV infusion: 15mg/1mL, 15 mg/5mL, 30 mg/2mL, 30 mg/10mL, 60 mg/4mL, 60 mg/10mL, 90 mg/6mL, 90 mg/10mL
    Injection: 15mg, 30mg, 90mg
    09.05.01.02 Disodium pamidronate 

    Injection: 30mg

    02.03.02 Disopyramide  Injection: 50mg/5ml
    02.03.02 Disopyramide  Capsules: 100mg, 150mg
    04.10.01 Disulfiram  Tablets: 200 mg
    13.05.02 Dithranol Dithrocream®

    Cream - 0.1%, 0.25%, 0.5%, 1.0%, 2.0%

     

    1st line Dithranol preperations

    13.05.02 Dithranol in Full Strength Lassar’s Paste 

    0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6%, 8%

     

    13.05.02 Dithranol with Salicylic Acid 

    Dithranol 1% and salicyclic acid 2% in emulsifying ointment 100g

    Dithranol 2% and salicyclic acid 2% in emulsifying ointment 100g

    Dithranol 4% and salicyclic acid 2% in emulsifying ointment 100g

    Dithranol 8% and salicyclic acid 2% in emulsifying ointment 100g

    Dithranol 16% and salicyclic acid 2% in emulsifying ointment 100g

    02.07.01 Dobutamine  Injection: 250mg/20ml and 250mg/50ml; pre-filled syringe in 5% dextrose
    08.01.05 Docetaxel 

    Injections: 20mg, 80mg

    01.06.02 Docusate Sodium  Capsules: 100mg
    Liquid: 12.5mg/5ml*, 50mg/5ml
    * for use in paediatrics only
    05.03.01 Dolutegravir Tivicay®

    Tablets: 10mg, 25mg, 50mg

    05.03.01 Dolutegravir, abacavir and lamivudine Triumeq®

    Tablets: 50mg/600mg/300mg

    01.02 Domperidone  Tablets: 10mg
    Liquid: 5mg/5ml
    04.06 Domperidone  Tablets: 10 mg
    Liquid: 5 mg/5 mL
    Suppository: 30 mg
    04.11 Donepezil  Tablets: 5 mg, 10 mg
    Orodispersible tablets: 5mg, 10mg
    02.07.01 Dopamine  Injection: 200mg/5ml ampoule and prefilled syringe in 5% dextrose
    02.07.01 Dopexamine 

    Injection for infusion: 50mg/5ml (Dopacard)


    Used in critical care at City Hospitals Sunderland

    03.07 Dornase Alfa Pulmozyme® Vial: 2.5mg (2500 units)/2.5ml

    Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy
    11.06 Dorzolomide 

    Eye drops: 2%
    Eye drops PF: 2% (Brands include Eydelto PF)
    P/F unit dose eye drops: 2%

    11.06 Dorzolomide with Timolol 

    Eye drops: dorzolamide 2%, timolol 0.5% (Cosopt®) (Eylamdo PF)
    Single use (preservative free): dorzolamide 2%, timolol 0.5% (Cosopt®)

    04.03.01 Dosulepin  Capsules*: 25mg
    Tablets*: 75mg
    *For existing patients only - no new patients
    03.05.01 Doxapram Dopram® Injection: 100mg/5ml
    Infusion: 2mg/1ml in 5% glucose (500ml)
    15.01.07 Doxapram 

    Injection: 100 mg in 5 mL ampoules
    Infusion: 2 mg/ mL, 500 mL intravenous infusion in glucose 5%

    02.05.04 Doxazosin  Tablets: 1mg, 2mg and 4mg
    N.B. 4mg M/R and 8mg M/R are not included in this formulary - plain tablets are less expensive
    07.04.01 Doxazosin 

    *Tablets: 1mg, 2mg, 4mg
    *Legacy patients only

    08.01.02 Doxorubicin Hydrochloride 

    Injection: 50mg
    - includes use with DC Beads for use in transcatheter arterial chemoembolisation (TACE) therapy in patients with hepatocellular cancer

    Pegylated liposomal injection: 20mg & 50mg
    -approved for the treatment of recurrent ovarian cancer in line with NICE

    05.01.03 Doxycycline  Capsules: 50mg, 100mg
    Dispersible tablets: 100mg
    05.01.03 Doxycycline  Injection: 100mg
    13.06.02 Doxycycline 

     

    Last line oral preperations for acne

    02.03.02 Dronedarone  Tablets: 400mg
    03.01.05 Drug Delivery Device Volumatic® Available with or without paediatric mask
    03.01.05 Drug Delivery Device AeroChamber Plus® Infant (orange with mask)
    Child (yellow with mask)
    Adult (blue with or without mask)
    06.01.02.03 Dulaglutide  Injection (pre-filled pen): 0.75mg/0.5ml, 1.5mg/0.5ml
    04.03.04 Duloxetine  Capsules: 30mg, 60mg
    - For use on advice of psychiatrists as a 3rd line antidepressant but only for use in patients who cannot tolerate high dose (>150mg daily) venlafaxine, or patients with hypertension, established CHD or other cardiovascular risk factors which would make the use of high dose venlafaxine undesirable.
    04.07.03 Duloxetine  Capsules: 30mg, 60mg
    06.01.05 Duloxetine  Capsules: 30mg, 60mg
    07.04.02 Duloxetine 

    *Capsules: 20mg, 40mg
    (*Moderate to severe stress incontinence in combination with supervised pelvic floor excercises only)

    13.05.03 Dupilumab 

    300mg/2ml soln for inj in pre-filled syringe

     

     

    08.02.04 Durvalumab Imfinzi®

    Durvalumab (Imfinzi®) monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small cell lung cancer in adults whose tumours express PD‑L1 on at least 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation only if:

    • they have had concurrent platinum-based chemoradiation, and
    • the conditions in the managed access agreement are followed.
    06.04.02 Dutasteride  Capsules: 500 micrograms
    07.04.01.02 Dutasteride 

    Capsules: 500micrograms

    09.01.03 Eculizumab 

    Solution for infusion: 300mg

    02.08.02 Edoxaban 

    Tablets: 15mg, 30mg, 60mg

    10.02.01 Edrophonium Chloride 

    Injection: 10 mg/1 mL
    Hospital use only. This is only used as a diagnostic test in some suspected cases of MG. It has a brief effect to improve the symptoms.

    05.03.01 Efavirenz Sustiva®

    Tablets: 600mg
    Capsules: 50mg, 100mg 200mg

    07.05.05 Eflornithine  Vaniqa®

    Cream: 11.5%

    13.09 Eflornithine 

    11.5% cream

    09.01.04 Eltrombopag Revolade®

    1st line for ITP patients who require treatment for bleeding, profound thrombocytopenia or to cover surgery during the Covid-19 pandemic
    3rd line for severe, refractory ITP – choice according to patient preference

    Tablets: 25mg, 50mg, 75mg

    01.04.02 Eluxadoline Truberzi

    Tablets: 75mg, 100mg

    05.03.01 Elvitegravir Vitekta

    Tablets: 85mg, 150mg

    13.02.01 Emollient preparation ZeroAQS®

    500g

    13.02.01 Emollient preparation Epaderm®

    50g, 150g, 500g

    06.01.02.03 Empagliflozin 

    Tablets: 10mg, 25mg

    05.03.01 Emtricitabine Emtriva®

    Capsules: 200mg
    Oral solution: 10mg/ml

    05.03.01 Emtricitabine and tenofovir Descovy®

    Tablets: 200mg/10mg
    Tablets: 200mg/25mg 

    05.03.01 Emtricitabine rilpivirine and tenofovir Eviplera®

    Tablets: 200mg/25mg/245mg

    05.03.01 Emtricitabine, rilpivirine and tenofovir Odefsey®

    Tablets: 200mg/25mg/25mg

    13.02.01 Emulsifying wax 30%, WSP 50%, liquid paraffin 20% Emulsifying Ointment BP

    50g, 100g, 250g, 500g

     

    1st line ointments

    02.05.05.01 Enalapril   Tablets*: 2.5mg, 5mg, 10mg, 20mg
    *For existing patients only, no new patients to be started on enalapril
    08.01.05 Encorafenib Braftovi®

    Capsules: 50 mg and 75 mg

    05.03.01 Enfuvirtide Fuzeon®

    Powder and solvent for solution for injection vials: 108mg

    02.08.01 Enoxaparin  Injection (pre-filled syringe): 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 300mg/3ml, 120mg/0.8ml, 150mg/1ml
    04.09.01 Entacapone  Tablets: 200 mg
    05.03.03.01 Entecavir  Tablets: 500 micrograms (white), 1mg (pink)
    Oral solution: 250 micrograms/5ml
    15.01.02 Entonox® 
    08.01.05 Entrectinib 

    Capsules: 100mg and 200mg

    08.03.04.02 Enzalutamide 

    Tablets: 40mg

    13.02.01 Epaderm ointment  Epaderm ointment ®

    125g, 500g

     

    3rd line ointments

    02.07.02 Ephedrine 

    Injection:30mg/1ml amps
    Prefilled syringe: 30mg/10ml


    Used in critical care at City Hospitals Sunderland

    08.01.02 Epirubicin hydrochloride 

    Injections: 50mg
    unlicensedunlicensed Injection: 100mg  

    02.02.03 Eplerenone 

    Tablets: 25mg, 50mg

    09.01.03 Epoetin alfa Eprex®

    Injection (pre-filled syringe): 1000, 2000, 3000, 4000, 5000, 6000, 8000, 10000, 20000, 30000, 40000units

    09.01.03 Epoetin beta NeoRecormon®

    Injection (pre-filled syringe): 500 units, 2,000 units, 3,000 units, 4,000 units, 5,000 units, 6,000 units, 10,000 units, 20,000 units, 30,000 units

    09.01.03 Epoetin Zeta 

    Injection (pre-filled syringe): 1000 units, 2000 units, 3000 units, 4000 units, 5000 units, 6000 units, 8000 units, 10000 units, 20000 units, 30000 units, 40000 units

    02.08.01 Epoprostenol 

    Infusion vial: 500 micrograms

    09.06.04 Ergocalciferol 

    Injection: 300,000 units/1 mL, 600,000 units/2 mL

    07.01.01 Ergometrine 

    Injection: 500 micrograms in 1ml

    07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®

    Injection: ergometrine maleate 500micrograms and oxytocin 5 units

    08.01.05 Eribulin Halaven®

    Vial: 0.88mg/2ml
    Vial: 1.32mg/3ml

    08.01.05 Erlotinib Tarceva®

    Tablets: 25mg, 100mg & 150mg

    05.01.02.02 Ertapenem  Injection: 1g
    06.01.02.03 Ertugliflozin 

    Tablets: 5mg, 15mg

    Approved as monotherapy or with metformin for the treatment of type 2 diabetes in line with NICE

    05.01.05 Erythromycin 

    Injection for infusion: 1g vial*


    *For use as a prokinetic

    05.01.05 Erythromycin  Tablets: 250mg, 500mg
    Oral suspension (sugar-free available): 125mg/5ml, 250mg/5ml, 500mg/5ml
    13.06.02 Erythromycin 

     

    Last line preperations for acne

    13.06 Erythromycin 2%topical solution 
    13.06 Erythromycin 40mg with Zinc Acetate 12mg/mL Zineryt®

    30ml, 90ml

    02.04 Esmolol  Injection: 100mg/10ml
    Infusion: 2.5g/250ml
    06.04.04 Estradiol 

    Tablets: 1 mg & 2 mg

    Patches: Twice weekly matrix patches releasing approximately 25, 50, 75 & 100 microgram/24 hours

    Gel: 0.5 mg & 1 mg sachets; 28 sachets (Sandrena®)
    Gel: 0.06% (0.75 mg per actuation); 80 g pump (Oestrogel®)

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    07.02.01 Estradiol 

    Vaginal tablets: 10 microgram (Oestradiol)


     

    08.01.01 Estramustine 

    Capsules: 140mg

    07.02.01 Estriol 

    Cream: 0.01% (Gynest) 80g 
    Cream: 0.1% (Ovestin)

    10.01.03 Etanercept  

    Injection (pre-filled syringe) (Enbrel) 25mg, 50mg

    Injection (pre-filled syringe) (Benepali) 50mg

    Injection (vial) (Enbrel) 25mg

    Injection (paediatric) (Enbrel) 10mg, 25mg

    13.05.03 Etanercept 

    25mg, 50mg  injection (Enbrel & Benapali)

     

     

     

    09.05.01.02 Etelcalcitide 

    Vials: 2.5mg in 0.5ml, 5mg in 1ml, 10mg in 1ml

    05.01.09 Ethambutol  

    Tablets: 100mg, 400mg
    Suspension: 400mg/5ml. This is the nationally recommended standard strength.

    Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.

    11.03.01 Ethanol  

    unlicensed P/F Eye Drops: 18%

    04.08.01 Ethosuximide  Capsules: 250 mg
    Liquid: 250 mg/5 mL
    15.02 Ethyl Chloride 

    Spray: 100 mL

    10.01.01 Etodolac  Capsules: 300mg
    MR tablets: 600mg
    15.01.01 Etomidate Hypnomidate®

    Injection: 20 mg/10 mL ampoules
    Injection (emulsion): 20 mg/10 mL ampoules (Lipuro®)

    07.03.02.02 Etonorgestrel Nexplanon®

    Implant: 68mg

    08.01.04 Etoposide 

    Capsules: 50mg & 100mg
    Injections: 100mg in 5ml & 500mg in 25ml

    10.01.01 Etoricoxib 

    Tablets: 30mg, 60mg, 90mg, 120mg


    Indications:
    Long-term for ankylosing spondylitis

    10.01.04 Etoricoxib 

    Tablets: 120 mg

    Note: Maximum of 8 days treatment for gout

    05.03.01 Etravirine Intelence®

    Tablets: 25mg, 100mg, 200mg

    08.01.05 Everolimus Votubia®

    Capsules: 2.5mg, 5mg, 10mg


    -Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
    -a
    pproved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy


    Tablets: 5mg and 10mg


    - Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
    - Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
    - Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    -Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE


     

    02.12 Evolocumab Repatha®

    Solution for injection (pre-filled syringe): 140mg/ml
    Solution for injection (pre-filled pen): 140mg/ml

    To be used in line with NICE TA394
    N.B. Supply currently only available via secondary care. No prescribing in primary care.

    07.03.01.05 Evra® 

    *Self adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin /24hours


     


    *For use in a small number of women with gastrointestinal absorption problems or with compliance issues

    08.03.04.01 Exemestane 

    Tablets: 25mg

    06.01.02.03 Exenatide  Injection (250 microgram/1ml pre-filled pens): 5 microgram/dose, 10 microgram/dose

    MR Pen: 2mg pen
    02.12 Ezetimibe  Tablets: 10mg
    10.01.04 Febuxostat 

    Tablets: 80 mg, 120 mg

    02.06.02 Felodipine  M/R tablets: 2.5mg, 5mg, 10mg
    07.03.01 Femodene® 

    Tablets: Ethinylestradiol 30mcg / gestodene 75 mcg

    07.03.01 Femodene® ED 

    Tablets: Ethinylestradiol 30mcg / gestodene 75 mcg

    07.03.01.04 Femodette® 

    Tablets: Ethinylestradiol 20mcg / gestodene 75 mcg

    07.03.02 Femulen® 

    Tablets: 500microgram (Ethynodiol)

    02.12 Fenofibrate  Capsules: 67mg, 200mg, 267mg
    Tablets: 160mg
    04.07.02 Fentanyl  Transdermal patches: 12, 25, 50, 75 and 100 micrograms/hour
    15.01.04.03 Fentanyl 

    Injection: 100 micrograms/2 mL, 500 micrograms/10 mL ampoules
    With levobupivacaine
    unlicensedunlicensed Levobupivacaine 0.1% with fentanyl 2 micrograms, 500 mL infusion bag

    04.07.02 Fentanyl Lozenges 

    Lozenges*: 200mcg, 400mcg

    *Existing chronic or palliative care patients only

    04.07.02 Fentanyl Nasal Spray PecFent®

    Nasal spray (PecFent): 100 micrograms/metered spray, 400 micrograms/metered spray

    N.B. For short term use in palliative care only.

    Specialist initiation only - consult pain team or palliative care before use.

    04.07.02 Fentanyl sublingual tablets Abstral®

    Sublingual tablets (Abstral): 100 micrograms, 200 micrograms, 300 micrograms, 400 micrograms, 600 micrograms, 800 micrograms

    N.B. For short term use in palliative care only.

    Specialist initiation only - consult pain team or palliative care before use.

    09.01.01.02 Ferric Carboxymaltose Ferinject®

    Solution for injection: 100mg/2ml, 500mg/10ml

    09.01.01.01 Ferric maltol Feraccru

    Capsules: 30mg

    09.01.01.01 Ferrous Fumarate Fersaday®

    Tablets: 210mg (68mg iron)
    Syrup 140mg/5ml

    09.01.01.01 Ferrous Sulphate 

    Tablets: 200mg (65mg elemental iron)

    07.04.02 Fesoterodine 

    MR tablets: 4mg, 8mg

    03.04.01 Fexofenadine  Tablets: 120mg, 180mg

    Only after trialling other options
    05.01.07 Fidaxomicin 

    Tablets: 200mg

    MUST ONLY BE PRESCRIBED ON THE ADVICE OF A MICROBIOLOGIST

    See also link above to Risk assessment tool for C Difficile.

    09.01.06 Filgrastim Neupogen®

    (1st line) Injection (Nivestim® - biosimilar): 12 million units (120 micrograms)/0.2mL, 30 million units (300 micrograms)/0.5mL, 48 million units (480 micrograms)/0.5mL


    Injection (Neupogen®): 30 million units (300 micrograms)/mL


    Injection (pre-filled pen, Neupogen® Singleject®): 30 million units (300 micrograms)/0.5mL, 48 million units (480 micrograms)/0.5 mL

    06.04.02 Finasteride  Tablets: 5mg
    06.04.04 Finasteride 

    Tablets: 5 mg

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    07.04.01.02 Finasteride 

    Tablets: 5mg

    07.05.05 Finasteride 

    Tablets: 1mg

    08.02.04 Fingolimod 

    Capsules: 500microgram - - approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE - approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line withNHS EnglandClinical Commissioning Policy

    02.03.02 Flecainide  Injection: 150ml/15ml
    02.03.02 Flecainide  Tablets: 50mg, 100mg
    13.04 Flucinolone Acetonide 0.025% Synalar®

    Cream, ointment, gel

     

    Potent topical corticosteroids

    13.04 Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N®

    Cream, ointment

     

    1st line potent topical corticosteroids with antimicrobials

    05.01.01.02 Flucloxacillin  Capsules: 250mg, 500mg
    Oral solution (sugar-free available): 125mg/5ml, 250mg/5ml
    05.01.01.02 Flucloxacillin  Injection: 250mg, 500mg, 1g
    05.02 Fluconazole  Capsules: 50mg, 150mg, 200mg
    Oral solution: 50mg/5ml, 200mg/5ml
    05.02 Fluconazole  IV infusion: 50mg/25ml, 200mg/100ml
    12.03.02 Fluconazole 

    Capsules: 50 mg, 150 mg, 200 mg Oral solution: 50 mg/5mL, 200 mg/5mL

    08.01.03 Fludarabine 

    Tablets: 10mg
    Injection: 50mg

    06.03.01 Fludrocortisone  Tablets: 100 micrograms
    13.04 Fludroxycortide  Haelan®

    (4mcg/cm2)

     

    1st line moderately potent topical corticosteroids

    15.01.07 Flumazenil Anexate®

    Injection (amps): 500 micrograms/5 mL

    23.01 Flumazenil 

    Injection: 500 micrograms/5 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    12.01.01 Flumetasone with Clioquinol  Locorten-Vioform®

    Ear drops: flumetasone (as pivalate) 0.02% and clioquinol 1% ear drops

    13.04 fluocinolone acetonide 0.025% with clioquinol 3% Synalar C®

    Cream, ointment

     

    1st line potent topical corticosteroids with antimicrobials

     

     

    11.04.01 Fluocinolone intravitreal implant 

    Intravitreal implant: 190 micrograms

    11.08.02 Fluorescein Sodium 

    Minims® (preservative free): 1%, 2%

    11.04.01 Fluorometholone FML®

    Eye drops: 0.1% with polyvinyl alcohol 1.4%

    08.01.03 Fluorouracil 

    Injections: 2.5g in 50ml & 2.5g in 100ml
    unlicensedunlicensed Subconjunctival injection: 10mg in 0.4ml
    (FOLFIRINOX is approved for the management of selected patients with inoperable pancreatic cancer in patients with performance status 0-1).

    13.08.01 Fluorouracil Efudix®

    5% cream

    04.03.03 Fluoxetine  Fluoxetine
    Capsules: 20 mg
    Dispersible tablets: 20mg - 1st choice in patients unable to use the capsules
    Liquid: 20 mg/5 mL
    04.02.01 Flupentixol  Tablets: 500 microgram, 1mg, 3mg
    04.02.02 Flupentixol Decanoate  Injection: 20mg/1ml, 40mg/2ml, 50mg/0.5ml, 100mg/1ml, 200mg/1ml
    10.01.01 Flurbiprofen  Tablets: 50mg, 100mg
    For use in Sunderland eye infirmary only
    08.03.04.02 Flutamide 

    Tablets:  250mg

    12.02.01 Fluticasone furoate 

    Nasal spray: 27.5 micrograms/spray

    03.02 Fluticasone furoate & vilanterol Relvar Ellipta®

    Revlar Ellipta Dry Powder Inhaler

    92/22: Fluticasone 92mcg & Vilanterol 22mcg per dose inhaler

    First choice for new patients

     

    184/22: Fluticsone184 mcg & Vilanterol 22mcg per dose inhaler 

    Approved for use in the treatment of ASTHMA only.

    03.01.04 Fluticasone Furoate/Umeclidinium bromide/Vilanterol 92/55/22mcg Trelegy Ellipta®

    Trelegy Ellipta ® 92/55/22 mcg Dry Powder Inhaler

    Triple therapy ICS/LAMA/LABA inhaler for COPD.

    Formulary approved for use in COPD only.

     

    03.02 Fluticasone propionate  Alternative corticosteroid

    CFC-free MDI: 50mcg, 125mcg, 250mcg per puff
    12.02.01 Fluticasone Propionate 

    Nasal spray: 50 micrograms/spray
    Nasal drops: 400 micrograms/unit dose

    03.02 Fluticasone propionate and formoterol Flutiform®

    Flutiform® MDI


    50/5mcg per puff
    125/5mcg per puff
    250/10mcg per puff

    03.02 Fluticasone propionate and salmeterol Seretide®

    Seretide Evohaler ®
    50/25 mcg, 125/25mcg and 250/25mcg

    Seretide Accuhaler ®
    100/50mcg (for paediatric use only)
    250/50mcg (for use in asthma only)
    500/50mcg (for use in asthma only)

    Approved for the treatment of ASTHMA only

    Not a first line choice on the Sunderland COPD guideline for new patients. Can be continued in existing patients if guideline options are unsuitable.

    09.01.02 Folic Acid 

    Tablets: 400micrograms, 5mg
    Oral solution: 2.5mg/5ml (sugar-free available)
    unlicensed unlicensed Injection: 15mg/1ml

    23.01 Folinic acid (calcium folinate) 

    Injection: 30 mg/10 mL, 300 mg/30 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    06.05.01 Follitrophin alfa Gonal F®

    Prefilled pens: 300 units

    23.01 Fomepizole (4-methylpyrazole)  

    Injection: 100 mg/20 mL, 1.5 g/1.5 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    02.08.01 Fondaparinux  Injection (pre-filled syringe): 2.5mg/0.5ml
    13.07 Formaldehyde 

    10%, 75% & 90% solutions

    03.01.01.01 Formoterol   Breath actuated DPI: 6mcg/puff, 12mcg/puff
    05.03.01 Fosamprenavir Telzir®

    Tablets: 700mg
    Oral suspension: 50mg/ml

    04.06 Fosaprepitant Ivemend®

    150mg powder for infusion vials

    Approved for second-line use when oral aprepitant is not tolerated

    05.01.07 Fosfomycin Monuril Sachets: 3g
    04.07.04.02 Fremanezumab Ajovy®

    Solution for injection: pre-filled syringes 225mg/1.5mL

    Recommended for use according to NICE criteria (TA631)

    13.05.02 Fumaric acid esters 

    30mg and 120mg tablets

     

    Other treatments for psoriasis

    02.02.02 Furosemide  Tablets: 20mg, 40mg, 500mg
    Liquid: 1mg/1ml, 20mg/5ml, 40mg/5ml
    Injection: 20mg/2ml, 50mg/5ml, 250mg/25ml
    11.03.01 Fusidic Acid Fucithalmic®

    Eye drops in gel basis (liquifies on contact with eye: 1%)

    13.10 Fusidic Acid 2% 

    Cream and ointment

    04.07.03 Gabapentin  Capsules: 100mg, 300mg, 400mg
    Tablets: 600mg, 800mg
    Oral solution: 250mg/5ml
    04.08.01 Gabapentin  Capsules: 100 mg, 300 mg, 400 mg
    Tablets: 600 mg, 800 mg
    Oral solution: 50mg/mL
    06.01.05 Gabapentin  See section 4.8 for preparations
    17 Gadobutrol Gadovist® 1mmol/mL as 7.5 mL
    17 Gadoxetate Primovist®

    0.25 mmol/mL as a 10 mL pre-filled syringe

    04.11 Galantamine 

    Tablets: 8 mg, 12 mg
    MR capsules: 8mg, 16mg, 24mg
    Oral solution (sugar-free): 4 mg/1 mL
    (preferred brand in primary care is Luventa XL)

    04.07.04.02 Galcanezumab Emgality®

    Solution for injection: Pre-filled pen 120 mg/1 mL

    Recommended for use according to NICE criteria (TA659)

    05.03.02.02 Ganciclovir  IV infusion: 500mg
    11.03.03 Ganciclovir 

    Eye gel: 0.15%

    17 Gastrografin® 

    100 mL Contains sodium amidotrizoate, meglumine amidotrizoate

    01.01.02 Gaviscon Advance  Sugar-free suspension (sodium alginate 500 mg, potassium bicarbonate 100 mg/5 mL. Contains 2.3 mmol Na+/5mL)

    Tablets (sodium alginate 500 mg, potassium bicarbonate 100 mg. Contains 2.25 mmol Na+/tablet)
    01.01.02 Gaviscon Infant  Oral powder, sugar-free
    07.03.01.04 Gedarel 20/150 ® 

    Tablets: Ethinylestradiol 20mcg / desogestrel 150mcg

    07.03.01 Gedarel 30/150 ® 

    Tablets: Ethinylestradiol 30mcg / desogestrel 150mcg

    08.01.05 Gefitinib Iressa®

    Tablets: 250mg

    09.02.02.02 Gelatin Gelofusine®

    Isoplex Intravenous Infusion: 500 mL
    Volplex Intravenous Infusion: 500 mL
    Gelofusine Intravenous Infusion: 500 mL

    12.03.01 Gelclair® 

    Oral gel sachets: 15 mL

    08.01.03 Gemcitabine 

    Injection: 200mg, 1g, 2g

    07.01.01 Gemeprost 

    Pessaries: 1mg

    08.01.05 Gemtuzumab ozogamicin Mylotarg®
  • Approved for untreated acute myeloid leukaemia in line with NICE
  • 05.01.04 Gentamicin  Injection: 20mg/2ml, 40mg/1ml, 80mg/2ml
    11.03.01 Gentamicin Genticin®

    Eye drops: 0.3%

    11.03.01 Gentamicin 

    unlicensed unlicensed Eye drops: 1.5%
    unlicensed unlicensed Eye drops (preservative free)1.5%

    12.01.01 Gentamicin  

    Eye/ear drops: 0.3%

    12.01.01 Gentamicin with hydrocortisone 

    Ear drops: hydrocortisone 1% with gentamicin 0.3% (as sulfate) (Gentisone HC®)

    08.01.05 Gilteritinib (as fumarate) 

    Tablets: 40mg

    12.03.05 Glandosane® 

    Spray

    08.02.04 Glatiramer Acetate 

    Prefilled syringe injection: 20mg

    05.03.03.02 Glencaprevir-pibrentasvir Maviret

    Tablets: 300mg/120mg

    06.01.02.01 Gliclazide  Tablets: 40mg, 80mg
    MR tablets: 30mg

    N.B. the MR tablets should not be used 1st line
    06.01.02.01 Glimepiride  Tablets: 1 mg, 2 mg, 3 mg, 4 mg
    06.01.04 Glucagon  Injection: 1mg
    23.01 Glucagon  

    Injection: 1 mg syringe


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    08.01 Glucarpidase 

    unlicensedunlicensed Vials: 1000units -approved for the urgent treatment of methotrexate-induced renal dysfunction (subject to NHS England funding)

    06.01.04 GlucoGel®  Glucose 40% (3 x 25g tubes), each tube is equivalent to 10g carbohydrate

    09.02.02.01 Glucose Intravenous 

    IV infusion: 5% 100ml, 250ml, 500ml & 1000ml
    IV infusion: 10% 500ml & 1000ml
    IV infusion: 20% 500ml
    IV infusion: 40% 500ml
    IV infusion: 50% 500ml
    Injection: 50% 50ml

    13.07 Glutaraldehyde Glutarol®

    10% solution

    01.06.02 Glycerol (Glycerin)  Suppositories: 1g*, 2g*, 4g
    * For use in paediatrics only
    13.02.01 glycerol 10% w/w, light liquid paraffin, white soft paraffin 5% w/w QV Cream®

    100g, 500g

    02.06.01 Glyceryl Trinitrate  Spray: 400 micrograms/spray
    02.06.01 Glyceryl Trinitrate 

    Ampoules: 5mg/5ml, 10mg/10ml, 50mg/50ml
    Injection for infusion: 25 mg/5 mL amps
    Patches*: 5mg, 10mg
    *Hospital use only e.g. vascular access, tendonitis

    07.01.04 Glyceryl trinitrate 

    Spray: 400micrograms/dose

    23.01 Glyceryl trinitrate  

    Injection: 10 mg/10 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    01.07.04 Glyceryl Trinitrate 0.4% Rectogesic® Ointment: 0.4% (Rectogesic®)
    07.04.04 Glycine 

    1.5% solutions (up to 3 litres)

    13.12 Glycopyrrolate 1% cream 
    03.01.04 Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler®

    Ultibro breezhaler: device and capsules containing powder for inhalation

    Each dose delivers indacaterol 85 micrograms/glycopyrronium 43 micrograms

    03.01.02 Glycopyrronium Seebri breezhaler®

    Seebri Breezhaler® breath actuated DPI: 50mcg/puff (equivalent to 44mcg glycopyrronium)

     

    15.01.03 Glycopyrronium 

    Injection: 200 micrograms/1 mL, 600 micrograms/3 mL ampoules


    With neostigmine
    Injection: glycopyrronium 500 microgram & neostigmine 2.5mg in 1ml ampoules

    04.06 Glycopyrronium 2mg/5ml SF suspension 

    Suspension*: 2mg/5ml
    *Only for use in patients with excessive secretions

    01.05.03 Golimumab 
    10.01.03 Golimumab  Injection (pre-filled pen, pre-filled syringe): 50 mg

    Note: Option if anti-TNF withdrawn during 1st 6 months due to adverse effects
    06.05.01 Gonadorelin  Injection: 100 micrograms
    06.04.04 Goserelin 

    Implant: 3.6 mg & 20.8 mg

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    08.03.04.02 Goserelin 


    Green+ Traffic Light OR Amber Traffic Light

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Implants: 3.6mg & 10.8mg

    06.07.02 Goserelin (as acetate) 

    Implant: 3.6mg, 10.8mg

    GREEN PLUS when used for licensed indications other than in the treatment of prostate cancer.

    GREEN PLUS when used for gender dysphoria.

    AMBER for some patients with prostate cancer. Status will be notified by the initiating specialist.

    03.04.02 Grass pollen extract Grazax®

    Oral lyophilisate containing grass pollen extract 75,000 units

    04.04 Guanfacine Intuniv® Prolonged release tablets: 1mg, 2mg, 3mg, 4mg
    13.05.03 Guselkumab▼ 

    100mg/1ml pre-filled syringe

    01.03.05 H Pylori eradication  First line: Amoxicillin (1g BD) + Clarithromycin (500mg BD) + Omeprazole (20mg BD)
    Second line: Amoxicillin (1g BD) + Metronidazole (400mg BD) + Omeprazole (20mg BD)
    Penicillin allergic - first line: Clarithromycin (500mg BD) + Metronidazole (400mg BD) + Omeprazole (20mg BD)

    Biopsy for culture and sensitivity after first line treatment failure
    14.04 Haemophilus influenzae type B 

    Use combined vaccines

    04.02.01 Haloperidol  Capsules: 500 microgram
    Tablets: 1.5mg, 5mg, 10mg
    Oral liquid: 1mg/1ml, 2mg/1ml
    Injection: 5mg/1ml, 20mg/2ml
    04.02.02 Haloperidol decanoate  Injection: 50mg/1ml, 100mg/1ml
    09.02.02.01 Hartmann's solution (compound sodium lactate) 

    Infusion: 500ml, 1000ml

    15.01.02 Heliox 21  
    02.08.01 Heparin 

    unlicensed unlicensed Heparin 500 Units in sodium chloride 0.9% 500 mL infusion bag

    02.08.01 Heparin  Injection (ampoule); 1,000 units/1ml, 5,000 units/5ml, 10,000 units/10ml, 20,000 units/20ml
    02.08.01 Heparin (for flushing)  Injection: 50 units/5ml, 200 units/2ml
    14.04 Hepatitis A vaccine 

    Hepatitis A (inactivated, adsorbed) vaccine (HAV)
    Prefilled syringe: 1 mL (Havrix Monodose®, VAQTA® Adult)
    Prefilled syringe: 0.5 mL (AVAXIM®)
    Prefilled syringe: 0.5 mL (Havrix Junior Monodose®, VAQTA® Paediatric)
    May contain traces of neomycin
    VAQTA® Adult and Paediatric may contain traces of formaldehyde, glutaraldehyde, streptomycin, neomycin, polymyxin B and bovine serum albumin


     


    With typhoid vaccine


    Hepatitis A (inactivated) and Typhoid Polysaccharide vaccine (adsorbed).
    Prefilled syringe: 1 mL (Hepatyrix®)


     


    Hepatitis A (inactivated, adsorbed) and Typhoid polysaccharide vaccine
    Prefilled syringe: 1 mL (ViATIM®)
    May contain traces of neomycin

    14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®

    Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
    Prefilled syringe: 1 mL (Twinrix® Adult); 0.5 mL (Twinrix® Paediatric)
    May contain traces of neomycin
    Prefilled syringe: 1 mL (Ambirix®)

    14.04 Hepatitis B vaccine 

    Prefilled syringe: 10 micrograms, 1 mL; 5 micrograms, 0.5 mL (HBVAXPRO®)
    Vial: 40 micrograms, 1 mL, (HBVAXPRO®)
    May contain traces of formaldehyde and potassium thiocyanate
    Prefilled syringe: 10 micrograms, 0.5 mL; 20 micrograms, 1 mL, (Engerix®)
    Prefilled syringe: 20 micrograms, 0.5 mL, (Fendrix®)

    11.03.01 Hexamidine 

    unlicensed unlicensed Eye drops: 0.1%

    13.10.05 Histoacryl skin adhesive Histoacryl®
    09.02.02.02 Human Albumin Solution 

    Solution 4.5%: 50ml, 100ml, 500ml
    Solution 20%: 50ml, 100ml


    (Obtain via blood bank)

    14.04 Human papilloma virus vaccine 

    Human Papillomavirus 9-valent (Recombinant, adsorbed) vaccine (HPV).
    Prefilled syringe: 0.5 mL (Gardasil 9®)

    10.03.01 Hyaluronidase  Ampoules: 1,500units
    02.05.01 Hydralazine  Ampoules: 20mg
    02.05.01 Hydralazine  Tablets: 25mg, 50mg
    01.05 Hydrocortisone  Injection: 100mg
    Suspension: 1mg/1ml (unlicensed)

    Both for hospital use only
    01.05.02 Hydrocortisone Colifoam® Foam: 10% (Colifoam®)
    06.03.01 Hydrocortisone  Tablets: 10mg, 20mg
    06.03.02 Hydrocortisone 

    MR tablets: 5mg, 20mg

    06.03.02 Hydrocortisone 

    Injection (as sodium succinate): 100mg
    Injection (as sodium phosphate) amps: 100mg/1ml*

     

    *Used for home self-administration in an emergency

    06.03.02 Hydrocortisone Alkindi® 0.5mg, 1mg, 2mg, 5mg - An option for children
    06.03.02 Hydrocortisone  Tablets: 10mg, 20mg
    12.03.01 Hydrocortisone 

    Mucoadhesive buccal tablets: 2.5mg

    13.04 Hydrocortisone 0.1% cream 

    15g, 30g

     

    2nd line mildly potent topical corticosteroids

    13.04 Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone®

    15g

     

    1st line mildy potent topical corticosteroids with other ingredients 

    13.04 Hydrocortisone 0.5% cream 

    15g, 30g

    13.04 Hydrocortisone 0.5% ointment 

    15g, 30g

    13.04 Hydrocortisone 1% cream 

    15g, 30g, 50g

     

     

    13.04 Hydrocortisone 1% ointment 

    15g, 30g

     

     

    13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®

    15g, 30g

     

    1st line mildly potent corticosteroids with antimicrobials

    13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort®

    15g OTC 30g

     

    1st line mildly potent topical corticosteroids with antimicrobials

    13.04 Hydrocortisone 1%, Oxytetracycline 3% Terra-Cortril ®

     30g

     

    2nd linen mildly potent topical corticosteroids with antimicrobials

    10.01.02.02 Hydrocortisone acetate Hydrocortistab® Injection: 25mg/1ml (Hydrocortistab)
    13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H®

    15g, 30g

     

    2nd line mildly potent topical corticosteroids with antimicrobials

    13.04 Hydrocortisone Butyrate Locoid®

    Cream, ointment

     

    Potent topical corticosteroids

    12.03.04 Hydrogen Peroxide 

    Mouthwash: 1.5%, 6% (BP)

    13.11.06 Hydrogen Peroxide 1% cream Crystacide®
    13.02.01 Hydromol Intensive® Urea 10% Hydromol® Intensive

    30g, 100g

     

    2nd line Urea containing emollient

    13.02.01 Hydromol® Hydromol ointment®

    100g, 125g, 500g, 1000g

     

    2nd line ointments

    04.07.02 Hydromorphone 

    IR capsules 1.3 mg, 2.6 mg
    SR capsules : 2 mg, 4 mg, 8 mg, 16 mg, 24 mg

    Specialist initiation only - consult pain team or palliative care before use.

    04.07.02 Hydromorphone  Ampoules*: 10mg/ml

    *For palliative care use only
    09.01.02 Hydroxocobalamin 

    Injection: 1mg/1ml

    23.01 Hydroxocobalamin 

    Injection: 5000 mg vial (Cyanokit®)


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    08.01.05 Hydroxycarbamide 

    Capsules: 500mg
    unlicensedunlicensed Suspension: 500mg in 5ml

    13.05.03 Hydroxychloroquine 

    Tablets: 200 mg 

    10.01.03 Hydroxychloroquine sulfate  Tablets: 200 mg
    03.04.01 Hydroxyzine  Tablets: 10mg, 25mg
    Syrup: 10mg/5ml
    11.08.01 Hylo Night Ointment 

    Eye ointment (containing retinol palmitate (vitamin A) 250iu/g, white soft paraffin, light liquid paraffin, liquid paraffin and wool fat)

     

    N.B. This product was previously branded 'VitA-POS'

    01.02 Hyoscine Butylbromide Buscopan® Tablets: 10mg
    Injection: 20mg/1ml
    04.06 Hyoscine Hydrobromide  Tablets: 300mcg
    Transdermal patch: 1mg/72hrs
    04.06 Hyoscine Hydrobromide  Tablets: 150mcg*
    Ampoules: 400mcg/1ml**
    *For paediatric use only
    **For palliative care use only
    15.01.03 Hyoscine Hydrobromide 

    Injection (amps): 400 micrograms/1 mL

    11.08.01 Hypromellose 

    Eye drops: 0.3%, 0.5%, 1%
    Eye drops (preservative-free): 0.3%
    unlicensed unlicensed Eye drops (preservative-free): 0.5%, 1%, 2%

    06.06.02 Ibandronic Acid  Tablets: 50mg

    Pre-filled syringe*: 3mg/3mL

    *Only for use where oral bisphosphonates are not appropriate (not tolerated, contra-indicated because of upper gastro-intestinal problems or insufficiently effective).
    08.01.05 Ibrutinib Imbruvica®

    Capsules: 140mg

    04.07.04.01 Ibuprofen  Tablets: 200 mg, 400 mg
    Suspension: 100 mg/5 mL
    10.01.01 Ibuprofen  Tablets: 200mg, 400mg, 600mg
    Suspension (sugar-free available): 100mg/5mL
    10.03.02 Ibuprofen  Gel: 5%, 10%
    03.04.03 Icatibant Firazyr® Pre-filled syringe: 30mg/3ml (Firazyr®)
    Symptomatic treatment of acute episodes of hereditary angioedema (HAE)
    13.05.01 Ichthammol 1% w/w paste with zinc oxide Ichthopaste®

    7.5cm x 6cm bandage

    12.01.01 Ichthammol glycerine 

    Solution

    08.01.02 Idarubicin Hydrochloride 

    Capsules: 5mg & 10mg
    Injection: 10mg

    02.08 Idarucizumab Praxbind® 2.5g/50ml solution for injection/infusion

    Limited to haematology use and kept under the control of haematology (location = ED)
    08.01.05 Idelalisib 

    Film coated tablets: 100mg, 150mg

    08.01.01 Ifosfamide 

    Injection: 2g

    02.05.01 Iloprost injection  

    Injection for infusion 50micrograms/0.5ml amps


    Used in critical care at City Hospitals Sunderland

    08.01.05 Imatinib 

    Capsules: 100mg & 400mg

    04.03.01 Imipramine  Tablets: 10 mg, 25 mg
    Syrup: 25 mg/5 mL

    13.07 Imiquimod 

    5% cream 12 scahet pack

    13.08.01 Imiquimod cream 3.75% Zyclara®

    250mg sachets

    03.01.01.01 Indacaterol  Breezhaler® breath actuated DPI: 150mcg, 300mcg
    02.02.01 Indapamide  Tablets: 2.5mg
    MR Tablets: 1.5mg
    13.10.05 Indermil X-Fine Indermil®
    05.03.01 Indinavir Crixivan®

    Capsules: 200mg

    10.01.01 Indometacin  Capsules: 25 mg, 50 mg
    SR Capsules: 75 mg
    Suppositories: 100 mg
    13.11 Industrial Methylated Spirit BP 

    70% liquid

    01.05.03 Infliximab See 10.01.03 for preparations
    10.01.03 Infliximab  Solution for infusion: 100mg

    Note: Intravenous 2nd line with MTX
    13.05.03 Infliximab  

    100mg injection (Remicade, Inflectra & Remsima)

    14.04 Influenza vaccine  

    Public Health England (PHE) information for vaccine ordering for 2018-19 influenza season can be found here: https://www.england.nhs.uk/wp-content/uploads/2018/02/vaccine-ordering-18-19-influenza-season-gp-pharm.pdf


    Inactivated influenza vaccine (split virion) BP


    Adjuvanted trivalent influenza vaccine (aTIV) for 65 years and over (Fluad®)


    Quadrivalent influenza vaccine (QIV) for at risk adults under 65 years of age (including pregnant women and health care workers).


    For the children’s vaccination programme


    Influenza vaccine (live attenuated, nasal)
    Nasal applicator: 0.2 mL (Fluenz Tetra®)

    13.08.01 Ingenol mebutate Picato®

    150 microgram/g & 500 microgram/g gel

     

    06.07 Inotersen 

    Inotersen is recommended, within its marketing authorisation, as an option for treating stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis. It is recommended only if the company provides inotersen according to the commercial arrangement.

    08.01.05 Inotuzumab ozogamicin Besponsa®
  • Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE
  • 06.01.01.01 Insulin - Actrapid 100 units/ml 

    Vial: 10ml

    Hospital note - Humulin S® will be listed on EP to allow patients to use own supplies. Message “This is not available – use alternative” Patients who do not have their own supply can be given Actrapid® vials and syringes in the short term.

    06.01.01.01 Insulin - Humulin S 100 units/ml 

    Cartridge: 3ml – for Autopen® Classic or HumaPen®

    Vial: 10ml

    06.01.01.01 Insulin - Insuman Rapid 100 units/ml 

    Cartridge: 3ml – for ClikSTAR® and Autopen® 24

    Hospital note - Fast acting soluble human insulin – NOT a rapid acting insulin analogue. NOT SUITABLE FOR IV INFUSION

    06.01.01.01 Insulin Aspart - NovoRapid 100 units/ml 

    Cartridge:3ml for Novopen /Novopen penmate® and 1.6ml PumpCart®

    Prefilled pen:3ml FlexPen®,3mlFlexTouch®

    Vial: 10ml


    Hospital note – preloaded pen not stocked but available on request. Minimal stock of vials.

    06.01.01.02 Insulin degludec - Tresiba 100 units/ml  

    ONLY THE 100 UNITS/ML STRENGTH IS ON THE FORMULARY.

    THE 200 UNITS/ML STRENGTH MUST NOT BE PRESCRIBED IN PRIMARY CARE.


    Cartridge: 3ml

    Prefilled pen: 3ml FlexTouch

    Evaluation of response after 3 months is required. If there has been no significant improvement in the key parameter after 3 months then insulin degludec should be stopped.

    06.01.01.02 Insulin Detemir - Levemir 100units/ml 

    Cartridge: 3ml for NovoPen® Novopen PenMate®

    Prefilled pen:3ml Flexpen® and 3ml Levemir Innolet®

    Vial: 10ml

    Hospital note – minimal stock of vials held.
    Levemir InnoLet Pen – not stocked but available on request.

    06.01.01.02 Insulin Glargine - Lantus 100 units/ml 

    Cartridge: 3ml for ClikSTAR® or Autopen® 24

    Prefilled pen: 3ml SoloStar®

    Vial: 10ml

    Hospital note – minimal stock of vials held

    06.01.01.02 Insulin Glargine - Toujeo 300 units/ml 

    **HIGH STRENGTH INSULIN 300 units/ml**

    For specialist initiation only - can be continued in primary care. See information leaflet link below.

     

    Solostar prefilled pen: 300units/ml 

    06.01.01.01 Insulin Glulisine - Apidra 100 units/ml 

    Cartridge: 3ml – for ClikSTAR® and Autopen® 24

    Prefilled pen:3ml SoloStar®

    Vial: 10ml

    06.01.01.01 Insulin Lispro - Humalog ® Junior KwikPen 100 units/ 1mL 

    Pre-filled pen: 3mL KwikPen

    NOTE: Can dose in half-unit increments. Please reserve prescribing in circumstances where half-unit dosing is required.

    06.01.01.01 Insulin Lispro - Humalog 100 units/ml 

    note ONLY THE 100 UNITS/ML STRENGTH IS ON THE FORMULARY.

    THE 200 UNITS/ML STRENGTH IS NOT TO BE PRESCRIBED IN PRIMARY CARE.

    Cartridge:3ml for Autopen® Classic or HumaPen® Savvio

    Prefilled pen:3ml Kwikpen®

    Vial: 10ml

    Hospital note – minimal stock of vials

    08.02.04 Interferon alfa-2b 

    Multidose pen injections: 10 mega units, 30 mega units

    08.02.04 Interferon beta-1a 

    Prefilled pen (Avonex): 30 micrograms (6 million units)
    Prefilled pen (Rebif): 22 microgram (6 million units) & 44 microgram (12 million units)
    Cartridge for use in rebismart device: 22 microgram per 0.5ml and 44 microgram per 0.5ml
    Prefilled pen: 44 microgram per 0.5ml (Rebidose)
    -approved for use when the cartridges and prefilled syringes are unsuitable.

    08.02.04 Interferon beta-1b 

    Vials for preparing 750 microgram in 3ml injection (Betaferon)
    Vials for preparing 250 microgram in 1ml injection (Extavia)

    23.01 Intralipid® 

    Injection: 20% infusion 500 mL


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    06.02.02 Iodine Lugol’s Iodine® Total iodine 130mg/1 mL
    17 Iohexol Omnipaque®

    140 mg/mL as 50ml, 200ml
    300mg/ml as 50ml, 75ml, 100ml, 200ml
    350mg/ml as 50ml, 100ml, 500ml

    17 Iopamidol Gastromiro®

    61.24% as 100ml

    08.01.05 Ipilimumab 

    Vial for preparing IV infusion: 50mg

    03.01.02 Ipratropium 

    Inhaler (MDI): 20mcg/puff
    Nebules: 250mcg/1ml, 500mcg/2ml

    It is recommended that nebulised ipratropium should be administered via a mouthpiece and NOT a facial mask due to the risk or precipitating glaucoma.

    20mcg/puff inhaler is an alternative for chronic asthma.

    12.02.02 Ipratropium Bromide 

    Nasal spray: 21 micrograms/spray

    02.05.05.02 Irbesartan  Tablets: 75mg, 150mg, 300mg
    08.01.05 Irinotecan 

    Injection: 40mg in 2ml & 100mg in 5ml

    09.01.01.02 Iron Isomaltose 1000 Diafer

    Solution for injection: 50mg/ml

    09.01.01.02 Iron Isomaltoside 1000 Monofer®

    Solution for injection: 100mg/1ml (1ml,5ml, 10ml vials)

    08.02.03 Isatuximab Sarcusa®

    Vill: concentrate for infusion 100 mg/5 mL and 500 mg/25 mL

    15.01.02 Isoflurane 

    250ml

    05.01.09 Isoniazid 

    Tablets: 50mg, 100mg

    Liquid 50mg in 5ml . This is the nationally recommended standard strength.

    Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.

     

    05.01.09 Isoniazid  Injection: 50mg/2ml
    06.01.01.02 Isophane Insulin - Insulatard 100 units/ml 

    Cartridge: 3ml for NovoPen® Novopen penmate

    Prefilled pen: 3ml Innolet®

    Vial 10ml

    Hospital notes - Humulin I® will remain on EP to allow patients to use own supplies. Message states : This is not available – use alternative.
    Give patients who do not have own supply Human Insulatard® using vials and syringes as a temporary measure. 3ml pen not stocked but available on request.

    02.07.01 Isoprenaline 

    Injection for infusion:2.25mg/2ml vial


    Used in critical care at City Hospitals Sunderland

    13.02.01 Isopropyl myristate 150mg/1g & liquid paraffin 150mg/1g Zerodouble® Gel

    100g, 500g

     

    1st choice Gel

    02.06.01 Isosorbide Dinitrate 

    Infusion: 25mg/50ml (0.05%), 50mg/50ml (0.1%)
    Amps: 10 mg/10 mL (0.1%) 

    23.01 Isosorbide dinitrate 

    Injection: 0.05% (25 mg/50 mL) vial
    Injection: 0.1% (10 mg/10 mL) vial


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    02.06.01 Isosorbide Mononitrate  Tablets: 10mg, 20mg, 40mg
    SR tablets: 60mg
    SR tablets are only to be used when the plain tablets are unsuitable
    13.06.02 Isotretinoin 

    5mg and 20mg 

    Supplied in accordance with companies pregnancy prevention programme.

    women of child bearing age will only be supplied 1 month. See BNF for further details.

    01.06.01 Ispaghula Husk  3.5g/sachet
    05.02 Itraconazole  Capsules: 100mg
    Oral solution: 50mg/5ml
    02.06.03 Ivabradine  Tablets: 5mg, 7.5mg
    13.06 Ivermectin cream 

     

    topical preperations for rosacea

    08.01.05 Ixazomib Ninlaro®

    Capsules: 4mg

    10.01.03 Ixekizumab Taltz®
    13.05.03 Ixekizumab 

    80mg solution for injection prefilled pen

    Approved for the treatment of moderate to severe plaque psoriasis in adults in line with NICE

     

    04.07.02 Ketamine 

    Injection: 10 mg/1 mL, 50 mg/1 mL, 100 mg/1 mL
    Oral solution: 50mg/5mL

    15.01.01 Ketamine injection Ketalar®

    Injection (vials): 50 mg/2 mL, 200 mg/20 mL, 500 mg/10 mL, 1000 mg/10 mL

    06.07 Ketoconazole Ketoconazole HRA Tablets: 200mg

    Indication: Cushing's Syndrome
    13.10.02 Ketoconazole Nizoral®

    cream

    13.09 Ketoconazole 2% shampoo 
    11.08.02 Ketorolac 

    Eye drops: 0.5%

    15.01.04.02 Ketorolac 

    Injection (amps): 30 mg/1 mL
    For Hospice use only

    11.04.02 Ketotifen  Ketofall®

    Unit dose eye drops: 0.25 mg/mL, 0.4 mL

    01.06.05 Klean-Prep®  Oral powder (sachets)
    02.04 Labetalol  Tablets: 50mg, 100mg, 200mg, 400mg
    02.04 Labetalol  Injection: 100mg/20ml
    04.08.01 Lacosamide   Tablets: 50 mg, 100 mg, 150 mg, 200 mg
    Syrup (sugar-free): 50 mg/5 mL
    01.06.04 Lactulose  Liquid
    (Not recommended for first line use in primary care)
    05.03.01 Lamivudine Epivir®, Zeffix®

    Tablets: 100mg, 150mg, 300mg (brands include Epivir®, Zeffix®)
    Oral solution: 50mg/5ml (Epivir®)

    04.08.01 Lamotrigine  Tablets: 25 mg, 50 mg, 100 mg, 200 mg
    Dispersible Tablets: 2 mg, 5 mg, 25 mg, 100 mg
    08.03.04.03 Lanreotide 

    Long acting Injection: 30mg
    Autogel injections: 60mg, 90mg & 120mg

     

    Green Plus for palliative care indications (leaflet in development)

    08.03.04.03 Lanreotide 

    Long acting Injection: 30mg
    Autogel injections: 60mg, 90mg & 120mg

    RED for acromegaly, neuroendocrine tumour and carcinoid

    01.03.05 Lansoprazole  Capsules: 15mg, 30mg
    Orodispersible tablets: 15mg, 30mg (with SALT input documented or pending)
    09.05.02.02 Lanthanum Fosrenol ®

    Tablets: 500 mg, 750 mg, 1 g (as carbonate hydrate)
    Powder: 750 mg, 1 g

    08.01.05 Larotrectinib 

    Oral solution: 20mg/mL

    Recommended for use according to NICE criteria (TA630)

    11.06 Latanoprost 

    Eye drops: 50 micrograms/1 mL
    Unit dose eye drops (preservative-free): 50 micrograms/1 mL

    11.06 Latanoprost with Timolol 

    Eye drops: latanoprost 50 micrograms/1 mL, timolol 5 mg/1 mL (Xalacom®)

    20 Lecicarbon A  Suppository: Sodium hydrogen carbonate 0.500g, sodium dihydrogen phosphate 0.680g
    05.03.03.02 Ledipasvir and Sofosbuvir Harvoni® Tablets: 400mg/90mg
    10.01.03 Leflunomide  Tablets: 10 mg, 20 mg
    08.02.04 Lenalidomide 

    Capsules: 5mg, 10mg, 15mg, & 25mg

    09.01.06 Lenograstim Granocyte®

    (1st line for stem cell harvesting only)


    Injection: 13.4 million-unit (105 micrograms), 33.6 million-unit (263 micrograms)

    08.01.05 Lenvatinib Lenvima®

    Capsules: 4mg and 10mg

    02.06.02 Lercanidipine  Tablets: 10mg, 20mg
    05.03 Letermovir 

    Letermovir is recommended, within its marketing authorisation, as an option for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) in adults who are seropositive for CMV. It is recommended only if the company provides it according to the commercial arrangement.

    08.03.04.01 Letrozole 

    Tablets: 2.5mg

    06.04.04 Leuprorelin 

    Injection: 3.75 mg & 11.25 mg

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    08.03.04.02 Leuprorelin Acetate 


    Green+ Traffic Light OR Amber Traffic Light

     

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Prefilled syringes: 3.75mg, 11.25mg

    07.03.01 Levest® 

    Tablets: Ethinylestradiol 30micrograms/ norgestimate 150 micrograms

    04.08.01 Levetiracetam  Tablets: 250 mg, 500 mg, 750 mg, 1 g
    Oral solution: 100 mg/1 mL
    Granules: 250 mg/sachet, 500 mg/sachet, 1 g/sachet

    04.08.01 Levetiracetam  Vials: 500mg/5ml*
    *Hospital use only

    11.06 Levobunolol 

    Eye drops: 0.5%
    Unit dose eye drops: 0.5%

    15.02 Levobupivacaine Chirocaine®

    Injection (amps): 25 mg/10 mL, 50 mg/10 mL, 75 mg/10 mL 

    05.01.12 Levofloxacin 

    Tablets: 500mg (12 week prophylactic course in patients with myeloma)

    11.03.01 Levofloxacin 

    Eye drops: 0.5%
    Unit dose eye drops: 0.5%

    04.02.01 Levomepromazine  Tablets: 25mg
    Injection: 25mg/1ml - for use in palliative care
    04.02.01 Levomepromazine  Tablets: 6mg
    07.03.05 Levonogrestrel 

    Tablets: 1500 micrograms

    As Upostelle® or Levonelle® - Upostelle® to be used in primary care

    07.03.02.03 Levonorgestrel Mirena®

    T-shaped intra-uterine system: 52mg


     


    - For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.

    07.03.02.03 Levonorgestrel Jaydess®

    T-shaped intra-uterine progestogen only system: 13.5mg

     

    Second line option when other methods are rejected or not appropriate

    07.03.02.03 Levonorgestrel Levosert®

    T-shaped intra-uterine system: 52mg

     

    Levosert is more cost effective compared with Mirena however extra training may be required regarding insertion of the device.

    Please note: there are differences between Levosert and Mirena which may affect choice of device. Most notable differences:

    • Levosert is licensed to last for up to 4 years
    • Levosert is licensed for contraception and the treatment of heavy menstrual bleeding only
    06.02.01 Levothyroxine  Tablets: 25 micrograms, 50 micrograms, 100 micrograms
    Oral solutions are available
    01.07.01 Lidocaine  Gel: 1%, 2%
    Ointment: 5%
    Prolonged use of lidocaine (more than 2 weeks) should be avoided. Can cause sensitivity reactions.
    02.03.02 Lidocaine  Injection: 1% (10 mg/1 mL), 2% (20 mg/1 mL)
    Hospital use only
    02.03.02 Lidocaine  Infusion: 0.2% (2 mg/1 mL) in dextrose 5%, 500 mL
    04.07.03 Lidocaine Versatis®

    Plasters: 5% (700mg/medicated plaster)

    To be initiated by the pain and palliative care teams only

    12.03.01 Lidocaine  

    unlicensedunlicensed Lollies: 100mg

    12.03.01 Lidocaine  

    Spray: 10%

    15.02 Lidocaine  topical

    Gel: 2%, 10 g
    Ointment: 5%, 15 g
    Cream: 4%, 5 g (LMX4®)
    Green+ Traffic Light   Spray: 10% (supplying 10 mg/dose), 50 mL (500 sprays) (Xylocaine®)

    15.02 Lidocaine  topical

    unlicensedunlicensed Topical: 4%, 50 mL

    15.02 Lidocaine  

    unlicensedunlicensed Lolly: 100 mg

    15.02 Lidocaine 

    1% Injection: 5ml, 10ml
    2% Injection: 5ml, 20ml

    15.02 Lidocaine for dental use

    Cartridges: lidocaine 1% with adrenaline 1 in 80,000, 2.2 mL

    11.07 Lidocaine with Fluorescein 

    P/F unit dose eye drop: 4%/0.25%

    13.03 Lidocaine 2% in Lutrol Gel Lidocaine 2% in Lutrol Gel

    5ml used by pallative care.

    13.03 Lidocaine 5% ointment Lidocaine 5% ointment®

    15g

     

    1st choice Local Anaesthetics

    12.02.03 Lidocaine and Phenylephrine 

    unlicensedunlicensed Nasal spray: 2.5ml

    15.02 Lidocaine with adrenaline (epinephrine) 

    Injection: lidocaine 1% with adrenaline 1 in 200,000, 20 mL vials
    Injection: lidocaine 2% with adrenaline 1 in 200,000, 20 mL vials

    15.02 Lidocaine with adrenaline (epinephrine) and tetracaine 

    unlicensedunlicensed Gel: Lidocaine 4% + Adrenaline 0.1% + Tetracaine 0.5% (LAT), 3 mL

    15.02 Lidocaine with phenylephrine 

    unlicensedunlicensed Nasal spray: Lidocaine 5% with phenylephrine 0.5%, 2.5 mL

    15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®

    Gel: 11ml (Lidocaine 2% and chlorhexidine gluconate 0.25%)

    01.06.07 Linaclotide  Capsules: 290 micrograms
    For the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C)
    06.01.02.03 Linagliptin 

    Tablets: 5mg

    05.01.07 Linezolid  Tablets: 600mg
    Oral solution: 100mg/5ml
    05.01.07 Linezolid  IV infusion: 600mg/300ml
    06.02.01 Liothyronine 

    Tablets: 20 micrograms
    Injection: 20 micrograms

    13.10.05 LiquiBand Optima LiquiBand®
    13.10.05 LiquiBand tissue adhesive LiquiBand®
    11.08.01 Liquid Paraffin 

    Eye ointment:  white soft paraffin 57.3%, liquid paraffin 42.5%, wool alcohols 0.2%. (Lacri-Lube®)

    13.02.01 Liquid paraffin 110mg/1g Zerobase®

    50g, 500g

    13.02.01 Liquid paraffin 6%w/w white soft paraffin 15%w/w Aquamax®

    100g, 500g

    13.02.01 Liquid paraffin light 105mg/1g & WSP 132mg/1g Cetraben®

    50g, 150, 500g

    13.02.01 Liquid Paraffin, White Soft Pariffin Zeroderm ointment ®

    125g, 500g

    1st line ointments

    06.01.02.03 Liraglutide 

    Injection (pre-filled pen): 18 mg/3 mL (0.6 mg/dose)

    Green +   for the treatment of diabetes

    Red   for managing overweight and obesity in line with NICE TA664 criteris

    04.04 Lisdexamfetamine Elvanse®

    Capsules: 20mg, 30mg, 40mg, 50mg, 60mg, 70mg (Elvanse®)
    - For 3rd line use after an inadequate response to methylphenidate.
    - For specialist initiation and only transferred to GPs after at least 6 month stable symptoms control.

    02.05.05.01 Lisinopril  Tablets: 2.5mg, 5mg, 10mg, 20mg
    04.02.03 Lithium Carbonate  Tablets: 250mg (6.8mmol Li+)
    MR Tablets: 200mg & 400mg (5.4 & 10.8 mmol Li+)
    - lithium should be prescribed by brand name
    04.02.03 Lithium Citrate  Liquid: 509mg/5mL (5.4 mmol Li+/5mL), 1,018mg/5mL (10.8 mmol Li+/5mL)
    M/R Tablets: 564mg (6 mmol Li+)
    - lithium should be prescribed by brand name
    06.01.02.03 Lixisenatide  Injection (pre-filled pen): 10 micrograms/dose, 20 micrograms/dose

    Consider as 1st line G-L-P1 receptor agonist – lowest acquisition cost
    07.03.01 Lizinna® 

    Tablets: Ethinylestradiol 35micrograms/ norgestimate 250 micrograms

    11.04.02 Lodoxamide 

    Eye drops: 0.1%

    07.03.01.04 Loestrin 20® 

    Tablets: Ethinylestradiol 20 mcg / norethisterone 1.5mg

    07.03.01 Loestrin 30® 

    Tablets: Ethinylestradiol 30 micrograms / norethisterone 1.5mg

    04.03.01 Lofepramine  Tablets: 70 mg
    Sugar-free oral suspension: 70 mg/5 mL
    - Safer than amitriptyline in overdosage, but not as effective.
    04.10.03 Lofexidine  Tablets: 200 micrograms
    07.03.01.03 Logynon® 

    Tablets

    07.03.01.03 Logynon® ED 

    Tablets

    08.01.01 Lomustine 

    Capsules: 40mg
    unlicensedunlicensed capsules: 10mg

    01.04.02 Loperamide  Capsules: 2mg
    Syrup: 1mg/5ml
    Orodispersible tablets: 2mg*
    * For high output stoma only
    05.03.01 Lopinavir and ritonavir Kaletra®

    Tablets: 100mg/25mg, 200mg/50mg
    Oral solution: 400mg/100mg in 5ml

    03.04.01 Loratadine  Tablets: 10mg
    Oral solution: 5mg/5ml
    04.01.02 Lorazepam  Tablets: 1mg, 2.5mg
    Injection: 4mg/1ml
    Oral solution: 1mg/5ml
    04.08.02 Lorazepam  Injection: 4 mg/1 mL
    23.01 Lorazepam  

    Injection: 4 mg/1 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    08.01.05 Lorlatinib 

    Tablets: 25mg, 100mg

     

    Recommended for use according to NICE criteria (TA628)

    02.05.05.02 Losartan  Tablets: 12.5mg, 25mg, 50mg, 100mg
    Oral suspension: 12.5mg/5ml
    11.04.01 Loteprednol Lotemax®

    Eye drops: 0.5%

    01.06.07 Lubiprostone  Capsules: 24 micrograms
    07.03.01 Lucette® 

    Tablets: Ethinylestradiol 30 mcg / drospirenone 3 mg

    09.01.04 Lusutrombopag 

    3mg film-coated tablets

    Approved for use according to criteria in NICE TA617

    05.01.03 Lymecycline  Capsules: 408mg (= tetracycline 300mg)
    13.06.02 Lymecycline 

     

    Last line oral preperation for acne

    23.01 Macrogol ‘3350’ 

    Sachet: Klean-Prep®


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    01.06.04 Macrogol oral powder  Prescribers should use the product with the lowest acquisition cost.
    01.06.04 Macrogol paediatric sachet  Hospital use only
    07.03.01 Maexeni ® 

    Tablets: Ethinylestradiol 30 microgram/levonorgestrel 150 microgram

    13.11.06 Magenta paint BPC (Castellani’s paint) 

    Paint containg magenta 0.4% boric acid 0.8% phenol 0.0004%, resorcinol 8%, acetone and alcohol (or industrial methylated spirit)

    09.05.01.03 Magnesium Aspartate Magnaspartate®

    Oral powder: 6.5g (10 mmol/sachet)

    09.05.01.03 Magnesium Glycerophosphate 

    Magnesium glycerophosphate tablets (Neomag)
    Tablets: 4mmol (97mg)


    unlicensed unlicensed 


    Liquid: equivalent to magnesium 5 mmol; also contains phosphate 5 mmol /5 mL


     


    Prescribers should prescribe the product with lowest acquisition cost

    07.01.04 Magnesium Sulphate 

    Ampoules: 20% in 10ml

    09.05.01.03 Magnesium Sulphate 

    10%, 1 g in 10 mL (equivalent to magnesium 4 mmol/10 mL
    50%, 1 g in 2 mL (equivalent to magnesium 4 mmol/2 mL)
    50%, 2.5 g in 5 mL (equivalent to magnesium 10 mmol/5 mL)
    50%, 5 g in 10 mL (equivalent to magnesium 20 mmol/10 mL)

    13.10.05 Magnesium Sulphate Paste BP 

     

     

    Preperations for boils

    13.10.04 Malathion 0.5% Derbac-M®

    Liquid (aqueous)

    02.02.05 Mannitol  Intravenous infusion: 10%, 500ml; 20%, 250ml, 500ml
    03.07 Mannitol  Inhalation powder, hard capsule (for use with disposable inhaler device): 40mg
    Available through a managed pathway in line with NICE criteria
    Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy
    05.03.01 Maraviroc Celsentri®

    Tablets: 150mg, 300mg

    07.03.01 Marvelon 30/150 ® 

    Tablets: Ethinylestradiol 30mcg / desogestrel 150mcg

    14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 

    Measles, Mumps & Rubella vaccine (MMR)
    Vial with solvent in a pre-filled syringe 0.5 mL (MMRVaxPro®)
    Pre-filled syringe: 0.5 mL (Priorix®)
    May contain traces of neomycin

    05.05.01 Mebendazole  Tablets (chewable): 100mg
    Oral suspension: 100mg/5ml
    01.02 Mebeverine Hydrochloride  Tablets: 135mg
    MR capsules: 200mg
    13.02.02 Medi Derma-Pro Foam & Spray Skin Cleanser And Skin Protectant Ointment Medi Derma-Pro Foam & Spray Skin Cleanser®

    Medi-Derma-Pro Foam & Spray incontinence cleanser 63582 (Foam Medicareplus international Ltd) 250ml

    13.02.02 Medi Derma-S barrier cream Medi Derma-S® barrier cream

    28, 90g

    13.02.02 Medi Derma-S barrier film Medi Derma-S ®barrier film

    Medi Derma-S non-sting barrier film foam 1ml applicator 61076 Medicareplus internatioal LTD) 5 device

    Medi-derma-s non-sting medical barrier film aerosol 60819 (Medicareplus International Ltd) 50ml, 

    06.04.01.02 Medroxyprogesterone Acetate  Tablets: 2.5 mg, 5 mg, 10 mg
    07.03.02.02 Medroxyprogesterone Acetate 

    Depot injection: 150mg in 1ml (Depo-Provera®)
    S/C injection: 104mg/0.65ml (Sayana Press®)

    07.05.04 Medroxyprogesterone acetate 

    Tablets: 10mg


     

    08.03.02 Medroxyprogesterone Acetate 

    Tablets: 100mg & 200mg
    Injections: 500mg in 2.5ml

    10.01.01 Mefenamic Acid  Capsules: 250 mg
    Tablets: 500 mg
    Suspension: 50 mg/5 mL

    Note: Obs & gynae use only
    08.03.02 Megestrol Acetate 

    Tablets: 160mg

    04.01.01 Melatonin  Solution: 1mg/1ml

    RAG status depends on indication:


    Amber Traffic Light  For the management of sleep-wake disorders in children and young people


    Green+ Traffic Light For the management of sleep-wake disorders in people over the age of 18 and over (note; check BNF for licensing information)


    Green+ Traffic Light  Not currently approved by NTW for use in licensed indication, but approved for use in some other sleep disorders


    Please refer to information sheet for up to date information regarding approved indications
    04.01.01 Melatonin 

    MR tablets (Circadin ®): 2 mg – 1st line
    MR tablets (Circadin ®): 2 mg (crushed) – 2nd line
    MR tablets (Slenyto ®): 1mg, 5 mg (as per licensed indications)

    RAG status depends on indication:


    Amber Traffic Light  For the management of sleep-wake disorders in children and young people under the age of 18


    Green+ Traffic Light For the management of sleep-wake disorders in people over the age of 18 and over (note; check BNF for licensing information)


    Green+ Traffic Light  Not currently approved by NTW for use in licensed indication, but approved for use in some other sleep disorders


    Please refer to information sheet for up to date information regarding approved indications

    08.01.01 Melphalan 

    Tablets: 2mg
    Injection: 50mg

    04.11 Memantine  Tablet: 10 mg, 20 mg
    Oral solution: 5 mg/actuation (10 mg/1 mL)
    09.06.06 Menadiol Sodium Phosphate 

    Tablets: 10 mg

    14.04 Meningococcal vaccine 

    Meningococcal group A, C, W135 and Y conjugate vaccine (MenACWY)
    Vial: 0.5 mL (Menveo®)
    Pre-filled syringe: 0.5 mL (Nimenrix®)


    Meningococcal group B (rDNA, component, adsorbed) vaccine (4CMenB)
    Prefilled syringe: 0.5 mL (Bexsero®) 


    Hib meningococcal group C combined vaccine (Hib/MenC)
    Vial: 0.5 mL (Menitorix®)

    13.03 Menthol 1% in Aqueous Cream Menthol 1% in Aqueous Cream®

    100g, 500g

     

    1st line Antipruritics

     

    Alternatives include calamine lotion and Eurax (crotamiton) which should be encouraged to be purchased OTC

    15.02 Mepivacaine for dental use Scandonest Plain®

    Injection: 3%, 2.2 mL cartridge

    03.04.02 Mepolizumab Nucala

    Powder for solution for injection: 100mg

    01.05.03 Mercaptopurine  Tablets: 50mg
    08.01.03 Mercaptopurine 

    Tablets: 50mg
    unlicensedunlicensed Suspension: 20mg in 1ml


     


    Note, mercaptopurine is amber if used for inflammatory bowel disease

    07.03.01.04 Mercilon® 

    Tablets: Ethinylestradiol 20mcg / desogestrel 150mcg

    05.01.02.02 Meropenem  Injection: 500mg, 1g
    01.05.01 Mesalazine Octasa® Tablets: 400mg, 800mg
    Octasa® is the first line brand in primary care
    01.05.01 Mesalazine Asacol® Tablets: 400mg, 800mg (Asacol® is the second line brand in primary care)
    Suppositories: 250mg, 500mg
    Foam enema: 1g (preparation choice will depend on site of action required - choice between foam enema and retention enema depends on patient preference).
    01.05.01 Mesalazine Pentasa®

    SR Tablets: 500mg, 1g
    SR Granules: 1g sachet, 2g sachet
    Suppositories: 1g
    Retention enema: 1g/100ml (preparation choice will depend on site of action required - choice between foam enema and retention enema depends on patient preference).

    01.05.01 Mesalazine Salofalk® Tablets: 250mg, 500mg
    01.05.01 Mesalazine  Mezavant® XL SR Tablets: 1.2g
    01.05.01 Mesalazine Salofalk®

    Granules GR MR: 500mg, 1g, 1.5g, 3g

    08.01 Mesna 

    Injection: 1g in 10ml
    Tablets: 400mg

    23.01 MESNA (sodium 2-mercapto-ethanesulphonate) 

    Injection: 400 mg/4 mL ampoules
    Tablets: 400 mg


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    13.02.02 Metanium ointment Barrier preparation Metanium®

    30g

    02.07.02 Metaraminol  Ampoules: 10mg/1ml
    06.01.02.02 Metformin  Tablets: 500mg, 850mg
    MR Tablets: 500mg, 750mg, 1g
    Oral solution (sugar-free): 500mg/5mL
    N.B. The MR tablets are only to be prescribed where patients have failed to tolerate the conventional tablets despite careful dose titration
    07.05.01.01 Metformin 

    Tablets: 500mg
    (For fertility indications)

    04.07.02 Methadone 

    Tablets: 5 mg
    Linctus: 2 mg/5 mL
    Oral Concentrate: 10mg/mL
    Injection: 10 mg/1 mL

     

    Specialist initiation only - consult pain team or palliative care before use as an analgesic.

    (Red when used for addiction)

    04.10.03 Methadone 

    Oral solution (sugar-free available, must be specified): 1 mg/1 mL
    Injection: 50 mg/2 mL, 50 mg/1 mL

     

    RED when used to treat substance misuse, where initiation by specialist includes specialist substance misuse services

    05.01.13 Methenamine Hippurate Hiprex®

    Tablets 1g

    BNF states this drug is "Less suitable for prescribing". 

    May be initiated as a Green plus drug by urology in some patients and can be continued in general practice in these circumstances.

    Please clarify with the specialist the duration of treatment.

    08.01.03 Methotrexate 

    Tablets: 2.5mg
    unlicensedunlicensed Oral solution: 10mg in 5ml
    unlicensedunlicensed Injections (various strengths) – including prefilled syringes
    Intrathecal injection: 5mg in 2ml

     

    Note, methotrexate is amber if used in chronic inflammarory conditions, e.g. Crohn's disease, rheumatoid arthritis

    10.01.03 Methotrexate  Tablets: 2.5 mg
    Prefilled pen (Metoject): 7.5mg, 10mg, 12.5mg, 15mg, 17.5mg, 20mg, 22.5mg, 25mg, 27.5mg, 30mg

    Note: ONLY 2.5mg strength tablets to be prescribed. No other strengths to be prescribed
    13.05.03 Methotrexate 
    09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®

    Injection (pre-filled syringe): 30 micrograms/0.3 mL, 50 micrograms/0.3 mL, 75 micrograms/0.3 mL, 100 micrograms/0.3 mL, 120 micrograms/0.3 mL, 150 micrograms/0.3 mL, 200 micrograms/0.3 mL, 250 micrograms/0.3 mL, 360 micrograms/0.6 Ml

    13.05.02 Methoxypsoralen 1.2% bath additive 

     

    Psoralens (used with phototherpay)

    02.05.02 Methyldopa  Tablets: 125mg, 250mg, 500mg
    04.04 Methylphenidate 
     

    Tablets: 5mg, 10mg

    MR Tablets: 18mg, 27mg, 36mg, 54mg (Xaggitin XL® or Concerta XL®)

    MR Capsules: 5mg, 10mg, 20mg, 30mg, 40mg (Medikinet XL®)

    MR Capsules: 10mg, 20mg, 30mg (Equasym XL®)

    NOTE

    - Concerta XL is also approved for the treatment of narcolepsy in patients

    06.03.02 Methylprednisolone  Tablets: 2mg, 4mg, 16mg, 100mg
    06.03.02 Methylprednisolone  Injection: (as sodium succinate): 40mg, 125mg, 500mg, 1g, 2g
    10.01.02.02 Methylprednisolone Acetate Depo-Medrone® Depot injection: 40 mg/mL (Depo-Medrone®)
    10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine Depot injection (with lidocaine): 40 mg (+ 10 mg)/1 mL, 80 mg (+ 20 mg)/2 mL (Depo-Medrone with Lidocaine®)
    23.01 Methylthioninium chloride (methylene blue) 

    Injection: 1 % (100 mg/10 mL) ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    01.02 Metoclopramide  Tablets: 10mg
    Liquid: 5mg/5ml
    04.06 Metoclopramide  Tablets: 10 mg
    Liquid: 5 mg/5 mL
    04.06 Metoclopramide  Injection: 10 mg/2 mL

    RAG status is RED unless prescribing in end of life care
    02.02.01 Metolazone  Tablets: 2.5mg, 5mg
    02.04 Metoprolol  Tablets: 50mg, 100mg
    SR Tablets: 200mg
    02.04 Metoprolol   Oral solution: 50mg/5ml
    02.04 Metoprolol  Injection: 5mg/5ml
    05.01.11 Metronidazole 

    IV infusion: 100mg/20ml, 500mg/100ml

    05.01.11 Metronidazole  Tablets: 200mg, 400mg, 500mg
    Suspension: 200/5ml
    Suppositories: 500mg, 1g

    07.02.02 Metronidazole 

    Vaginal gel: 0.75%

    13.10 Metronidazole 0.75% gel  

    Gel, cream

    06.07.03 Metyrapone  Capsules: 250mg
    02.03.02 Mexiletine 

    Capsules: 50mg, 167mg (NaMuscla® 167mg equivalent to 200mg mexiletine HCl) 

    ONLY APPROVED FOR USE ON THE FORMULARY FOR THE FOLLOWING INDICATIONS. HOSPITAL ONLY DRUG FOR ALL INDICATIONS

    * Myotonia in non-dystrophic myotonic disorders

    * Neuropathic pain (unlicensed indication)

    * Ventricular arrhythmia (unlicensed indication)
    10.02 Mexiletine NaMuscla®

    Capsules: 167mg (NaMuscla® 167mg equivalent to 200mg mexiletine HCl) 

    ONLY APPROVED FOR USE ON THE FORMULARY FOR THE FOLLOWING INDICATIONS. HOSPITAL ONLY DRUG FOR ALL INDICATIONS

    * Myotonia in non-dystrophic myotonic disorders

    * Neuropathic pain (unlicensed indication)

    * Ventricular arrhythmia (unlicensed indication)
    12.03.02 Miconazole 

    Oral gel (sugar-free): 24 mg/1 mL (20 mg/1 g) (Daktarin)     

    07.03.01 Microgynon 30® 

    Tablets: Ethinylestradiol 30mcg / levonorgestrel 150mcg

    07.03.01 Microgynon ED ® 

    Tablets: Ethinylestradiol 30mcg / levonorgestrel 150mcg

    07.03.02 Micronor® 

    Tablets: 350 micrograms (Norethisterone)

    04.08.02 Midazolam 

    Oromucosal solution (Buccolam®): 2.5 mg/0.5 mL, 5 mg/1 mL, 7.5 mg/1.5 mL, 10 mg/2 mL

    Liquid: 10mg/5mL

    15.01.04.01 Midazolam 

    Injection (vials): 2 mg/2 mL, 5 mg/5 mL, 10 mg/2 mL ampoules; 50 mg/50 mL


    note: 10mg/2ml is Green + if used in palliative medicine

    02.07.02 Midodrine  Tablets: 2.5mg, 5mg
    08.01.05 Midostaurin Rydapt ® 25mg capsules
    08.02.04 Mifamurtide 

    Vial: 4mg

    07.01.02 Mifepristone 

    Tablets: 200mg

    07.03.01.04 Millinette 20/75 ® 

    Tablets: Ethinylestradiol 20mcg / gestodene 75 mcg

    07.03.01 Millinette 30/75 ® 

    Tablets: Ethinylestradiol 30mcg / gestodene 75 mcg

    02.01.02 Milrinone 

    Amps: 10mg/10ml


    Used in critical care at City Hospitals Sunderland

    07.03.01.07 Mini TT 380 Slimline® 

    Intrauterine device - replacement every 5 years

    05.01.03 Minocycline  Tablets: 50mg, 100mg
    02.05.01 Minoxidil  Tablets: 2.5mg, 5mg, 10mg
    07.04.02 Mirabegron 

    M/R tablets: 25mg, 50mg


     

    04.03.04 Mirtazapine  Tablets: 15mg, 30mg, 45mg
    Orodispersible tablets: 15mg, 30mg, 45mg
    - Orodispersible tablets should only be prescribed for use when other formulations are unsuitable
    07.01.01 Misoprostol 

    Tablets: 200 micrograms

    08.01.02 Mitomycin 

    Injection: 10mg, 20mg & 40mg
    - Also approved for treatment in combination with 5-Fluorouracil for bladder cancer concurrent with radiotherapy.

    08.01.02 Mitomycin 

    unlicensedunlicensed Preservative free eye drop: 0.04% preservative free eye drops

    08.01.05 Mitotane 

    Tablets: 500mg

    08.01.02 Mitoxantrone 

    Injection: 20mg in 10ml

    15.01.05 Mivacurium Chloride 

    Injection (amps): 10 mg/5 mL, 20 mg/10 mL

    04.03.02 Moclobemide 

    Tablets: 150 mg, 300 mg

    04.04 Modafinil  Tablets: 100 mg
    - Only approved for limited use in the treatment of patients with narcolepsy
    14.04 Moderna mRNA-1273 COVID-19 vaccine 
    12.02.01 Mometasone Furoate 

    Nasal spray: 50 micrograms/spray

    13.04 Mometasone Furoate 0.1% Elocon®

    0.1% ointment, 0.1% scalp application

     

    Potent topical corticosteroids

    03.03.02 Montelukast  Tablets: 10mg
    Chewable tablets: 4mg, 5mg
    Sachets: 4mg
    04.07.02 Morphine Sulphate  IR tablets: 10 mg, 20 mg, 50 mg
    MR capsules for twice daily administration (Zomorph®): 10 mg, 30 mg, 60 mg, 100 mg, 200 mg
    MR tablets: 5 mg, 15 mg
    MR suspension sachets: 20 mg, 30 mg, 60 mg, 100 mg, 200 mg
    N.B. the MR suspension sachets are only for use when other formulations are unsuitable
    Oral solution: 10 mg/5 mL, 20 mg/1 mL
    Injection: 10 mg/1 mL, 15 mg/1 mL, 20 mg/1 mL, 30 mg/1 mL
    Suppositories: 10 mg, 15 mg, 20 mg, 30 mg
    01.06.05 Moviprep®  Oral powder (sachets)
    05.01.12 Moxifloxacin  Tablets: 400mg
    05.01.12 Moxifloxacin 

    Injection for infusion: 400 mg/250mL

    11.03.01 Moxifloxacin 

    Eye drops: 0.5%

    02.05.02 Moxonidine  Tablets: 200 micrograms, 300 micrograms, 400 micrograms
    12.03.01 Mucogard® 

    Oral rinse: 250ml

    09.06.07 Multivitamin preparations Renavit ®

    Tablets: contains ascorbic acid 60 mg, thiamine 1.5 mg, riboflavin 1.7 mg, nicotinamide 20 mg, pyridoxine hydrochloride 10 mg, folic acid 800 micrograms, cyanocobalamin 6 micrograms, D-biotin 300 micrograms, pantothenic acid 10 mg


    For patients on dialysis

    09.06.07 Multivitamin preparations Ketovite®

    Tablets: contains Ascorbic acid, Riboflavin, Thiamine, Pyridoxine, Nicotinamide, Calcium pantothenate, Alpha tocopheryl acetate, Inositol, Biotin, Folic acid and Acetomenaphthone
    Liquid (sugar-free 150mL): contains Vitamin A, Ergocalciferol, Choline chloride and Cyanocobalamin

    09.06.07 Multivitamin preparations Abidec®

    Abidec drops, 25mL
    Contains Vitamins A (1,333 units as palmitate per 0.6mL dose), B group, C and D. Includes arachis (peanut) oil

    09.06.07 Multivitamin preparations Dalivit®

    Drops, 25mL
    Contains Vitamins A (5,000 units as palmitate per 0.6mL dose), B group, C and D

    09.06.07 Multivitamins and minerals Valupak®

    Tablets: contains vitamin A 800 mcg (2666 units), vitamin B1 (thiamine) 1.1 mg, vitamin B2 (riboflavin) 1.4 mg, vitamin B3 (niacin) 16 mg, vitamin B6 (pyridoxine) 1.4 mg, vitamin B12 (cyanocobalamin) 2.5 mcg, vitamin C (ascorbic acid) 80 mg, vitamin D2 (ergocalciferol) 200 units, vitamin E (α-tocopheryl) 12 mg, pantothenic acid (Vitamin B5) 6 mg, folic acid 200 mcg, calcium 50 mg, copper 1 mg, iodine 450 mcg, iron 14 mg, manganese 2 mg, magnesium 16.5 mg, phosphorous 38.5 mg, zinc 10 mg

    09.06.07 Multivitamins and minerals Forceval Soluble®

    Soluble tablets: contains vitamin A 2,500 units, vitamin B1 (thiamine) 1.2 mg, vitamin B2 (riboflavin) 1.6 mg, vitamin B3 (niacin) 18 mg, vitamin B6 (pyridoxine) 2 mg, vitamin B12 (cyanocobalamin) 3 mcg, vitamin C (ascorbic acid) 60 mg, vitamin D2 (ergocalciferol) 400 units, vitamin E (α-tocopheryl) 10 mg, biotin (vitamin H) 100 mcg, pantothenic acid (Vitamin B5) 4 mg, folic acid 400 mcg, calcium 100 mg, chromium 200 mcg, copper 2 mg, iodine 140 mcg, iron 12 mg, manganese 3 mg, magnesium 30 mg, molybdenum 250 mcg, phosphorous 77 mg, potassium 4 mg, selenium 50 mcg, zinc 15 mg

    12.02.03 Mupirocin 

    Nasal ointment: 2% in white soft paraffin (Bactroban®)
    2nd line for peanut allergy (in primary care)

    13.10 Mupirocin 2% Bactroban®

    15g

    09.06.07 Mutivitamin 

    Capsules: Multivitamins BPC

    10.01.03 Mycophenolate  Capsules: 250mg
    Tablets: 500mg
    08.02.01 Mycophenolate Mofetil 

    Capsules: 250mg
    Tablets: 500mg
    Oral suspension: 1g in 5ml (200mg/ml)
    Vial for preparing IV infusion: 500mg

    08.02.01 Mycophenolate Sodium Myfortic®

    E/C tablets: 180mg & 360mg
    – 2nd line therapy in patients who do not tolerate mycophenolate mofetil

    04.06 Nabilone  Capsules*: 1mg
    *Hospital use and existing patients only. No new patients
    03.07 N-Acetylcysteine  solution for nebulisation
    06.04.04 Nafarelin 

    Nasal spray: 200 micrograms per spray; 60 dose spray

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    02.06.04 Naftidrofuryl  Capsules: 100mg
    01.06.06 Naldemedine 

    Tablet: 200 micrograms

    04.10.01 Nalmefene  Tablets: 18mg
    01.06.06 Naloxegol  Tablets: 12.5mg, 25mg
    15.01.07 Naloxone 

    Injection (amps): 400 micrograms/1 mL
    Prefilled syringe: 2 mg/2 mL

    23.01 Naloxone  

    Injection: 400 micrograms/1 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    04.10.03 Naltrexone 

    Tablets: 50 mg

    For use under drug misuse specialist 

    04.07.04.01 Naproxen  Tablets: 250mg, 500mg
    10.01.01 Naproxen  Tablets: 250mg, 500mg
    10.01.04 Naproxen  Tablets: 250 mg, 500 mg
    08.02.04 Natalizumab 

    Vial for preparing infusions: 300mg in 15ml (20mg/ml)
    - approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE

    11.03.02 Natamycin 

    unlicensed unlicensed Eye drops: 5%

    11.04.02 Neodocromil 

    Eye drops: 2%

    10.02.01 Neostigmine  Tablets: 15 mg
    Injection: 2.5 mg/1 mL
    15.01.06 Neostigmine 

    Injection (amps): 2.5 mg/1 mL

    15.01.06 Neostigmine with Glycopyrronium 

    Injection: Neostigmine metisulfate (methylsulphate) 2.5 mg with glycopyrronium 500 micrograms, 1 mL

    11.08.02 Nepafenac  

    Eye drops: 1 mg/1 mL

    04.06 Netupitant and Palonosetron Akynzeo®

    Capsules: 300mg/0.5mg

    05.03.01 Nevirapine Viramune®

    Oral suspension: 10mg/1ml
    MR tablets: 100mg, 400mg
    Tablets: 200mg

    02.06.03 Nicorandil  Tablets: 10mg, 20mg
    04.10.02 Nicotine  Nicorette®
    Microtab (sublingual): 2 mg
    Chewing gum: 2 mg, 4 mg
    Patches (Invisi or non-Invisi): ‘5 mg' patch (releasing approx. 5 mg/16 hours), ‘10 mg' patch (releasing approx. 10 mg/16 hours), ‘15 mg' patch (releasing approx. 15 mg/16 hours)
    Oral spray: 1 mg/metered dose
    Nasal spray: 500 micrograms/metered spray
    Inhalator: 10 mg/cartridge, 15 mg/cartridge

    Nicotinell®
    Lozenge: 1 mg, 2 mg
    Patches: TTS 10 patch (releasing approx. 7 mg/24 hours), TTS 20 patch (releasing approx. 14 mg/24 hours), TTS 30 patch (releasing approx. 21 mg/24 hours)
    02.06.02 Nifedipine  Capsules: 5mg, 10mg
    Oral drops: 20mg/ml*
    *Hospital use only
    07.01.04 Nifedipine 

    Capsules: 5mg, 10mg

    02.06.02 Nifedipine modified release  Tablets: 10mg, 20mg, 30mg 60mg

    Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed. Modified-release formulations may not be suitable for dose titration in hepatic disease
    08.01.05 Nilotinib 

    Capsules: 150mg, 200mg

    02.06.02 Nimodipine  Tablets: 30mg
    Infusion: 0.02%
    08.01.05 Nintedanib Vargatef®

    Soft capsules: 100mg, 150mg

    08.01.05 Niraparib Zejula® Niraparib tosylate monohydrate 100mg capsules
    15.01.02 Nitric oxide 
    05.01.13 Nitrofurantoin  Tablets: 50mg, 100mg
    MR capsules: 100mg
    Oral suspension (sugar-free available): 25mg/5ml*

    *Note: Liquid presentations of nitrofurantoin are very expensive compared to tablets and capsules. Current costs are £446.95 for 300ml (May 2017 drug tariff). Please consider whether capsules can be used. Macrodantin capsules can either be swallowed whole, or the capsules can be opened. DO NOT crush the tablets
    13.10 Nitrofurazone Soluble 0.2% Ointment For limited use in burns/ plastic surgery patients only 
    15.01.02 Nitrous oxide 
    08.02.04 Nivolumab 

    Concentrate for IV infusion: 10mg in 1ml concentrate for IV infusion as (4ml, 10ml & 24ml vials)

     

     

     

    For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults

    07.03.03 Nonoxynol '9' Gygel®

    Gel: 2%

    02.07.02 Noradrenaline  

    Injection for infusion amps: 4mg/4ml


    Used in critical care at City Hospitals Sunderland

    06.04.01.02 Norethisterone  Tablets: 5mg
    07.05.04 Norethisterone 

    Tablets: 5mg


    Note: Anticipatory prescribing for postponement of menstruation while travelling should not be provided on NHS prescription in primary care. Supplies can be made on private prescription.

    08.03.02 Norethisterone 

    Tablets: 5mg

    07.03.02 Norgeston® 

    Tablets: 30 micrograms (Levonorgestrel)

    07.03.02 Noriday® 

    Tablets: 350 micrograms norethisterone

    14.05.01 Normal immunoglobulin 

    Human normal Immunoglobulin (HNIG)
    Infusion: 100 mg/mL; 5 g/50 mL, 10 g/100 mL (Iqymune®) preferred product
    Infusion: 100 mg/mL; 5 g/50 mL, 10 g/100 mL (Kiovig®)
    For patients who cannot have Iqymune®

    04.07.03 Nortriptyline   Tablets: 10 mg, 25 mg
    For use after trialling other options as detailed above
    07.03.01.07 Nova T 380® 

    Intrauterine device - replacement every 5 years

    10.02 Nusinersen 

    Nusinersen is recommended as an option for treating 5q spinal muscular atrophy (SMA) only if:

    • people have pre-symptomatic SMA, or SMA types 1, 2 or 3 and

    • the conditions in the managed access agreement are followed.

    07.03.01.06 NuvaRing® 

    Vaginal ring releasing ethinylestradiol approximately 15 micrograms/24hours and etonogestrel approximately 120 micrograms/24hours

    05.02 Nystatin  Oral suspension: 100,000 units/ml
    12.03.02 Nystatin 

    Oral suspension: 100,000 units/1 mL
    1st line for oral candidiasis

    01.09.01 Obeticholic acid Ocaliva

    Tablets: 5mg and 10mg

    08.02.03 Obinutuzumab Gazyvaro ®

    Concentrate for IV infusion: 1000mg in 40ml


    -for use in chronic lymphocytic leukaemia in combination with chlorambucil in patients who have co-morbitities that make fulldose fludarabinebased therapy unsuitable for them, only if bendamustinebased therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding)

    08.02.03 Ocrelizumab Ocrevus® Solution for infusion 30mg per 1mL
    11.08.02 Ocriplasmin 

    Concentration for solution for intravitreal injection: 2.5mg/ml

    08.03.04.03 Octreotide 

    Injections: 50, 100 & 500 microg. in 1ml & 1mg in 5ml
    Long-acting injections: 10mg, 20mg & 30mg

     

    GREEN PLUS for palliative care indications (leaflet in development)

    08.03.04.03 Octreotide 

    Injections: 50, 100 & 500 microg. in 1ml & 1mg in 5ml
    Long-acting injections: 10mg, 20mg & 30mg

    RED for acromegaly, neuroendocrine tumour and carcinoid

    23.01 Octreotide  

    Injection: 50 micrograms/1 mL, 100 micrograms/1 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    06.04.01.01 Oestrogen only HRT patch  Patches: Twice weekly matrix patches releasing approximately 25, 50, 75 and 100mcg/24 hours (e.g. Evorel®)

    Patches: Once weekly matrix patches releasing approximately 50 and 100mcg estradiol/24 hours (Progynova TS®)
    06.04.01.01 Oestrogen only HRT tablet Premarin Tablets: 625mcg, 1.25mg (Premarin)
    06.04.01.01 Oestrogens for HRT Sandrena® Gel: 0.1% (Sandrena®)
    06.04.01.01 Oestrogens for HRT Estradiol® Tablets: 1mg, 2mg
    06.04.01.01 Oestrogens for HRT Lenzetto®

    Lenzetto®
    Spray: estradiol 1.53 mg/dose, transdermal spray

    05.01.12 Ofloxacin  IV infusion: 200mg/100ml
    05.01.12 Ofloxacin  Tablets: 200mg, 400mg
    04.02.01 Olanzapine  Tablets: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
    Orodispersible tablets: 5mg, 10mg, 15mg
    N.B. The orodispersible tablets should only be used in situations where the plain tablets are unsuitable

    10mg injection
    - For rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
    - The orodispersible tablets and injection are also approved for 2nd/3rd line use in the management of delirium in critical care patients – unlicensed indication.
    08.01.05 Olaparib 

    Capsules: 50mg

    - Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed

    - approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in line with NICE

    08.01.05 Olaratumab 

    Concentrate for solution for infusion: 10 mg/mL

    12.01.03 Olive Oil 

    Ear drops

    11.04.02 Olopatadine 

    Eye drops: 1 mg/1 mL

    03.04.02 Omalizumab Xolair® Prefilled syringe: 75mg/0.5ml, 150mg/1ml

    Review effectiveness after 16 weeks of commencing treatment
    05.03.03.02 Ombitasvir/ paritaprevir/ ritonavir Viekirax® Tablets containing ombitasvir 12.5mg, paritaprevir 75mg and ritonavir 50mg
    01.03.05 Omeprazole 

    Capsules: 10mg, 20mg,40mg
    Tablets (MUPS): 20mg
    Liquid: 20mg/5ml* (unlicensed)
    *For use in paediatrics only

    01.03.05 Omeprazole IV  Infusion vial: 40mg
    04.06 Ondansetron  Tablets: 4 mg, 8 mg
    Orodispersible films: 4 mg, 8 mg
    Oral solution: 4 mg/5 mL
    Suppositories: 16mg
    04.06 Ondansetron  Injection: 4 mg/2 mL, 8 mg/4 mL

    RAG status is RED unless prescribing in end of life care
    04.09.01 Opicapone  50mg capsules

    Adjunct to co-beneldopa or co-careldopa in Parkinson's disease
    12.03.01 Orabase 

    Paste: 30 g

    07.05.04 Oral contraceptives 

    Co-cyprindol, Lucette (as per contraceptive section)

    07.05.05 Oral contraceptives 

    Co-cyprindol, Lucette - formulations as per contraceptives

    09.02.01.02 Oral Rehydration Salts Dioralyte®

    Oral powder: sachets containing sodium chloride 470 mg, potassium chloride 300 mg, disodium hydrogen citrate 530 mg, glucose 3.56 g/sachet (Dioralyte®)

    01.04 Oral rehydration solution  Prescribers should choose the product with the lowest acquisition cost
    04.05.01 Orlistat  Tablets: 120mg
    04.09.02 Orphenadrine  Tablets: 50mg
    Syrup: 50mg/5ml
    12.03.05 Orthana® 
    05.03.04 Oseltamivir Tamiflu® Capsules: 30mg, 45mg, 75mg
    Oral suspension (sugar-free): 30mg/5ml
    08.01.05 Osimertinib 

    Tablet: 40mg and 80mg

    07.03.01 Ovranette® 

    Tablets: 150 micrograms levonorgestrel and 30 micrograms ethinylestradiol

    07.03.01 Ovysmen® 

    Tablets: Ethinylestradiol 35 mcg / norethiserone 500mcg

    08.01.05 Oxaliplatin 

    Injections: 50mg, 100mg

    04.07.03 Oxcarbazepine  Tablets: 150mg, 300mg, 600mg
    Indicated in for trigeminal neuralgia and compression neuralgia after trialling carbamazepine
    04.08.01 Oxcarbazepine  Tablets: 150 mg, 300 mg, 600 mg
    Liquid (sugar-free): 300 mg/5 mL
    11.07 Oxybuprocaine Hydrochloride 

    Minims® eye drops (preservative free): 0.4%

    07.04.02 Oxybutynin 

    Tablets: 2.5mg, 5mg
    Elixir: 2.5mg in 5ml
    Self-adhesive patch: 36mg

    04.07.02 Oxycodone  IR capsules: 5 mg, 10 mg, 20 mg
    Liquid: 5 mg/5 mL, 10 mg/1 mL
    Injection: 10 mg/1 mL, 20 mg/2 mL, 50 mg/1 mL
    MR tablets: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg
    15.01.02 Oxygen 
    05.01.03 Oxytetracycline  Tablets: 250mg
    13.06.02 Oxytetracycline 

     

    Last line oral preperations for acne

    07.01.01 Oxytocin 

    Injection: 5 units in 1 ml, 10 units in 1ml

    08.01.05 Pablociclib Ibrance®

    Recommended for use according to NICE criteria

    08.01.05 Paclitaxel 

    Concentrate for preparing IV infusion: 30mg in 5ml, 100mg in 16.7ml and 150mg in 25ml

    22.01 Paediatric 

    Red Adrenaline 1 mg/10 mL (1:10,000) prefilled syringe
    Red Adrenaline Auto injector - 150 micrograms
    Red Adrenaline Auto injector - 300 micrograms
    Red Amiodarone 300 mg/10 mL prefilled syringe
    Red Atropine 3 mg/10 mL prefilled syringe 
    Red Calcium chloride 1000 mg/10 mL (10%) prefilled syringe
    Red Dextrose 10%, 500 mL
    Red Gelatin plasma substitute (Gelofusine or Volpex), 500 mL
    Red Naloxone 400 micrograms/1 mL ampoules
    Red Sodium bicarbonate 8.4%, 200 mL 
    Red Sodium chloride 0.9% flush, 10 mL prefilled syringe
    Red Sodium chloride 0.9% solution, 1000 mL


    *These medications are red in the context of the paediatric resuscitation trolley. Please see other chapters for formulary status when used for other indications

    13.07 Paint Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol®
    08.03.04.01 Palbociclib 

    Capsules: 125mg

    04.02.02 Paliperidone  Pre-filled syringe: 50mg, 100mg, 150mg
    -NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-Acting Injections in the North of England
    04.06 Palonosetron  Injection: 250 micrograms/5 mL
    01.09.04 Pancreatin Pancrex® V Powder: 300G
    01.09.04 Pancreatin Pancrease® HL Capsules
    01.09.04 Pancreatin Nutrizym® 22 Capsules
    01.09.04 Pancreatin Creon® Capsules: Creon® 10,000, Creon® 25,000, Creon® 40,000
    15.01.05 Pancuronium Bromide 

    Injection (amps): 4 mg/2 mL

    08.01.05 Panobinostat Farydak®

    Hard capsules: 10mg, 15mg, 20mg

    15.01.05 Papaverine hydrochloride 

    unlicensedunlicensed Injection: 30 mg/2 mL ampoules

    04.07.01 Paracetamol  Tablets: 500 mg
    Soluble Tablets: 500 mg
    Suspension: 120 mg/5 mL, 250 mg/5 mL
    Suppository: 60 mg, 125 mg, 250 mg, 500 mg
    Injection: 500 mg/50 mL, 1g/100 mL
    04.07.04.01 Paracetamol  Soluble Tablets: 500 mg
    04.07.01 Paracetamol and codeine Co-codamol 8/500

    Tablets: 8/500

    11.08.01 Paraffin Yellow Soft 

    Ointment: liquid paraffin 10%, wool fat 10% in yellow soft paraffin (Simple Eye Ointment)

    04.08.02 Paraldehyde in olive oil  Injection: 50 mg/50 mL
    15.01.04.02 Parecoxib 

    Injection (vials): 40 mg 

    09.06.04 Paricalcitol Zemplar®

    Capsules: 1 microgram, 2 micrograms, 4 micrograms
    Injection: 5 micrograms/1 mL

    04.03.03 Paroxetine  Tablets: 10 mg, 20 mg, 30 mg
    Liquid (sugar-free): 10 mg/5 mL
    09.02.01.01 Patiromer calcium Veltassa ®

    Oral powder sachetes 8.4g, 16.8g, 25.2g

    Recommended for use according to NICE criteria

    08.01.05 Pazopanib 

    Tablets: 200mg, 400mg

    08.01 Pegasparagase 

    Vial: 3750 international units

    08.02.04 Peginterferon alfa-2a 

    Injections in prefilled syringes 135 microgram, 180 microgram
    Prefilled pens: 135 micrograms and 180 micrograms

    08.02.04 Peginterferon alfa-2b 

    Prefilled injection pens: 50, 80, 100, 120, 150 micrograms
    -approved for chronic hepatitis C as peginterferon alffa 2a

    08.02.04 Peginterferon beta-1a 

    Prefilled pen: 125 microgram (Plegridy)

    08.01.05 Pembrolizumab Keytruda®

    Concentrate for infusion: 100 mg/4 mL

    See below for NICE approved indications

    08.01.03 Pemetrexed 

    Injection: 100mg & 500mg

    10.01.03 Penicillamine 

    Tablets: 125 mg, 250 mg

    Note: this is as an alternative after biologics

    *FOR NEUROLOGY INDICATIONS (SUCH AS WILSON'S), PENICILLAMINE SHOULD BE CONSIDERED A RED DRUG*

    07.04.03 Pentosan polysulphate sodium 

    Capsules: 50mg, 100mg

    01.02 Peppermint Oil 

    Capsules: 0.2ml

    modified and instant release.

    01.01.02 Peptac  Sugar-free suspension (sodium alginate 250mg, sodium bicarbonate 133.5mg, calcium carbonate 80mg in 5mL. Contains 3.1 mmol Na+/5mL)
    04.08.01 Perampanel  Tablets: 2mg, 4mg, 8mg
    02.05.05.01 Perindopril erbumine  Tablets: 2mg, 4mg, 8mg
    13.10.04 Permethrin 1% Lyclear® Creme Rinse
    13.10.04 Permethrin 5% Lyclear® Dermal Cream
    04.02.01 Perphenazine  Tablets: 2mg, 4mg
    08.01.05 Pertuzumab Perjeta®

    Vial: 420mg

    04.07.02 Pethidine 

    Injection: 50 mg/1 mL, 100 mg/2 mL, 50 mg/5 mL, 100 mg/10 mL

     

    Only for use by midwives or in palliative care.

    14.04 Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 
    04.03.02 Phenelzine 

    Tablets: 15mg
    - For use on advice from psychiatrists only

    04.08.01 Phenobarbital  Tablets: 15 mg, 30 mg, 60 mg
    Elixir: 15mg/5 mL

    CHM advise brand specific prescribing
    (Alcohol-free elixir available from Rosemont Pharmaceuticals - unlicensed)
    04.08.01 Phenobarbital  Alcohol free Solution: 50mg/5ml* (Unlicensed from Rosemont)
    *For paediatric use only
    04.08.02 Phenobarbital  Injection: 15mg/1 mL, 30 mg/1 mL, 60 mg/1 mL, 200 mg/1 mL
    02.05.04 Phenoxybenzamine Hydrochloride  Capsules: 10mg
    05.01.01.01 Phenoxymethylpenicillin (Penicllin V)  Tablets: 250mg
    Oral Solution (sugar-free available): 125/5ml, 250mg/5ml
    23.01 Phentolamine 

    Injection: 10 mg/1 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    10.01.01 Phenylbutazone 

    Tablets: 100mg

    Indication: Ankylosing Spondylitis. Only be used by a specialist in severe cases where other treatments have been found unsuitable
    This is to be used for existing patients only. No new patients should be commenced on phenylbutazone.

    02.07.02 Phenylephrine 

    Ampoules: 10mg/1ml
    unlicensed unlicensed Prefilled syringe: 3 mg/ 30 mL

    11.05 Phenylephrine Hydrochloride 

    Minims® (preservative free): 2.5%, 10%
    unlicensed unlicensed Eye drops: 2.5%

    04.08.01 Phenytoin  Chewable Tablets (as Phenytoin base): (Infatabs®): 50 mg
    Capsules (as phenytoin sodium): 25 mg, 50 mg, 100 mg, 300 mg
    Suspension (as Phenytoin base) (Epanutin®): 30 mg/5 mL

    CHM advise brand specific prescribing
    04.08.02 Phenytoin  Injection: 250 mg/5 mL
    03.09.01 Pholcodine Linctus, BP 

    5mg/5ml,

    09.05.02.01 Phosphate (oral supplements) 

    Effervescent tablets: equivalent to phosphorus 500 mg, 16.1 mmol; sodium 468.8 mg, 20.4 mmol; potassium 123 mg, 3.1 mmol (Phosphate-Sandoz®)

    09.05.02.01 Phosphate Polyfusor® 

    Intravenous infusion: 500 mL

    01.06.04 Phosphates (Rectal) Fleet® Ready to use Enema
    09.06.06 Phytomenadione Konakion® MM

    Capsules: 1 mg (in oily basis)
    Injection: 10 mg/1 mL (Konakion® MM), 2 mg/0.2 mL (Konakion® MM Paediatric)
    NB) Konakion® MM Paediatric can be given orally, by intramuscular injection or be intravenous injection. Oral dispensers are provided in each pack for safe administration.

    23.01 Phytomenadione (vitamin K) 

    Injection: 10 mg/1 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    01.06.05 Picolax®  Oral powder (sachets)
    11.06 Pilocarpine 

    Eye drops: 1%, 2%, 4%
    Minims® (preservative free): 2%

    12.03.05 Pilocarpine Hydrochloride 

    Tablets: 5 mg

    13.05.03 Pimecrolimus Elidel®

    1% cream

    06.01.02.03 Pioglitazone  Tablets: 15mg, 30mg, 45mg
    05.01.01.04 Piperacillin and Tazobactam  Injections: 2.25g (containing piperacillin 2g & tazobactam 250mg/2.25g vial) , 4.5g (containing piperacillin 4g & tazobactam 500mg/4.5g vial)
    04.02.02 Pipotiazine Palmitate  Injection: 50 mg/1 mL, 100 mg/2 mL
    - specialist initiation only
    03.11 Pirfenidone Esbriet® Capsules: 267mg

    Newcastle tertiary referral
    10.03.02 Piroxicam  Gel: 0.5%
    04.04 Pitolisant  Tablets: 20mg
    - approved for use in patients with narcolepsy who experience psychomotor side effects with modafinil and dexamfetamine.
    05.01.01.05 Pivmecillinam  Tablets: 200mg
    08.01.02 Pixantrone 

    Injection: 29mg powder for reconstitution injection
    -approved as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma if they have previously been treated with rituximab and they are having third- or fourth-line treatment NICE

    04.07.04.02 Pizotifen  Tablets: 500 micrograms, 1.5 mg
    09.01.07 Plerixafor Mozobil®

    (2nd line for stem cell harvesting – needs Cancer Drugs Fund application)


    Injection: 24 mg/1.2 mL

    14.04 Pneumococcal vaccine 

    Pneumococcal conjugate (13 serotypes) vaccine (PCV13)
    Prefilled syringe: 0.5 mL (Prevenar 13®)


    Pneumococcal polysaccharide (23 serotypes) vaccine (PPV23)
    Vial: 0.5 mL (MSD)

    13.07 Podophyllotoxin Warticon®

    0.15% cream

    08.01.05 Polatuzumab vedotin 

    Vial: 30mg and 150mg, powder for concentrate for solution for infusion.

    11.03.01 Polihexanide 

    unlicensed unlicensed P/F eye drops: 0.02%
    unlicensed unlicensed Eye drops: 0.06%

    14.04 Poliomyelitis Vaccine Live (oral)  

    Use combined vaccines

    13.10 Polyfax Ointment Bacitracin with polymyxin B Polyfax®

    4g, 20g

    09.02.01.01 Polystyrene Sulphonate Resins Calcium Resonium®

    Powder: 300g

    11.08.01 Polyvinyl Alcohol 

    Eye drops: 1.4% (Liquifilm Tears® and Sno Tears®)

    08.02.04 Pomalidomide Imnovid®

    Capsules: 1mg, 2mg, 3mg, 4mg

    08.01.05 Ponatinib Iclusig®

    Tablets: 15mg, 45mg

    03.05.02 Poractant Alfa  Vials: 120mg, 240mg
    05.02 Posaconazole (oral)  Oral solution: 200mg/5ml
    09.05.02.01 Potassium acid phosphate 

    unlicensed unlicensed Oral solution (for use in paediatrics): 1mmol/1ml, 100ml

    11.03.01 Potassium ascorbate 

    unlicensed unlicensed Eye drops: 10%
    unlicensed unlicensed P/F eye drops: 10%

    09.02.01.01 Potassium Chloride 

    Modified-release tablets: equivalent to potassium 8 mmol per tablet (Slow-K®)

    09.02.01.01 Potassium Chloride 

    Effervescent tablets: equivalent to potassium 12 mmol per tablet (Sando-K®)
    Syrup (sugar-free):  equivalent to potassium 1 mmol/mL (Kay-Cee-L®)

    13.11.06 Potassium Permanganate Solution 

    Solution Tablets - 400mg

    11.08.01 Povidone  

    unlicensed unlicensed Single dose units (preservative-free): 5%

    13.11.04 Povidone-Iodine 

    2.5% dry powder spray

    10% alcoholic solution

    7.5% surgical scrub

    10% antiseptic solution (aqueous)

    04.09.01 Pramipexole  Tablets: 88 micrograms, 180 micrograms, 350 micrograms, 700 micrograms
    MR tablets: 260 micrograms, 520 micrograms, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, 3.15 mg
    02.09 Prasugrel  Tablets: 5mg, 10mg
    02.12 Pravastatin   Tablets: 10mg, 20mg, 40mg
    01.05.02 Prednisolone  Tablets: 1mg, 5mg
    Retention enema: 20mg/100ml (Predsol®)
    Suppositories: 5mg
    06.03.02 Prednisolone  Tablets: 1mg, 5mg
    Tablets (soluble): 5mg
    Oral solution: 5mg/5ml

    NB. Oral solution or soluble tablets should only be used when the patient has swallowing difficulties where plain tablets are not suitable. The oral solution has a lower acquisition cost than soluble tablets in primary care.
    06.03.02 Prednisolone  Tablets: 25mg*
    *Specialist use only
    10.01.04 Prednisolone  Injection: 25 mg/mL (Deltastab)

    See section 6.3.2
    Can be used as an alternative for those who cannot tolerate NSAIDs or who are resistant to other treatments

    See section 6.3.2 for other preparations
    11.04.01 Prednisolone 

    Eye drops: 0.5%
    Minims® (preservative free): 0.5%
    unlicensed unlicensed Eye drops: 0.003%, 0.01%, 0.03%, 0.1% and 0.3%
    unlicensed unlicensed Eye drops (preservative free): 0.01%, 0.03%, 0.1%, 0.3%, 0.5% and 1%

    11.04.01 Prednisolone 

    Eye drops: 1% (Pred Forte)

    10.01.02.02 Prednisolone Acetate Deltastab® Depot injection: 25 mg/1 mL (Deltastab®)

    See section 6.3.2 for other preparations
    12.01.01 Prednisolone sodium phosphate 

    Eye/ear drops: 0.5%

    04.07.03 Pregabalin  Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg
    Liquid: 20mg/mL

    For use after trialling other options as detailed above
    04.08.01 Pregabalin  Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg
    Oral solution: 20 mg/1 mL
    06.01.05 Pregabalin  See section 4.8 for preparations
    09.02.02.01 Premixed potassium infusion bags 

    Infusion: 0.15% (10 mmol) potassium chloride & 0.9% sodium chloride 500ml
    Infusion: 0.15% (20 mmol) potassium chloride & 0.9% sodium chloride 1000ml
    Infusion: 0.15% (10 mmol) potassium chloride & 5% glucose 500ml
    Infusion: 0.15% (20 mmol) potassium chloride & 5% glucose 1000ml
    Infusion: 0.15% (10 mmol) potassium chloride & 10% glucose 500ml
    Infusion:  0.15% (10 mmol) potassium chloride, 0.18% sodium chloride & 4%  glucose 500ml
    Infusion:  0.15% (20 mmol) potassium chloride, 0.18% sodium chloride & 4%  glucose 1000ml
    Infusion:  0.15% (10 mmol) potassium chloride, 0.9% sodium chloride & 5%  glucose 500ml
    Infusion:  0.2% (13.5 mmol) potassium chloride & 0.9% sodium chloride 500ml
    Infusion: 0.2% (27 mmol) potassium chloride & 0.9% sodium chloride 1000ml
    Infusion:  0.2% (13.5 mmol) potassium chloride & 5% glucose 500ml
    Infusion:  0.2% (27 mmol) potassium chloride & 5% glucose 1000ml
    Infusion:  0.2% (13.5 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
    Infusion: 0.2% (27 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
    Infusion:  0.3% (20 mmol) potassium chloride & 0.9% sodium chloride 500ml
    Infusion: 0.3% (40 mmol) potassium chloride & 0.9% sodium chloride 1000ml
    Infusion: 0.3% (20 mmol) potassium chloride & 5% glucose 500ml
    Infusion:  0.3% (40 mmol) potassium chloride & 5% glucose 1000ml
    Infusion: 0.3% (20 mmol) potassium chloride & 10% glucose 500ml
    Infusion:  0.3% (20 mmol) potassium chloride & 20% glucose 500ml
    Infusion:  0.3% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
    Infusion: 0.3% (40 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
    Infusion:  0.3% (20 mmol) potassium chloride, 0.45% sodium chloride & 5% glucose 500ml
    Infusion:  0.3% (20 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml
    Infusion:  0.6% (40 mmol) potassium chloride & 0.9% sodium chloride 500ml
    Infusion:  0.6% (40 mmol) potassium chloride & 5% glucose 500ml

    15.02 Prilocaine Hydrochloride Prilotekal®

    Injection (amps): 100 mg/5 mL (2%)

    15.02 Prilocaine Hydrochloride Citanest®

    Injection (vials): 500 mg/50 mL (1%) 

    15.02 Prilocaine hyperbaric solution 

    2% hyperbaric solution, 5ml amp: Prilocaine hydrochloride 20mg/ml and glucose 60mg/ml

    04.08.01 Primidone  Suspension: 50 mg/5 mL, 250 mg/5 mL (available from Rosemont Pharmaceuticals)

    CHM advise brand specific prescribing
    04.08.01 Primidone 

    Tablets: 50mg, 250 mg

    CHM advise brand specific prescribing

    10.01.04 Probenecid 

    Tablets: 500mg


    unlicensedunlicensed



    Note: This drug has been discontinued (community supplies may not be possible)

    08.01.05 Procarbazine 

    Capsules: 50mg

    04.06 Prochlorperazine  Tablets: 5 mg
    Syrup: 5 mg/5 mL
    Injection: 12.5 mg/1 mL
    Buccal tablets: 3 mg – for the treatment of nausea associated with migraine when the oral route cannot be used due to vomiting
    04.09.02 Procyclidine  Tablets: 5 mg
    Syrup (sugar-free): 2.5 mg/5 mL, 5 mg/5 mL
    04.09.02 Procyclidine  Injection: 10 mg/2 mL
    23.01 Procyclidine 

    Injection: 10 mg/2 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    13.10.05 Proflavine Cream, BPC  

     

    antiseptics

    06.04.01.02 Progesterone  Pessaries: 200mg, 400mg
    Injection: 50mg/1mL
    04.01.01 Promethazine Hydrochloride  Tablets: 10mg, 25mg
    Elixir: 5mg/5ml
    Injection: 25mg/1ml
    04.06 Promethazine Hydrochloride  Tablets: 10 mg, 25 mg
    Liquid: 5 mg/5 mL
    Injection: 25 mg/1 mL
    13.11.02 Prontosan  

    solution containing Betadine 0.1% (surfactant) and Polyhexadine 0.1% (a chlorhexadine polymer). Mainly for use from 40ml plastic ampoules. Also available as gel.

    07.04.02 Propiverine 

    Tablets: 15mg

    15.01.01 Propofol 

    Injection (emulsion): 0.5% (100 mg/20 mL) vials (Lipuro®)
    Injection (emulsion): 1% (200 mg/20 mL) and (1 g/100 mL) vials (Lipuro®)

    02.04 Propranolol  Ampoule*: 1mg/1ml (unlicensed)
    *Hospital use only
    02.04 Propranolol  M/R Capsule: 80mg, 160mg
    04.07.04.02 Propranolol  Tablets: 10mg*, 40 mg, 80 mg
    Solution: 10mg/5ml**, 40 mg/5 mL

    *10mg tablets may also be used for anxiety
    **Hospital use for paediatrics only
    06.02.02 Propylthiouracil  Tablets: 50mg
    02.08.03 Protamine Sulphate  Injection: 50mg/5ml
    23.01 Protamine sulphate  

    Injection: 50 mg/5 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    06.05.01 Protirelin TRH Injection: 200 micrograms/1 mL
    11.07 Proxymetacaine Hydrochloride Minims®

    Minims® eye drops (preservative free): 0.5%

    01.06.07 Prucalopride  Tablets: 1mg, 2mg
    05.01.09 Pyrazinamide 

    Tablets: 500mg

    Liquid: 500mg/5ml. This is the nationally recommended strength:

    Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines.

    10.02.01 Pyridostigmine Bromide Mestinon® Tablets: 60 mg
    Used as the standard initial symptomatic treatment for MG. Maximum beneficial dose is usually 360mg daily. Steroids and other immunosuppressant drugs are used to obtain remission those with more severe disease who do not respond sufficiently well to pyridostigmine.
    23.01 Pyridoxine (high dose) 

    Injection: 100 mg/2 mL ampoules
    Injection: 300 mg/2 mL ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    09.06.02 Pyridoxine Hydrochloride 

    Tablets: 10 mg, 20 mg, 50mg

    09.06.02 Pyridoxine Hydrochloride 

    unlicensed unlicensed Injection: 50 mg/2 mL
    Paediatric use only

    04.02.01 Quetiapine 

    Tablets: 25mg, 100mg, 150mg, 200mg, 300mg
    Prolonged release tablets: 50mg, 150mg, 200mg, 300mg, 400mg
    – this formulation is only approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital


     


    (note: preferred brand of quetiapine XL in primary care is Biquelle XL)

    06.07.01 Quinagolide  Tablets: 75micrograms, starter pack of 3 x 25microgram tablets and 3 x 50microgram tablets
    10.02.02 Quinine 

    Tablets: 300mg

    The MHRA advises:

    • Quinine should not be used routinely for nocturnal leg cramps
    • Only consider use when cramps cause regular disruption of sleep.
    • Trial for 4 weeks and discontinue if no benefit.
    • Reassess after 3 months. 
    08.01.05 Radium-223 dichloride 
    06.04.01.01 Raloxifene Hydrochloride Evista®

    Tablets: 60 mg

    05.03.01 Raltegravir Isentress ®

    Tablets: 400mg

    02.05.05.01 Ramipril  Capsules: 1.25mg, 2.5mg, 5mg, 10mg
    11.08.02 Ranibizumab 

    Intravitreal injection: 10mg in 1ml as a 0.23ml vial (dose 0.5mg/0.05ml)

    01.03.01 Ranitidine  Tablets: 150mg, 300mg
    Liquid: 75mg/5ml

    DotLiquid may contain alcohol; up to 405mg per 5ml spoonful, which is equivalent to about 11ml of beer or 5ml of wine

    Injection: 50mg/2ml
    02.06.03 Ranolazine  MR Tablets: 375mg, 500mg
    04.09.01 Rasagiline  Tablets: 1 mg
    10.01.04 Rasburicase Fastertec® Solution for infusion: 1.5 mg/mL
    Commissioned by NHS England
    04.03.04 Reboxetine  Tablets: 4mg
    - not licensed for use in the elderly
    08.01.05 Regorafenib Stivarga®

    Tablets: 40mg

    05.03 Remdesivir Veklury®

    Remdesivir 100mg/20mL concentrate for solution for infusion

    Remdesivir 100mg powder for concentrate for solution for infusion

    15.01.04.03 Remifentanil 

    Injection (vials): 1 mg, 2 mg, 5 mg

    06.01.02.03 Repaglinide  Tablets: 500 micrograms, 1mg, 2mg
    03.04.02 Reslizumab 

    Vials: 25mg, 100mg

    05.03.05 Ribavirin  Capsules: 200mg
    Tablets: 200mg
    Oral solution: 200mg/5ml
    08.03.04.01 Ribociclib 

    Tablets: 200mg

    05.01.09 Rifampicin  IV infusion: 600mg vials for IV infusion
    05.01.09 Rifampicin  Capsules: 150mg, 300mg
    Oral syrup: 100mg/5ml

    N.B. these formulations are GREEN+ when used in the treatment of tuberculosis
    05.01.09 Rifampicin and Isoniazid 

    Tablets: Rifinah® 150 tablets - rifampicin 150mg & isoniazid 100mg, Rifinah® 300 tablets - rifampicin 300mg & isoniazid 150mg

    05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater® Tablets: Rifater® tablets- rifampicin 120mg, isoniazid 50mg & pyrazinamide 300mg
    05.01.07 Rifaximin  Tablets: 550mg
    07.03.01 Rigevidon® 

    Tablets: Ethinylestradiol 30mcg / levonorgestrel 150mcg

    05.03.01 Rilpivirine hydrochloride Edurant®

    Tablets: 25mg

    04.09.03 Riluzole  Tablets: 50 mg
    13.05.03 Risankizumab 

    75mg prefilled pen

    Risankizumab is recommended as an option for treating plaque psoriasis in adults, only if:

    • the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and

    • the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and

    • the company provides the drug according to the commercial arrangement.

    06.06.02 Risedronate   Tablets: 5mg, 30mg, 35mg
    04.02.01 Risperidone  Tablets: 500 microgram, 1mg, 2mg, 3mg, 4mg, 6mg
    Oral liquid: 1mg/1ml
    Orodispersible tablets: 500 microgram, 1mg, 2mg (Quicklets ®)
    N.B. The dispersible tablets should only be used in situations where the plain tablets are unsuitable
    04.02.02 Risperidone  Long acting injection: 25 mg, 37.5 mg, 50 mg
    05.03.01 Ritonavir Norvir®

    Tablets: 100mg

    08.02.03 Rituximab 

    Concentrate for IV infusion: 100mg in 10ml & 500mg in 50ml


    -for musculoskeletal indications see chapter 10
    -approved for first line use in NHL in combination with CHOP in line with NICE
    -approved for maintenance therapy in follicular NHL that has responded to first line induction therapy with rituximab in combination with chemotherapy in line with NICE
    -approved for stage III and IV follicular lymphoma in previously untreated people in line with NICE
    -approved for replased or refractory follicular NHL in line with NICE
    -approved for Post-transplant lymphoproliferative disease
    - approved for first line use in CLL in combination with fludarabine and cyclophosphamide in line with  NICE
    -approved for combination with fludarabine and cyclophosphamide for relapsed or refractory CLL in line with NICE
    -approved for autoimmune haematological conditions (where conventional treatments have failed)
    – Autoimmune haemolytic anaemia
    (AIHA), Evans syndrome, pure red cell aplasia (PRCA), acquired haemophilia A & thrombocytopenia purpura (TTP).
    - Combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
    - a
    pproved for vasculitis (including Wegener’s granulomatosis in adults and children) that has not responded adequately to conventional treatment (e.g. corticosteroids, cyclophosphamide) NICE and additional NHS England criteria
    -NECDAG approved for the treatment of NLPHL
    -NECDAG approved for newly diagnosed mantle cell NHL in patients aged <60 years old approved in combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate NICE
    -NECDAG approved in combination with bendamustine for patients with CLL not fit for FCR chemotherapy or for patients who relapse within 2 years of FCR chemotherapy and not fit for alemtuzumab.
    -NECDAG approved with salvage chemotherapy for patients relapsing > 12 months post 1st line -therapy with R-CHOP
    -NECDAG approved with a standard NHL induction regimen in patients who cannot be given an anthracycline. Rituximab with other chemotherapy regimens is an alternative treatment option e.g. DECC, CVP for this group of patients, as part of their first line therapy. Also in addition to the MACOP-B regimen for the small number of young patients with DLBCL, subtype Primary Mediastinal B cell Lymphoma
    -NECDAG approved for the treatment of hairy Cell Leukaemia (HCL) or Hairy cell Leukaemia varian (HCL-v) who:


            -relapse early after purine analogue therapy (< 2 years post treatment)
            -are refractory to purine analogues.
    -NTAG approved for the treatment of immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children NTAG
    -approved for the treatment of immunobullous disease in line with NHS England Commissioning Policy



    SC injection: 1.4g solution


    -approved for use as maintenance single agent therapy in FL, mantle cell lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma in line with NHS ENGLAND SSC1434

    09.01.04 Rituximab 

    (1st line for ITP -Intravenous with oral Prednisolone or Dexamethasone)
    Injection: 100mg, 500mg

    10.01.03 Rituximab 

    Concentrate for solution for infusion: 100 mg/10 mL, 500 mg/50 mL

    Note: 2nd line with MTX on failure after 6 months of 1st line; or monotherapy if MTX contraindicated due to pulmonary fibrosis)


    NTAG approved in combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitors


    NTAG approved for combination with other (non-methotrexate) disease modifying antirheumatic drugs and as monotherapy in cases in which conventional treatment with tumour necrosis factor inhibitors or methotrexate is deemed unsafe

    02.08.02 Rivaroxaban  Tablets: 10mg, 15mg, 20mg
    04.11 Rivastigmine  Capsules: 1.5 mg, 3 mg, 4.5 mg, 6 mg
    Oral solution: 2 mg/1 mL
    Patches: 4.6 mg/24 hours, 9.5 mg/24 hours, 13.3mg/24hours
    15.01.05 Rocuronium Bromide Esmeron®

    Injection (vials): 50 mg/5 mL

    03.03.03 Roflumilast Daxas®

    Tablets: 500 micrograms

    09.01.04 Romiplostim Nplate®

    1st line for ITP patients who require treatment for bleeding, profound thrombocytopenia or to cover surgery during the Covid-19 pandemic
    3rd line for severe, refractory ITP – choice according to patient preference

    Injection: 250 micrograms

    04.09.01 Ropinirole 

    Tablets: 250 micrograms, 500 micrograms, 1 mg, 2 mg, 5 mg
    MR tablets: 2 mg, 4 mg, 8 mg


    (preferred brand in primary care is Repinex XL)

    15.02 Ropivacaine Hydrochloride Naropin®

    Injection: 20 mg/10 mL, 75 mg/10 mL, 100 mg/10 mL ampoules (Naropin®)
    Infusion: 400 mg/200 mL infusion bag (Naropin®)
    unlicensedunlicensed Infusor: 0.2%, 230 mL

    02.12 Rosuvastatin  Tablets: 5mg, 10mg, 20mg, 40mg
    14.04 Rotavirus vaccine 

    Rotavirus vaccine, live
    Oral suspension: 1.5 mL (Rotarix®)

    04.09.01 Rotigotine  Transdermal patches: 2 mg/24 hrs, 4 mg/24 hrs, 6 mg/24 hrs, 8 mg/24 hrs
    14.04 Rubella vaccine 

    Use combined vaccines

    08.01.05 Rucaparib 

    Film coated tablets: 200mg, 250mg, 300mg

    08.01.05 Ruxolitinib 

    Tablets: 5mg, 15mg, 20mg

    02.05.05 Sacubitril and valsartan Entresto® Tablets:
    24mg/26mg (containing 24.3mg sacubitril and 25.7mg valsartan as sacubitril valsartan sodium salt complex)

    49mg/51mg (containing 48.6mg sacubitril and 51.4mg valsartan as sacubitril valsartan sodium salt complex)

    97mg/103mg (containing 97.2mg sacubitril and 102.8mg valsartan as sacubitril valsartan sodium salt complex)
    04.09.01 Safinamide Xadago

    Tablets: 50mg, 100mg.

    Green Plus information leaflet: Click here.

    03.01.01.01 Salbutamol  Metered dose inhaler (MDI): 100mcg/puff
    Breath actuated MDI: 100mcg/puff
    Breath actuated dry powder inhaler (DPI): 100mcg/puff, 200mcg/puff
    Nebules: 2.5mg/2.5ml, 5mg/2.5ml
    Injection: 500mcg/1ml, 5mg/5ml
    13.07 Salicyclic acid 2% in aqueous cream 100g Salicylic acid:

    Specials from secondary care. For more info, see

    13.05.02 Salicylic acid: in emulsifying ointment Salicyclic acid 2% in aqueous cream 100g Salicylic acid
    12.03.05 Saliveze® 
    12.03.05 Salivix® 
    03.01.01.01 Salmeterol  Inhaler (MDI): 25mcg/puff
    Breath actuated inhaler (Accuhaler): 50mcg/puff
    05.03.01 Saquinavir Invirase®

    Tablets: 500mg

    10.01.03 Sarilumab 

    Pre-filled pen: 150mg, 200mg
    Syringe: 150mg, 200mg

    06.01.02.03 Saxagliptin 

    Tablets: 2.5mg, 5mg

    10.01.03 Secukinumab Consentyx ® Injection: 150 mg/mL,
    Pre-filled pen or pre-filled syringe: 150-mg
    13.05.03 Secukinumab 

    150 microgram prefilled pen and syringe.

    04.09.01 Selegiline Hydrochloride  Tablets: 5 mg
    09.05.05 Selenium 

    Tablets: 200 micrograms
    Oral solution available

    09.05.05 Selenium 

    Injection: 100micrograms in 2ml

    06.01.02.03 Semaglutide Ozempic®

    Injection (pre-filled pen): 0.25mg, 0.5mg and 1mg doses

    06.01.02.03 Semaglutide Rybelsus®

    Tablets: 3 mg, 7 mg and 14 mg

    01.06.02 Senna  Tablets: 7.5mg
    Syrup: 7.5mg/5ml
    04.03.03 Sertraline  Tablets: 50 mg, 100 mg
    Liquid: 50mg/5ml
    09.05.02.02 Sevelamer Carbonate Renvela®

    Powder for oral suspension: 2.4 g

    09.05.02.02 Sevelamer Hydrochloride  Renagel®

    Tablets: 800 mg

    15.01.02 Sevoflurane 

    250ml

    13.09 Shampoo Benzalkonium chloride Dermax®
    13.09 Shampoo Cetrimide with undecanoic acid Ceanel Concentrate®
    13.05.02 Shampoos T/Gel®

    125ml, 250ml

    02.05.01 Sildenafil  Liquid: 1mg/1ml*
    *Hospital use for paediatric patients
    02.05.01 Sildenafil  Tablets: 20mg, 25mg
    Oral suspension: 10mg/1ml
    07.04.05 Sildenafil 

    Tablets: 25mg, 50mg, 100mg

    13.07 Silver Nitrate 

    75% & 95% applicators

    13.11.06 Silver Nitrate Pencil 

    40%, 75% and 95%

    13.10 Silver Sulfadiazine Flamazine®

    20g, 50g, 250g, 500g

    01.01.01 Simeticone  Liquid: 40mg/1ml*
    *Hospital use only
    03.09.02 Simple Linctus, BP 
    03.09.02 Simple Linctus, Paediatric BP  *Hospital use only
    02.12 Simvastatin  Tablets: 10mg, 20mg, 40mg
    13.02.02 Siopel cream  Siopel®

    50g

    08.02.04 Siponimod Mayzent®

    Tablet: 250 micrograns and 2 mg

    08.02.02 Sirolimus 

    Tablets: 1mg & 2mg
    Oral solution: 1mg per ml

    06.01.02.03 Sitagliptin 

    Tablets: 25mg, 50mg, 100mg

    13.11 Skin preparation swabs Sterets 

    containing 70% isopropyl alcohol

    10.01.03 Sodium Aurothiomalate 

    Injection: 10 mg/0.5 mL, 50 mg/0.5 mL

    Note: this is as an alternative after biologics

    09.02.01.03 Sodium Bicarbonate 

    (to provide around 6-7 mmol)


    Tablets: 600 mg
    Capsules: 500 mg


    Prescribers should prescribe the product with lowest acquisition cost

    09.02.01.03 Sodium Bicarbonate 

    unlicensed unlicensed Oral solution (For use in paediatrics): 1mmol/1ml (100ml)

    09.02.02.01 Sodium Bicarbonate 

    Infusion: 1.26% 500ml
    Infusion: 4.2% 500ml
    Infusion: 8.4% 500ml

    12.01.03 Sodium Bicarbonate 

    Ear drops: 5%

    23.01 Sodium bicarbonate 

    Injection: 1.26 % Polyfusor® infusion 500 mL
    Injection: 8.4 % (840 mg/10 mL) ampoules, Polyfusor® infusion 200 mL


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    07.04.04 Sodium chloride 

    0.9% solutions (up to 3 litres)

    07.04.04 Sodium chloride 

    100ml sachets: 0.9% solution

    09.02.01.02 Sodium Chloride Slow Sodium®

    SR tablets: 600mg (equivalent to approximately 10mmol sodium)

    09.02.02.01 Sodium Chloride 

    Sodium Chloride 0.9%(normal saline)
    Injection: 5ml, 10ml & 20ml
    IV infusion: 100ml, 250ml, 500ml & 1000ml
    Irrigation: 1000ml & 3000ml



    Sodium Chloride 0.18%
    IV infusion: 500ml


    Sodium Chloride 0.45%
    IV infusion: 500ml


    Sodium Chloride1.8%
    IV infusion: 500ml


    Sodium Chloride 2.7%
    IV infusion: 500ml


    Sodium Chloride 5%
    IV infusion: 500ml


    Sodium Chloride 30%
    Injection: 10ml

    11.99.99.99 Sodium chloride 

    Unit dose eye drops: 0.9%
    Eye drops: 5%
    Eye ointment: 5%
    P/F eye drops: 5%

    12.02.02 Sodium chloride 

    Nasal drops: 0.9%

    13.11 Sodium Chloride 

    Sterile solution - bottles 25ml & 100ml sachets (Normosol) & 45ml plastic ampoules/pods (Miniversol)

    03.07 Sodium chloride 0.9%  Nebuliser solution: 10ml
    03.07 Sodium chloride 7% (Hypertonic) Nebusal® Nebuliser solution: 4ml
    09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion 

    IV infusion: 0.9%/5% 500ml
    IV infusion: 0.18%/4% 500ml & 1000ml
    IV infusion: 0.18%/10% 500ml
    Infusion: 0.45%/5% 500ml

    09.02.01.02 Sodium Chloride Oral solution  

    unlicensed unlicensed oral solution (for use in paediatrics): 5mmol/mL

    11.99.99.99 Sodium Citrate 

    P/F eye drops: 10.11%

    15.03 Sodium Citrate 

    Oral solution: 0.3 molar, 30 mL

    01.06.04 Sodium citrate micro-enema 
    06.06.02 Sodium Clodronate  Capsules: 400mg*
    *For breast pain/breast cancer/myeloma patients only
    11.04.02 Sodium Cromoglicate 

    Eye drops: 2%

    11.04.02 Sodium Cromoglicate 

    unlicensed unlicensed Eye drops (preservative free): 2%

    13.11.04 Sodium dichloroisocyanurate 

    500mg & 5g solution tablets: Granules.

    09.01.01.01 Sodium Feredetate Sytron®

    Sugar-free elixir: 190mg/5ml (27.5mg elemental iron/5ml)

    05.01.07 Sodium fusidate 

    Tablets: 250 mg
    Oral suspension: 250 mg/5 mL (as fusidic acid)

    05.01.07 Sodium fusidate 

    Vial: powder and solvent for solution for infusion, 500 mg

     

    07.04.03 Sodium hyaluronate Hyacyst 120

    Prefilled syringe: 120mg/50ml

    11.08.01 Sodium Hyaluronate 

    Eye drops (preservative-free): 0.1% (Hylo-Tear®)
    Eye drops (preservative-free): 0.2% (Hylo-Forte®)


    Brands in primary care may vary

    11.99.99.99 Sodium Hyaluronate  

    Prefilled syringe (Microvisc): 14mg/ml
    Prefilled siringe (Provisc): 10mg/ml
    Healon GV: 14mg/ml

    01.06.02 Sodium hydrogen carbonate / sodium dihydrogen phosphate Lecicarbon A® Suppository: Sodium hydrogen carbonate 0.500g, sodium dihydrogen phosphate 0.680g

    Only for pre-operative use for patients undergoing rectal surgery or diagnostic procedure.
    13.11.04 Sodium Hypochorite 1% sterilising Solution 1% 
    23.01 Sodium nitrite 

    Injection: 3% (300 mg/10 mL) ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    02.05.01 Sodium Nitroprusside 

    Injection for infusion: 50mg vial


    Used in critical care at City Hospitals Sunderland

    01.06.02 Sodium Picosulfate  Elixir: 5mg/5ml*
    *For use in paedatrics only
    09.02.01.01 Sodium polystyrene sulfonate Resonium A®

    Powder: 454g

    02.13 Sodium Tetradecyl Sulphate  Injection: 0.2%, 5ml ampoule
    Injection: 0.5%, 2ml ampoule
    Injection: 1%, 2ml ampoule
    Injection: 3%, 2ml, 5ml ampoule
    23.01 Sodium thiosulphate 

    Injection: 50% (10 g/20 mL) ampoules


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    04.02.03 Sodium valproate  M/R Tablets: 200mg, 300mg & 500mg
    - used for the prevention and treatment of manic episodes associated with bipolar disorder (unlicensed indication). May be useful in patients unresponsive to lithium. See section 4.8.1 for other sodium valproate formulations.
    04.08.01 Sodium Valproate 

    Tablets, crushable: 100 mg
    Tablets (e/c): 200 mg, 500 mg
    MR Tablets: 200 mg, 300 mg, 500 mg
    MR Granules: 50 mg, 100 mg, 250 mg, 500 mg, 750 mg, 1g
    Liquid (sugar-free available): 200 mg/5 mL

    04.08.01 Sodium Valproate  Injection: 400mg
    04.08.01 Sodium Valproate  Suppositories: 300 mg (unlicensed in the UK)
    09.02 Sodium zirconium cyclosilicate 

    Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used:

    • in emergency care for acute life-threatening hyperkalaemia alongside standard care or

    • in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they:

       

      • have a confirmed serum potassium level of at least 6.0 mmol/litre

      • are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and

      • are not on dialysis.

        Sodium zirconium cyclosilicate is recommended only if the company provides it according to the commercial arrangement.

    09.02.01.01 Sodium zirconium cyclosilicate Lokelma ®

    Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used:

    • in emergency care for acute life-threatening hyperkalaemia alongside standard care or

    • in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they:

       

      • have a confirmed serum potassium level of at least 6.0 mmol/litre

      • are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and

      • are not on dialysis.

         

    • Sodium zirconium cyclosilicate is recommended only if the company provides it according to the commercial arrangement.
    05.03.03.02 Sofosbuvir  Tablets: 400mg
    05.03.03.02 Sofosbuvir/velpatasvir/voxilaprevir Vosevi

    Tablets: 400mg/100mg/100mg

    07.04.02 Solifenacin 

    Tablets: 5mg, 10mg

    04.04 Solriamfetol Sunosi®

    Tablets: 75 mg and 150 mg

    Approved for the treatment of narcolepsy woth or without cataplexy in adults as an alternative to pitolisant in those who would have otherwise received pitolisant in line with NTAG guidance.

    06.05.01 Somatropin 
    08.01.05 Sorafenib 

    Tablets: 200mg

    06.01.02.03 Sotagliflozin 

    Tablet: 200mg

    Approved with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy in line with NICE

     

    02.04 Sotalol  Tablets: 40mg, 80mg, 160mg
    02.02.03 Spironolactone  Tablets: 25mg, 50mg, 100mg
    02.02.03 Spironolactone 

    Liquid: 50mg/5mL*
    *Specialist initiation/paediatric use only

    06.04.04 Spironolactone 

    Tablets: 25 mg & 100 mg

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    07.05.05 Spironolactone 

    Tablets: 50mg

    05.03.01 Stavudine Zerit®

    Capsules: 20mg, 30mg, 40mg
    Oral solution: 1mg/ml

    02.10.02 Streptokinase  Vials: 250,000 unit, 1.5 million-unit (MU)
    05.01.09 Streptomycin  Injection: 1g
    08.01.05 Streptozocin 

    unlicensedunlicensed Injection: 1g (only available on a named patient basis)

    01.03.03 Sucralfate  Tablets: 1g
    Suspension: 1g/5ml
    13.02.02 Sucralfate 4% cream 

    For limited use around gastrostomies when wound breakdown is thought to be aggravated by leakage of gastric acid

    13.02.02 Sudocrem Sudocrem®

    30g, 60g, 125g, 250g

    15.01.06 Sugammadex Bridion®

    Injection: 500 mg/5 mL ampoules

    01.05.01 Sulfasalazine  Tablets: 500mg
    10.01.03 Sulfasalazine  EC Tablets: 500 mg
    Oral suspension (sugar-free): 250 mg/5 mL
    10.01.04 Sulfinpyrazone 

    Tablets: 100mg, 200mg


     


    unlicensedunlicensed

    17 Sulphur hexafluoride SonoVue®

    Microbubbles 8 microlitres/mL

    04.02.01 Sulpiride  Tablets: 200mg, 400mg
    Oral solution (sugar-free): 200mg/5ml
    04.07.04.01 Sumatriptan 

    Tablets: 50 mg, 100 mg
    Nasal spray: 10 mg/0.1 mL actuation, 20 mg/0.1 mL actuation
    Injection (pre-filled syringe): 3 mg/0.5 mL and 6 mg/0.5 mL

    08.01.05 Sunitinib 

    Capsules: 50mg 100mg, 400mg

    15.01.05 Suxamethonium Chloride 

    Injection (amps): 100 mg/2 mL

    11.08.01 Systane (Contains hydroxypropyl guar, polyethylene glycol 400, propylene glycol (and other ingredients) 

    Eye drops: 10ml Multidose bottles
    Eye drops: 0.8ml Preservative free vials

    08.02.02 Tacrolimus 

    500 microgram Capsules: 1mg & 5mg (Prograf & Adoport)
    unlicensedunlicensed Oral suspension: 5mg/5mL  
    RED - Concentrate for preparing IV infusion: 5mg in 1 ml
    - approved for renal transplantation in children and adolescents in line with NICE

     

    MR Capsules (Advagraf): 500microgram, 1mg, 3mg & 5mg
    - only approved for use for prophylaxis of organ rejection in kidney and liver transplantation. Advagraf® is approved for use in patients who are currently prescribed Prograf, and de novo patients should be prescribed Adoport®.

     

    MR tablets (Envarsus): 750microgram, 1mg, 4mg
    - approved for the treatment of renal and liver transplant patients who are suffering from neurotoxicity with other formulations or for patients requiring large doses of tacrolimus.

    13.05.03 Tacrolimus Protopic®

    Ointment 0.03% & 0/1%

    07.04.01.02 Tadalafil 

    Tablets: 5mg
    (Green plus for indications involving urinary retention or benign prostatic hyperplasia)

    07.04.05 Tadalafil 

    *Tablets: 10mg, 20mg 
    (*For post radical prostatectomy)

    08.01.05 Talimogene laherparepvec Imlygic®

    Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml


    -approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy

    07.05.01.01 Tamoxifen 

    Tablets: 20mg

    08.03.04.01 Tamoxifen 

    Tablets: 10mg & 20mg
    Sugar-free oral solution: 10mg in 5ml

    07.04.01 Tamsulosin Hydrochloride 

    M/R capsules: 400 micrograms

    04.07.02 Tapentadol Palexia®

    Palexia® MR Tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
    Use only after trial with other strong opiates

    Specialist initiation only - consult pain team or palliative care before use.

    13.05.02 Tar Pomade Pomade containing 6% coal tar solution and salicylic acid 2% in an emulsifying ointment base Tar Pomade
    08.01.03 Tegafur with Uracil Uftoral®

    Capsules:  containing tegafur 100mg & uracil 224mg

    05.01.07 Teicoplanin  Injection (for IV infusion): 200mg, 400mg
    04.01.01 Temazepam  Tablets: 10mg, 20mg
    Oral solution: 10mg/5ml
    05.01.01.02 Temocillin  Vials: 1g*
    *Hospital use only
    08.01.05 Temozolomide 

    Capsules: 5mg, 20mg, 100mg, 250mg

    02.10.02 Tenecteplase  Vials: 40mg, 50mg
    05.03.01 Tenofovir and emtricitabine Truvada®

    Tablets containing: 200mg of emtricitabine and 245mg of tenofovir disoproxil (equivalent to 300mg of tenofovir disoproxil fumarate or 136mg of tenofovir)

    05.03.01 Tenofovir disoproxil Viread®

    Tablets: 123mg, 163mg, 204mg, 245mg (as tenofovir disoproxil fumarate)

    05.03.01 Tenofovir Disproxil  Tablets: 245mg
    Granules (sugar-free): 33mg/1g (7.5g contains approximately 245mg tenofovir disoproxil)
    05.03.01 Tenofovir, cobicistat, elvitegravir and emtricitabine Stribild®

    Tablets: 150mg/150mg/200mg/245mg

    05.03.01 Tenofovir, efavirenz and emtricitabine Atripla®

    Tablets: 600mg/200mg/245mg

    05.02 Terbinafine  Tablets: 250mg
    13.10.02 Terbinafine 1% cream 
    03.01.01.01 Terbutaline  Breath actuated DPI (Turbohaler): 500mcg/puff
    07.01.04 Terbutaline 

    Ampoules: 500micrograms/ml

    08.02.04 Teriflunomide 

    Film coated tablets: 14mg

    06.06.01 Teriparatide  Pre-filled pen: 250mcg/1mL
    06.05.02 Terlipressin  Injection: 1mg vial, 1 mg/8.5mL
    06.04.02 Testosterone 

    Gel: 23 mg/1.15 g (23 mg per actuation); 85.5 g (Testavan®)

    Gel: 50 mg/5 g (50 mg per tube); 30 tubes (Testim®)

    Gel: 16.2 mg/g (20.25 mg per actuation); 88 g (Testogel®)

    Gel: 50 mg/5 g sachet; 30 sachets (Testogel®)

    Gel: 20 mg/g (10 mg per actuation); 60 g (Tostran®)

     

    06.04.04 Testosterone 

    Gel: 23 mg/1.15 g (23 mg per actuation); 85.5 g (Testavan®)

    Gel: 50 mg/5 g (50 mg per tube); 30 tubes (Testim®)

    Gel: 16.2 mg/g (20.25 mg per actuation); 88 g (Testogel®)

    Gel: 50 mg/5 g sachet; 30 sachets (Testogel®)

    Gel: 20 mg/g (10 mg per actuation); 60 g (Tostran®)

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    06.04.04 Testosterone enantate 

    Ampoule: 250 mg/1 mL

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    06.04.02 Testosterone esters 

    Ampoule: 250 mg (as esters)/1 mL (Sustanon 250®)

     

    06.04.04 Testosterone esters 

    Ampoule: 250 mg (as esters)/1 mL (Sustanon 250<sup>®</sup>)

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    06.04.02 Testosterone oral Restandol Testocaps® Capsules: 40 mg
    06.04.02 Testosterone undecanoate  

    Injection: 1g in 4 mL (250 mg/mlL oily injection (Nebido®)

     

    06.04.04 Testosterone undecanoate  

    Injection: 1g in 4 mL (250 mg/mlL oily injection (Nebido®)

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    The medication is only green plus when used for treatment of gender dysphoria.

    For indications other than gender dysphoria please see 'Male sex hormones and antagonists - 06.04.02'

    14.04 Tetanus vaccine 

    Use combined vaccines

    04.09.03 Tetrabenazine  Tablets: 25 mg
    11.07 Tetracaine Hydrochloride 

    Minims® eye drops (preservative free): 0.5%, 1%

    06.05.01 Tetracosactide  Injection: 250 micrograms/1mL
    Depot injection: 1mg/1mL
    08.02.04 Thalidomide 

    Capsules: 50mg


    - approved in combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE
    - approved for the treatment of bleeding from bowel angiodysplasia in patients with an inherited/acquired bleeding disorder on specialist advice only.
    -approved for the treatment of severe epistaxis as a result of hereditary haemorrhagic telangiectasia (HHT) who have failed all other treatments.

    03.01.03 Theophylline 

    Theophylline SR
    Nuelin SA® tablets: 175mg, 250mg
    Uniphyllin® tablets: 200mg, 300mg, 400mg

    N.B. Modified release preparations must be prescribed by brand name

    Theophylline liquid
    50mg/5mL (Dilatrane®)
    50mg/5mL
    150mg/5mL

    09.06.02 Thiamine 

    Tablets: 50 mg, 100 mg

    15.01.01 Thiopental (thiopentone) sodium 

    Injection (vials): 500 mg 

    08.01.01 Thiotepa 

    Injection: 15mg

    06.04.01.01 Tibolone  Tablets: 2.5mg
    02.09 Ticagrelor 

    Tablets: 60mg, 90mg
    Ticagrelor in combination with low-dose aspirin is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes. However, selected patients at high risk may be offered ticagrelor 60mg bd for up to a maximum of three years by the initiating specialist in secondary care. This will be communicated to practices in the patients discharge letter.

    05.01.03 Tigecycline  Injection: 50mg
    13.05.03 Tildrakizumab 

    Indicated for treating moderate to severe plaque psoriasis as per NICE

    13.05.03 Tildrakizumab 

    100mg solution for injection in prefilled syringe

    NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis

    13.04 Timodine® Timodine Cream

    30g

     

    1st line Mildly potent topical corticosteroids with antimicrobials

    11.06 Timolol 

    Eye drops: 0.25%, 0.5%
    Unit dose eye drops (preservative-free): 0.25%, 0.5%
    Eye drops gel forming solution (once daily): 0.25%, 0.5%
    Eye drops (unit dose) (once daily, preservative-free): 0.1%
    Preservative free eye drops (Eysano PF): 0.25%, 0.5%

    05.01.11 Tinidazole  Tablets: 500mg*
    *After consultation with microbiology only
    07.04 Tiopronin 

    Used in the prevention of nephrolithiasis

    100mg, 250mg tablets

    03.01.02 Tiotropium 

    HandiHaler® Dry powder inhaler device and refill: 18mcg
    Refill: 18mcg
    Respimat®: 2.5mcg

    Braltus Zonda Dry powder inhaler : 10mcg (first choice option if tiotropium dry powder inhaler is required).

    Tiotropium Respimat is a step 4 option for chronic asthma and may be useful for patients with COPD who can not use a dry powder inhaler.

     

    03.01.04 Tiotropium & olodaterol® Spiolto Respimat

    Inhalation solution via respimat device: 2.5 microgram/2.5 microgram

    First choice for new patients

    05.03.01 Tipranavir Aptivus®

    Oral solution: 100mg/ml
    Capsules: 250mg

    02.09 Tirofiban  Infusion: 12.5mg/250ml
    08.01.05 Tisagenlecleucel Kymriah®
  • Indicated for treating 'paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse as per NICE

  • NICE has recommended tisagenlecleucel for use within the Cancer Drugs Fund for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies.
  • 08.01.05 Tivozanib Fotivda®

    Capsules: 890 mg and 1340 mg

     

    10.02.02 Tizanidine  Tablets: 2 mg, 4 mg
    05.01.04 Tobramycin inhaler TOBI Podhaler® TOBI Podhaler: 28mg

    Approved in line with NHS England specialised commissioning criteria for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Only to be prescribed by secondary care from April 2016 in line with NHS England Clinical Commissioning Policy.
    10.01.03 Tocilizumab 

    Concentrate for intravenous infusion: 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL
    Subcutaneous injection: 162mg/0.9mL (for rheumatoid arthritis only)

    Note: 3rd line with MTX on failure after 6 months of 2nd line; or monotherapy if MTX contraindicated due to pulmonary fibrosis

    10.01.03 Tofacitinib 

    Tablets: 5mg

    06.01.02.01 Tolbutamide  Tablets: 500mg
    04.09.01 Tolcapone 

    Tablets: 100mg

    07.04.02 Tolterodine 

    Tablets: 1mg, 2mg

    06.05.02 Tolvaptan Jinarc® Tablets: 15mg, 30mg
    Tablets (combination packs): 45mg/15mg, 60/30mg, 90/30mg
    06.05.02 Tolvaptan Samsca® Tablets: 15mg, 30mg
    04.08.01 Topiramate  Tablets: 25 mg, 50 mg, 100 mg, 200 mg
    Capsules: 15 mg, 25 mg, 50 mg
    08.01.05 Topotecan 

    Capsules: 0.25mg, 1mg capsules
    Vials: 1mg, 4mg

    08.01.05 Trabectedin Yondelis®

    Injection: 250microgram

    04.07.02 Tramadol  Capsules: 50 mg
    Soluble Tablets: 50 mg

    04.07.02 Tramadol 

    MR: 50mg, 100mg, 150mg, 200mg, 300mg, 400mg
    MR formulation only to be used on advice of pain specialists

    06.01.05 Tramadol  see section 4.7 for preparations
    08.01.05 Trametinib Mekinist®

    Film coated tablets: 500microgram, 2mg

    02.11 Tranexamic Acid  Tablets: 500mg
    Injection: 500mg/5ml

    For mouthwash: dissolve tablets in water as per hospital instruction
    12.03.04 Tranexamic Acid Mouthwash 

    Tablets: 500mg
    For mouthwash: dissolve tablets in water as per hospital instruction

    08.01.05 Trastuzumab Herceptin®

    Vial for preparing IV infusion: 150mg
    Injection: 600mg s/c injection

    08.01.05 Trastuzumab emtansine Kadcyla®
    11.06 Travoprost 

    Eye drops: 40 micrograms/1 mL

    11.06 Travoprost with Timolol 

    Eye drops: travoprost 40 micrograms/1 mL, timolol 5 mg/1 mL (DuoTrav®)

    04.03.01 Trazodone  Capsules: 50 mg, 100 mg
    Tablets: 150 mg
    Liquid (sugar-free): 50 mg/5 mL
    - Trazodone is widely used off-licence for night sedation and behavioural symptoms of dementia – see section 4.1
    08.01.01 Treosulfan 

    Infusion: 1g and 5g

    08.01.05 Tretinoin 

    Capsules: 10mg

    10.01.02.02 Triamcinolone Acetonide Adcortyl® Intra-articular injection: 10 mg/1 mL, 50 mg/5 mL (Adcortyl®)
    10.01.02.02 Triamcinolone Acetonide Kenalog® Intra-articular injection: 40 mg/1 mL, 80mg/2 mL (Kenalog®)
    12.01.01 Triamcinolone with neomycin, gramicidin and nystatin Kenacomb Otic®

    unlicensedunlicensed Ointment: 1 mg triamcinolone acetonide, 2.5 mg neomycin sulphate, 0.25mg gramicidin, 100,000 units nystatin per 5 g

    13.07 Trichloroacetic Acid 

    10%, 75%, & 90% solutions

    13.11.05 Triclosan Manusept®
    13.11.05 Triclosan 1% Skinsan®
    13.11.05 Triclosan 2% Aquasept®
    04.02.01 Trifluoperazine  Tablets: 1mg, 5mg
    Syrup: 1mg/5ml
    Oral sugar-free solution: 5mg/5ml
    11.03.03 Trifluorothymidine 

    unlicensed unlicensed Preservative free eye drops: 1%

    08.01.05 Trifluridine and tipiracil  

    Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy

    05.01.08 Trimethoprim  Tablets: 100mg, 200mg
    Oral suspension: 50mg/5ml
    06.04.04 Triptorelin 

    Injection: 3 mg, 3.75 mg, 11.25 mg and 22.5 mg

     

    Gender Dysphoria (unlicensed indication) - please see Northern Region Gender Dysphoria Service guidelines for further information

    08.03.04.02 Triptorelin 


    Green+ Traffic Light OR Amber Traffic Light

    Dependent on patient disease state (classified by module; this will be communicated by secondary care).

    Module 1 - medication is Green+

    Module 2 - medication is Amber

     

    Injection: 3 mg, 3.75 mg, 11.25 mg and 22.5 mg

    06.07.02 Triptorelin (as acetate) 

    Injection (pre-filled syringe): 3.75mg (Gonapeptyl Depot®)
    Injection (vial): 3mg, 11.25mg, 22.5mg (Decapeptyl SR®)



    Green+ Traffic Light  N.B. Green+ for precocious puberty indication

    07.03.01.03 Tri-regol® 

    Tablets

    11.05 Tropicamide 

    Eye drops: 0.5%, 1%
    Minims® (preservative free): 0.5%, 1%

    07.04.02 Trospium 

    Tablets: 20mg

    07.03.01.07 T-Safe® Cu 380 A 

    Intrauterine device - replacement every 10 years

    07.03.01.07 TT 380 Slimline® 

    Intrauterine device - replacement every 10 years

    14.04 Typhoid vaccine 

    Typhoid Polysaccharide vaccine
    Prefilled syringe: 0.5 mL (TYPHIM Vi®)
    Prefilled syringe: 0.5 mL (Typherix®)
    Gastro-resistant capsules: three capsules (Vivotif®)

    06.07.02 Ulipristal Esmya®

    Tablets: 5mg


    Please note additional safety guidance published by the MHRA in August 2018 (link below) Updated Sept 2020.

    07.03.05 Ulipristal EllaOne®

    Tablet: 30mg


    Recommended by NETAG as the preferred drug treatemnt option for post-coital contraception for patients who present between 72 hours and 120 hours following unprotected intercourse.

    03.01.04 Umeclidinium & vilanterol Anoro Ellipta®

    Anoro Ellipta® breath actuated DPI: 55/22mcg/puff

    First choice for new patients

    10.01.03 Upadacitinib Rinvoq®

    MR tablet: 15 mg

    13.02.01 Urea 5%, Lauromacrogols 3% Balneum®

    50g, 100g

     

    1st line urea containing emollient

    17 Urografin 150® 

    Ampoules: 10ml


    For infusion: 250ml

    02.10.02 Urokinase  Vials: 10,000 units, 25,000 units, 50,000 units, 100,000 units, 250,000 units, 500,000 units
    01.09.01 Ursodeoxycholic acid 

    Tablets: 150mg, 250mg, 300mg, 500mg
    Capsules: 250mg
    Suspension: 250mg/5ml (Ursofalk®) - for use in bariatric patients

    01.05.03 Ustekinumab Stelara

    Concentrate for solution for infusion: 130mg

    13.05.03 Ustekinumab 

    45mg vial

    10.01.03 Ustenkinumab  Solution for injection: 45mg
    05.03.02.01 Valaciclovir Valtrex® Tablets: 500mg
    05.03.02.02 Valganciclovir  Tablets: 450mg
    04.02.03 Valproic Acid (as semisodium valproate)  Tablets: 250 mg, 500 mg
    - licensed alternative to sodium valproate m/r tablets
    02.05.05.02 Valsartan  Capsules: 40mg, 80mg, 160mg
    05.01.07 Vancomycin  Injection (for IV infusion): 500mg, 1g
    05.01.07 Vancomycin  Capsules: 125mg
    11.03.01 Vancomycin  

    unlicensed unlicensed Eye drops: 1.4%

    04.10.02 Varenicline  Tablets: 500 micrograms, 1 mg
    Starter pack available
    14.04 Varicella-Zoster vaccine (VZ) 

    Varicella-zoster virus Oka strain (live, attenuated)
    Vial with solvent in a pre-filled syringe 0.5 mL strain) (Varilrix®)
    May contain traces of neomycin


    Varicella virus Oka/Merck strain (live, attenuated)
    Vial with solvent in a pre-filled syringe 0.5 mL (VARIVAX®)
    May contain traces of gelatin and neomycin


    For adult shingles vaccination programme


    Varicella-zoster virus Oka/Merck strain (live, attenuated)
    Vial with solvent in a pre-filled syringe 0.65 mL (Zostavax®)
    May contain traces of gelatin and neomycin

    06.05.02 Vasopressin (Argipressin)  Injection: 20 units/1mL
    15.01.05 Vecuronium Bromide Norcuron®

    Injection (vials): 10 mg

    01.05.03 Vedolizumab 
    08.01.05 Vemurafenib 

    Tablets: 240mg

    08.01.05 Venetoclax Venclyxto®

    Tablets: 10 mg, 50 mg & 100 mg

    04.03.04 Venlafaxine 

    Tablets: 37.5 mg, 75 mg
    Solution: 75mg/5ml*
    MR tablets: 75 mg, 150 mg
    - Patients who are deemed stable on doses of up to 225mg daily of MR Venlafaxine should be switched to the equivalent dose of immediate-release venlafaxine
    - MR preparations are only to be used in patients currently prescribed doses of 300mg and over and for whom there is no suitable alternative, those who have experienced discontinuation reactions (at any dose), and for patients who need to take the once daily formulation in order to facilitate care visits.
    (preferred brand of Venlafaxine XL in primary care is Vencarm XL)
    *Hospital use only

    02.06.02 Verapamil  Tablets: 40mg, 80mg, 120mg
    SR Tablets: 120mg, 240mg
    Oral solution: 40mg/5ml
    MR Capsules: 180mg
    02.06.02 Verapamil  Injection: 5mg/2ml (2.5mg/1ml)
    11.08.02 Verteporfin 

    Injection: 15 mg

    04.08.01 Vigabatrin  Tablets: 500 mg
    Powder: (sugar-free): 500 mg/sachet

    08.01.04 Vinblastine 

    Injection: 10mg

    08.01.04 Vincristine 

    Injection: 2mg in 2ml
    Prefilled syringe: 2mg in 20ml
    Infusion bags: 2mg in 50ml

    08.01.04 Vindesine Sulphate 

    Injection: 5mg

    08.01.04 Vinorelbine 

    Capsules: 20mg, 30mg
    Injections: 10mg in 1ml & 50mg in 5ml

    23.01 Viper venom antiserum 

    Injection: 1g vials


    Red as an emergency antidote held by City Hospital Sunderland. Please see other chapters for formulary status when used for other indications.

    09.06.01 Vitamins A and D 

    Capsules: containing vitamin A 4,000 units, vitamin D 400 units (10 micrograms)

    09.06.02 Vitamins B+C (Pabrinex® High Potency IV and IM) 

    IM High Potency Injection: 7 mL
    IV High Potency Injection: 10 mL

    05.02 Voriconazole  Tablets: 50mg, 200mg
    Injection (for IV infusion): 200mg

    To be used for:
    -Prophylaxis of fungal infection in haematological malignancy
    -Treatment of invasive aspergillosis
    -Treatment of candida infections resistant to narrower-spectrum azoles
    -Treatment of scedosporium and fusarium infections
    11.03.02 Voriconazole 

    unlicensed unlicensed Eye drops: 1%

    04.03.03 Vortioxetine  Tablets: 5mg, 10mg, 20mg

    - approved for the treatment of major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode in line with NICE
    02.08.02 Warfarin  Tablets: 500mcg, 1mg, 3mg, 5mg
    07.04.04 Water 

    Volumes (up to 3 litres)

    09.02.02.01 Water for Injection 

    Injection: 2ml, 5ml, 10ml, 20ml, 100ml & 500ml
    Irrigation: 1000ml
    Oral: 100ml

    13.11 Water for irrigation 
    13.02.01 White soft paraffin 15%, liquid paraffin 6% Epimax Cream®

    100g, 500g

    12.03.05 Xerotin 

    Spray (sugar-free):100 mL

    12.02.02 Xylometazoline 

    Nasal drops: 0.05%, 0.1%
    Nasal spray: 0.1%

    01.07.02 Xyloproct® ointment  Ointment containing lidocaine 5%, hydrocortisone acetate 0.275%, aluminium acetate 3.5% and zinc oxide 18%.

    Recommended for short-term use only
    07.03.01 Yasmin® 

    Tablets: ethinylestradiol 30 microgram/drospirenone 3mg

    14.04 Yellow fever vaccine 

    Only available from a designated Yellow Fever Vaccination Centre (YFVC) A listing of approved YFVCs in England, Wales, and Northern Ireland (EWNI) can be found at: https://nathnacyfzone.org.uk/search-centres

    05.03.04 Zanamivir inhalation  Dry powder for inhalation: 5mg/blister (via Diskhaler®)
    13.02.01 Zerocream® 

    50g, 500g

    05.03.01 Zidovudine Retrovir®

    Capsules: 100mg, 250mg
    Oral solution: 50mg/5ml
    Solution for infusion: 200mg/20ml

    05.03.01 Zidovudine and lamivudine Combivir®

    Tablets: 150mg/300mg

    13.05.02 Zinc & Coal Tar (White’s Tar Paste) Paste containing zinc oxide 6%, coal tar 6%, emulsifying wax 5%, starch 38% and yellow soft paraffin 45%. Zinc & Coal Tar (White’s Tar Paste)
    09.05.04 Zinc acetate 

    Capsules: 25mg

    13.05.02 Zinc and Salicylic Acid Paste BP Half Strength Lassar’s Paste
    09.05.04 Zinc Sulphate 

    Effervescent tablets: 125 mg (Solvazinc)

    06.06.02 Zoledronic Acid Aclasta® Infusion: 50mcg/1mL (Aclasta®)

    For the treatment of postmenopausal osteoporosis, osteoporosis in men and Paget’s disease

    N.B. prescribe by brand name (Aclasta®) to avoid confusion with a different strength product used to treat hypercalcaemia of malignancy and the prevention of skeletal events in patients with metastatic breast cancer.
    06.06.02 Zoledronic Acid Zometa Concentrate for intravenous infusion, vial: 4mg

    Indication:prevention of treatment associated osteoporosis and to reduce the risk of recurrence in post-menopausal patients with early breast cancer (note: unlicensed for this indication)
    08.03.04.01 Zoledronic acid (Zometa) 

    Concentrate for intravenous infusion (vial): 4mg


    Indication: prevention of treatment associated osteoporosis and to reduce the risk of recurrence in post-menopausal patients with early breast cancer (note: unlicensed for this indication)

    04.08.01 Zonisamide  Capsules: 25 mg, 50 mg, 100 mg
    04.01.01 Zopiclone  Tablets: 3.75mg, 7.5mg
    04.02.02 Zuclopenthixol acetate  Injection: 50 mg/1 mL
    - For short-term use by NTW specialists only
    04.02.02 Zuclopenthixol Decanoate  Injection: 200mg/1ml, 500mg/1ml
    Sunderland Joint Formulary